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1.1 Oligodendrocytes: the myelin-forming cells in the central nervous 
system (CNS) 
The CNS contains two major types of specialized cells, neurons and glial cells (Figure 1.1). 
Neurons are regarded as the elements mediating the electrical activity in the form of action 
potentials and are responsible for the relay of information throughout the nervous system. 
Neuroscience research of the past has mainly focused on this cell type, since until recently glial 
cells were believed to provide only structural support to neurons. However, it is now becoming 
increasingly clear that glial cells have active functions in the nervous system, as demonstrated by 
numerous experimental evidences showing that glial cells play a role in synaptic development and 
activity, provide guidance of neuronal migration and process outgrowth and influence the electrical 
activity of neurons. Thus, it is now recognized that different types of glial cells fulfil distinct tasks 
and are essential for the proper functioning of neural circuits. 
Based on morphology, function and location in the nervous system, glial cells are 
classified in three main categories: astrocytes, microglia and oligodendrocytes (OLs) (Barres, 
2008; Allen and Barres, 2009).  
Astrocytes are star-shaped cells which extend many processes that contact both blood 
vessels and neurons; they provide guiding structures during development and represent important 
elements for controlling the composition of the extracellular space mediating signals between the 
brain endothelium and the neuronal membrane.  
Microglial cells are the resident immuno-competent cells of the nervous system. They have 
crucial functions in surveillance and homeostasis of CNS, reacting to damage and infection, by 
removing cellular debris and actively participating to neural tissue remodelling after injury.  
OLs are the myelin-forming cells of the central nervous system that ensure a rapid signal 
conduction in the white matter. They are post-mitotic glial cells with small number of 
cytoplasmic processes, whose name comes from the Greek roots oligo, meaning ‘few’, dendro 
meaning ‘branch’, and kytos which denotes ‘cell’. This term was first introduced by Rio 
Hortega to describe those neuroglial cells that show few processes in material stained by 
metallic impregnation techniques.  
As mentioned before, the main function of OLs is to produce myelin and to form the 
myelin sheath around neuronal processes of CNS which is essential to ensure the insulation of 
axons and to allow the salutatory conduction of nerve impulses. OLs are also involved in 
neuronal development and survival, in the regulation of extracellular ion concentrations, in 
the distribution of potassium channel along the axons and in the axonal transport. Moreover, 
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some OLs form synapses with neurons and are actively involved in CNS functions (Barres, 
2008; Emery, 2010). 
 
 
Figure 1.1 - Glial populations within the CNS 
Schematic representation of the different types of glial cells in the CNS and their interactions, among 
themselves and with neurons. Astrocytes are stellate cells with numerous processes contacting several 
cell types in the CNS: soma, dendrites and axons of neurons, soma and processes of OLs, and other 
astrocytes; astrocytic feet also ensheath endothelial cells around blood capillaries forming the blood-
brain barrier. OLs are the myelinating cells of the CNS; they are able to myelinate up to 50 axonal 
segments, depending on the region of the CNS. Microglia, which represent the 20% of the total glial 
population within the CNS, keep the brain under surveillance for damage or infection. 
 
In 1992, Rio Hortega classified OLs in four categories based on the characteristics of the 
number and orientation of their cellular processes, the shape and size of their somata, the size 
of the axons they were associated with, and their distributions within the CNS (Rio-Hortega, 
1928). Type I and II OLs are indistinguishable and have four or more primary processes that 
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branch repeatedly to myelinate 10-30 axons less than 2 μm in diameter. Type I OLs can be 
found in the forebrain, cerebellum and spinal cord, whereas type II OLs are observed only in 
white matter. Type III OLs have large cell bodies, often applied directly to an axon, with one 
or more thick primary processes that rarely branch and myelinate a small number of axons, 
usually less than five, with external sheath diameters ranging 4 to 15 μm. They are localized 
in the cerebellar peduncles, the medulla oblongata and the spinal cord. Type IV OLs are 
similar to type III OLs but not have processes and form a single long myelin sheath over a 
large-diameter fiber; they are restricted to tracts containing the largest diameter fibers and 
occur near the entrance of nerve roots into the CNS (Baumann and Pham-Dinh, 2001). 
This first section will be focused on this latter glial cell type. Specifically, it will be 
described and discussed the embryonic and postnatal development of OLs and their functional 
roles in physiological and pathological conditions. 
 
1.1.1 Embryonic and postnatal development of OLs 
OLs are ubiquitous in both the white and grey matter of brain and spinal cord. They 
originate from pluripotent neuroepithelial cells of neural tube, that give rise to committed 
oligodendrocyte precursor cells (OPCs). These cells are able to divide and migrate throughout 
the CNS. OPCs first appear in the embryo starting at about embryonic day (E) 12.5 in the 
ventral ventricular zones of the spinal cord, where they originate together with motoneurons 
from a common class of precursor cells (pMN, precursors motoneuron), defined by the 
expression of the transcription factor Olig2 (Lu et al., 2002; Takebayashi et al., 2002; Zhou et 
al., 2000). This OPC production is dependent on Sonic hedgehog (Shh) signaling and bone 
morphogenetic proteins. At about E15, generation of a secondary wave of precursors starts in 
more dorsal regions of spinal cord by trans-differentiation of radial glia (Lu et al., 2002) and 
this generation is independent on Shh pathway (Cai et al., 2005). 
The origin of OPCs in the brain is instead more complex. In the embryonic telencephalon 
three different waves of OPC generations were observed, temporally progressing from ventral 
to dorsal regions (Kessaris et al., 2006). The first wave starts at E12.5 (overlapping with the 
appearance of OPCs in the spinal cord) in the medial ganglionic eminence (MGE) and in the 
anterior entopeduncular area (AEP). The second wave follows the first at E15.5, taking place 
in the lateral and caudal ganglionic eminence (LGE and the CGE) and final one arises at 
postnatal day 0 (P0) directly from the cortex (Kessaris et al., 2006). 
These three distinct waves of OPCs originate from three distinct types of neural 
progenitors, expressing different transcription factors. OPCs from the first wave express 
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platelet-derived growth factor receptor alpha (PDGFRα) reflecting their dependence on 
PDGF-AA for survival and proliferation (probably the most important molecule controlling 
the number of OLs in vivo); these cells successively migrate to the cortex (at E16) and, 
finally, disappear completely at P10. OPCs from second wave start at E15.5 and are generated 
from Gsh2-expressing progenitors and OPCs from third wave start around birth (P0) and 
derived from Emx1-expressing progenitors (Figure 1.2). This fine embryonic regulation of 
OPC origin led once again to the idea of distinct subsets of OPCs, devoted to different 
functions. However, so far no study has correlated a distinct origin to a specificity in OPC 
behavior in the postnatal and adult CNS. Future research will clarify this aspect. 
 
Figure 1.2 - Origins and migration of oligodendrocyte precursors in the rodent cervical spinal cord 
and telencephalon. 
(a) In the mouse spinal cord, ~85% of oligodendrocyte precursors are generated from pMN in the 
ventral ventricular zones (1), starting at about embryonic day (E)12.5. At about E15, generation of a 
secondary wave of precursors starts in more dorsal regions by trans-differentiation of radial glia (2). 
(b) In the telencephalon, the ventral-most precursors in the medial ganglionic eminence are produced 
from about E12.5 (1), production of the lateral ganglionic eminence derived precursors starts a few 
days later (2), and production of the cortex-derived precursors occurs mainly after birth (3) 
(Richardson et al., 2006). 
 
After the formation, OPCs migrate extensively from oligodendrogliogenic niches and 
colonise the entire CNS. The migration of these precursors is likely to be mediated by specific 
directional and substrate cues. Ventrally-generated OPCs predominate in the spinal cord, 
while the dorsally-generated ones prevail in the telencephalic vesicles; this distribution may 
reflect a compensatory redundancy to ensure rapid and efficient myelination throughout the 
entire CNS (Richardson, 2006). It is known that OPCs migrate along pre-existing axons. 
However, when these pre-existing axons are transected, the cell biology of OPCs does not 
change and they migrate properly, and even extensively, demonstrating that OPCs could 
respond to signals other than those expressed by viable axons (de Castro et al., 2005; 
Sugimoto et al., 2001; Ueda et al., 1999).  
To migrate and disperse correctly into the CNS parenchyma, OPCs interact with a plethora 
of environmental factors (adhesion molecules in the extracellular matrix, mitogens and 
 Introduction 
 
6 
 
secreted growth factors, chemokines, hormones and neurotransmitters) via their surface 
receptors (de Castro et al., 2005; Cohen, 2005). The growth factor FGF2 and PDGF-AA are 
examples of mitogenic factors important for OPC movement. They act via separate and highly 
specific pathways in a non-synergistic manner: PDGF controls OL migration by inducing 
alterations in intracellular Ca
2+
 levels (Simpson and Armstrong 1999) which, in turn, result in 
the activation of intracellular elements necessary for the detachment from the substratum at 
the rear, generation of motile force, and attachment at the leading edge process (Marks et al., 
1991; Fay et al., 1995; Elferink and de Koster, 1995); FGF2 acts as a chemoattractant by 
forming a complex with its receptor FGFR1 whose activity is impaired by anosmin-1, a 
protein expressed by retinal axons that is defective in the X-linked form of human Kallmann 
syndrome (Bribian et al., 2006). The direct consequence of the interaction of these growth 
factors and morphogens with molecules from the extracellular matrix (fibronectin, merosin, 
tenascin-C and PSA-NCAM) is the modification of OPC migration.  
Another remarkable group of contact-mediated molecules regulating OPC migration in the 
CNS is the ephrins (Ephs). Unlike ephrin A5 (that acts via EphA), the membrane-anchored 
B2 and B3 ephrins (that both interact with EphB receptors) reduce the adhesion of embryonic 
OPCs (isolated from the diencephalon), consequently decreasing their motility (Prestoz et al., 
2004; Petros et al., 2006). Indeed, EphB2 receptor over-expression has been shown to 
increase the invasiveness of migrating glioblastoma cells in vitro and in vivo, while blocking 
EphB produces the opposite result (Nakada et al., 2004). 
Interestingly, OPCs also have metalloproteinases that allow cells to move in the 
extracellular environment and let them extend processes to take contact with axons (Baumann 
and Pham-Dinh, 2001). 
Besides the molecules that promote OPC migration there are some “stop signals” which 
inhibit this process. In this respect, tenascin-C has been reported to block OL precursors at the 
optic nerve in conjunction with other signals (Bartsch et al., 1994; Kiernan et al., 1996), such 
as netrin-1 that is transiently expressed at the optic nerve head and it serves as a repulsive cue 
to stop the migration of precursors into retina (Deiner, 1997). Another candidate stop signal is 
the chemokine CXCL1, which is secreted by astrocytes and has been proposed to regulate 
spatial and temporal patterning of spinal cord myelination through inhibiting neonatal OPC 
motility during spinal cord development (Miller et al., 2002; de Castro et al., 2013). 
Globally, the factors described above, highlight how complex and fine-tuning is OPC 
migration. The control of all these mechanisms ensures the proper migration of these 
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precursors and allow them to migrate long distances and to populate the whole brain and 
spinal cord.  
1.1.2 Oligodendrogliogenesis 
During migration, the precursors maintain the capability to proliferate but, then, when they 
reach their final destination, exit the cell cycle and start differentiating in order to acquire a 
mature phenotype for the formation of myelin sheaths (Greenwood and Butt, 2003) . 
OPC differentiation is a very complex process during which cells encounter their fate 
through a series of fine regulated maturation stages, characterized by changes in cell 
morphologies, cell cycle exit and by the expression of genes and proteins required for 
maturation and myelination. At the beginning, OPCs have a bipolar morphology and express 
PDGFR-α, the proteoglycan NG2 (glial antigen 2), the isoform DM-20 of the proteolipidi 
protein (PLP) and the gangliosides A2B5 and GD3 (Baumann and Pham-Dinh, 2001) (Figure 
1.3). Other important markers of these cells are Olig1/Olig2, that are transcriptional factors 
present throughout all the development and the maturation process. Although these two 
transcriptional factors are structurally related, their biological functions are only partially 
redundant. Olig1 has a minor role in OPC specification and development, but it plays a 
pivotal role in terminal differentiation. By contrast, Olig2 functions at earlier developmental 
stages. Initially, Olig2 acts to oppose cell differentiation and sustains the replication 
competent state so as to expand the pool of progenitors. At later stages of development, Olig2 
promotes the fate choice decision to form early oligodedrocyte progenitors (Meijer et al., 
2012). However, it has been demonstrated that OPC terminal differentiation in the pMN 
domain requires the presence of both Olig1 and Olig2 and in some regions of CNS the role of 
ones prevail on the other (Wegner et al., 2008). Zhou and co-workers demonstrated that, 
during the last phase of OPC development, there is a reduction of Olig2 expression in parallel 
with an increase of Olig1, while Lu and its team claim that the expression of both genes 
remains throughout all the development in the adult CNS too (Wegner et al., 2001). 
In the developmental brain, cells of the premyelinating stage assume a more complex 
morphology with many branching processes and are characterized by the expression of the 
sulfatide O4 (oligodendrocyte marker O4), the tetraspanin protein CD9 and DM20. They start 
appearing in the corpus callosum and, then, they distribute in all the cortical parenchyma 
between P4 and P10; particularly at P7 all NG2-positive cells express O4 (Levine et al., 1993; 
Dawson et al., 2003). 
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Figure 1.3 – OPC differentiation process 
NG2 and PDGFRα are not expressed by neural stem cells but are expressed by proliferating 
progenitor cells (proliferation is indicated by the semicircular arrows) of the OL lineage. These OPCs 
differentiate into premyelinating OLs, they lose the expression of NG2 and PDGFRα and begin to 
express the immature OL antigen O4. The myelinating stage is characterized by the expression of 
myelin proteins such as MBP, MAG and PLP (not listed here). SOX10 is expressed throughout 
development, whereas Olig2 seems to be down-regulated in the mature OLs (adapted by Nishiyama et 
al., 2009). 
 
Subsequently, pre-oligodendrocytes become immature OLs. In this stage, cells start 
expressing the galactosylceramide GalC, the myelin-associated enzyme 2’, 3’-cyclic 
nucleotide 3’-phospho-diesterase (CNPase) and the ribosome inactivating protein (RIP), while 
they start losing the expression of NG2, A2B5 and GD3. Pre-oligodendrocytes further 
progress to the mature stage during which they synthetize the myelin basic protein (MBP), the 
myelin associated glycoprotein (MAG) and the mature isoform of PLP1 (PLP). These cells 
are not able to form myelin yet, since the formation of myelin sheaths requires the contact 
with neuronal axons. After the establishment of this contact, cells become myelinating cells 
and start expressing the myelin oligodendrocyte glycoprotein (MOG) (Solly et al., 1996). 
 
1.1.2.1 Factors necessary for OL survival and maturation 
Every aspect of an OL’s life is largely influenced by neuronal and astroglial signals which, 
in turn, regulate OL survival, proliferation, myelination rate and programmed cell death. An 
increasing number of studies highlighted the importance of one factor rather than others, in 
the control of OL behaviour. It is extremely difficult to extrapolate to in vivo conditions, as 
multiple factors may act in concert to achieve the fine regulation of the complex process of 
OL development and myelination. Combinations of factors often produce effects that are 
significantly different from those seen with any one factor alone (Baumann and Pham-Dinh, 
2001; Emery, 2010). 
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Here it will be summarized the factors known to be involved in the control of OL survival 
and differentiation. 
 
Growth and trophic factors 
Growth and neurotrophic factors have been known to be involved in the regulation OPC 
differentiation since the 1990s. These group of molecules include platelet-derived growth 
factor (PDGF), basic fibroblastic growth factor (bFGF), insulin like growth factor 1 (IGF1) 
and ciliary neurotrophic factor (CNTF). 
 PDGF is synthesized during development by both astrocytes and neurons. It is a 
survival factor and a potent mitogen for OPCs, although it triggers only a limited 
number of cell division. Its receptor, the PDGFR-α can be considered a typical 
marker of OPCs since the receptor disappears at the O4 stage of OL maturation. 
PDGF also stimulates in vitro the motility of OPCs and is chemoattractive. Of note, 
it is able alone to stimulate multipotent neuronal staminal cells to differentiate 
towards the oligodendrogial lineage by inducing the Olig2 expression (Hu et al., 
2008). During differentiation, OLs become insensible to PDGF because of the 
blockade of its intracellular signaling pathway and, then, of its synthesis. (Hart et 
al., 1989) 
 bFGF (also called FGF 2) is also a mitogen for neonatal OPCs. It up-regulates the 
expression of PDGFR-α and therefore increases the developmental period during 
which OPCs or pre-oligodendrocytes are able to respond to PDGF. Pre-
oligodendrocytes can even revert to the oligodendrocyte progenitor stage when 
cultured with both PDGF and bFGF. This inhibition of OL differentiation can be 
overridden by the presence of astrocytes (Baumann et and Pham-Dihn, 2001). 
 IGF1 has been reported to promote proliferation and survival of both OPCs and 
pre-oligodendrocytes, by interacting with the Type I receptor (IGF-1R), a 
heterotetramer with intrinsic tyrosine kinase activity and by activating two 
important intracellular downstream signaling pathways, the MEK/ERK and 
PI3K/Akt cascades (Bibollet-Bahena and Guillermina, 2009). On the other hand, 
the effect on OL development is related to the stimulation of protein synthesis 
through the phosphorylation not only of the MEK/ERK and PI3K/Akt cascades but 
also of the mammalian target of rapamycin (mTOR), which regulates protein 
translation through the phosphorylation of key-factors involved in this process 
(Bibollet-Bahena and Almazan, 2009). Moreover, in vivo studies performed in 
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transgenic mice that overexpressing IGF1 have shown that the percentage of 
myelinated axons and the thickness of the myelin sheaths were significantly 
increased. On the contrary, mice that ectopically express IGF binding protein-1 
(IGFBP-1), a protein able to inhibit IGF1 action had a decreased number of 
myelinated axons, together with a reduction of the myelin sheaths thickness. In 
addition, IGF1 could be involved in both the increase in OL number and in the 
amount of myelin produced by each OL (Carson et al., 1993). In this respect a 
phase II pilot study of the tolerability and efficacy of subcutaneously administered 
recombinant human IGF1 (CEP-151) in patients with Multiple Sclerosis (MS) has 
been completed, although no results have been reported yet. 
 CNTF is a neurotrophic factor that can also act as comitogen with PDGF. Animals 
deficient in CNTF have a reduced number of mitotic glial progenitors. It has also 
been demonstrated that CNTF promotes OL survival in vivo (Barres et al., 1993). 
 
Neurotrophins 
Neurotrophins are a family of proteins which include nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and NT-4/5. These molecules 
were initially shown to be important in the development of specific neuronal population 
(Barde et al., 1982; Huang and Reichardt, 2001). However, it is now recognized that 
neurotrophins also modulate cell-fate decisions (McTigue et al., 1998) and control various 
stages of glial development. 
 NT-3 is a mitogen for optic nerve oligodendroglial precursors only when added 
with high levels of insulin, with PDGF, or with a combination of them. NT-3 also 
promotes OL survival in vitro. Its receptor is the tropomyosin-related kinase C 
(TrkC) receptor that is expressed in OLs. In vivo studies demonstrated that, mice 
lacking NT-3 or its receptor TrkC, exhibit profound alterations in CNS glial cells, 
particularly in OPCs; there is an important reduction in the spinal cord diameter, 
thereby suggesting that cell populations other than neurons are affected (Kahn et 
al., 1999). It has been shown that NT-3 in combination with BDNF is able to 
induce proliferation of endogenous OPCs and the subsequent myelination of 
regenerating axons in a model of contused adult rat spinal cord (McTigue et al., 
1998).  
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Neuregulins 
Neuregulins are a family of four structurally related proteins that are part of the EGF 
family of proteins. These proteins have been shown to have diverse functions in the 
development of the nervous system, including Schwann cells and OL differentiation 
(Taveggia et al., 2010). Among neuregulins, the glial growth factor (GGF) has been shown to 
modulate OPC differentiation. It is a member of the neuregulin family of growth factors 
generated by alternative splicing, including Neu, heregulin, and the acetylcholine receptor-
inducing activity (ARIA); it is a neuronal factor, mitogenic on oligodendrocyte precursors; it 
is also a survival factor for these cells. It delays differentiation into mature oligodendrocytes. 
In mice lacking the family of ligands termed neuregulins, OLs in spinal cord failed to develop 
(Vartanian et al., 1999). This failure can be rescued in vitro by the addition of recombinant 
neuregulin to explants of spinal cord. In the embryonic mouse spinal cord, neuregulin 
expression by motoneurons and the ventral ventricular zone is likely to exert an influence on 
early OPCs. Neuregulin is a strong candidate for an axon-derived promoter of myelinating 
cell development (Barres and Raff, 1999). 
 
Neurotrasmitters and their receptors 
It has long been known that neurotransmitters have trophic functions on glial cells, besides 
their main role in neurotransmission. According to this, different receptors for 
neurotrasmitters have been found on OL plasmatic membranes. Once activated, these 
receptors can have positive or negative effects on OPC survival and maturation. 
Several data suggest that glutamate, the most abundant excitatory neurotransmitter in the 
mammalian brain is an excellent candidate signal for the neuronal regulation of OPCs 
development. Accordingly, the AMPA/Kainate subtype of glutamate receptors has been 
reported to be expressed and to play an important role in the early development of OPCs 
(Gallo et al., 1996; Gudz et al., 2006). Moreover, recent evidence shows that electrically 
active axons can induce myelin formation by vesicular release of glutamate that signals 
nearby OLs to start local production of a myelin-building protein (Wake et al., 2011; Araque 
et al., 2011). Although the responsible glutamate receptors in this process remain unexplored, 
these data suggest that glutamate may also be involved in the late development of OPCs and 
provide a novel insights into how experience can influence brain development. 
The other important subtype of ionotropic glutamate receptor, the NMDA receptor 
(NMDAR), has been reported to be extremely important for CNS function. Also NMDARs 
exist in the OL lineage cells and they contribute to myelin damage in pathological conditions 
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(Karadottir et al., 2005; Salter and Fern, 2005; Micu et al., 2006; Manning et al., 2008). In a 
recent work it has been demonstrated that NMDARs activation promotes OPC differentiation 
in vitro and remyelination in an in vivo model of demyelination, providing these receptors as a 
potential targets for the treatment of demyelination diseases (Li et al., 2013). 
The dopamine D3 receptor (D3R) has been found to be expressed by precursors and 
immature OLs, but not in mature OLs. Interestingly, by confocal microscopic analysis, it has 
been shown that D3R is associated with cell bodies and cell membranes, but not with the 
processes emanating from cell soma. Moreover, immunohistochemistry has revealed the 
presence of D3R in some OLs located mainly within parts of the corpus callosum during 
myelinogenesis. Treatment of glial cultures with a dopamine agonist altered the normal 
pattern of OL maturation and elaboration of myelin sheath (Bongarzone et al., 1998). Another 
dopamine receptor, D2R, is also present in a subset of mature interfascicular OLs in the rat 
corpus callosum (Howard et al., 1998). Although the identification of these receptors in OLs, 
their physiological role in these non-neuronal cells is still not known. 
OLs also express opioid receptors. μ-receptors are present since the earliest stages of OL 
development, while κ-receptors are detected later at the time that MBP is expressed. μ-
receptors stimulation has been shown to trigger a proliferative response in these cells (Knapp 
et al., 2000). 
Finally, extracellular ATP has been identified as an important activity-dependent axonal 
signal that, when non-synaptically released from electrically stimulated axons, activates 
purinergic P2 receptors on neighboring OPCs, promoting their differentiation. According to 
this, both ATP and adenine nucleotide such as ADP and uracil nucleotide such as UDP are 
able to trigger Ca
2+
 increases in OLs (Butt et al., 2006; Fumagalli et al., 2011). These cells, in 
fact, express different subtypes of P1 and P2 receptors (Agresti et al., 2005; Verkhratsky et 
al., 2009). Interestingly, non-synaptically released ATP has been shown to stimulate astrocyte 
release of the pro-myelinating cytokine leukemia inhibitory factor (LIF), that, acting on OLs, 
accelerates their terminal differentiation (Ishibashi et al., 2009). For further details see 
paragraph 1.1.4. 
 
Hormones 
It has also been demonstrated that hormones can influence the myelination process. 
According to this, the discovery that hyperthyroidism accelerates the myelination process and 
hypothyroidism decreases it, assumes that the thyroid hormone 3,3,5-triiodothyronine (T3) 
may be involved in OL development. Moreover, OL differentiation as well as the degree of 
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myelin synthesis is increased by thyroid hormone. In fact, in vitro studies, demonstrated that 
OPCs stop dividing and differentiate in the presence of T3. This hormone also promotes the 
morphological and functional maturation of postmitotic OLs, thus increasing the number of 
mature OLs. The effect of T3 is mediated by its interaction with specific receptor isoforms 
(TR). Only three TR isoforms are functional: α1, β1, and β2. OPCs mainly express α1 
isoform, although β2 may also be present, whereas mature OLs express α1 and β1. The 
expression of different receptors in relation to the maturation state of the OLs may mean that 
these effects are independently regulated by thyroid hormone. It has been shown that T3 
regulates the gene expression of MBP (Farsetti et al., 1991), PLP, MAG, and CNP (Ibarolla et 
al., 1997).  
To the same family of nuclear receptor of TR belong retinoid X receptors (RXRs). 
Recently, it has been shown that these receptors are positive regulators of OPC differentiation 
(Huang et al., 2011). RXRs are nuclear receptors that regulate cell proliferation and 
differentiation (Ahuja et al., 2003; Germain et al., 2006; Lefebvre et al., 2010). There are 
three members in the RXR family, RXRα, RXRβ and RXRγ, which form homodimers or 
heterodimers with other nuclear receptors, including retinoic acid receptors (RARs), TR, 
vitamin D receptors (VDRs), peroxisome proliferator activator proteins (PPARs), and liver X 
receptors (LXRs), to control transcription of target genes. Following CNS injury, all three 
members of RXR are highly expressed in lesions (Schrage et al., 2006). Interestingly, it has 
been recently found that RXRγ is highly expressed in OLs during the regenerative phase of 
CNS remyelination (Huang et al., 2011). In acute and remyelinating MS lesions, RXRγ is 
highly expressed by OLs, macrophages and astrocytes, but its expression is very low in 
chronic inactive lesions, suggesting that RXRγ is an active component of remyelination. 
Moreover, the in vitro transfection of cultured OPCs with siRNAs generated against RXRγ, 
resulted in less morphologically differentiated OLs. Based on these results, RXRγ emerges as 
a regulator of OL differentiation and as a promising pharmacological target for regenerative 
therapies of CNS (Huang et al., 2011).  
 
 
Micro-RNA (miRNAs) 
In recent years, increasing evidence indicate that also epigenetic mechanisms take part into 
OL development. These mechanisms include chromatin remodeling by histone deacetylases 
(HDACs), DNA methylation and, above all, gene silencing by miRNAs (Mehler, 2008; Liu 
and Casaccia, 2010; Yu et al., 2010). MiRNAs are a class of endogenous small non-coding 
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RNA that consist of about 22 nucleotides processed from endogenous genomic loci that bind 
primarily to the 3’ Untranslated region (UTR) of target mRNAs through an imperfect match 
to repress their translation and stability (Bartel, 2009). It is known that they play a critical role 
in various biological processes, including cell proliferation, differentiation, apoptosis and 
tumorigenesis (Zheng et al., 2010; 2012). Recently, several studies have demonstrated that 
miRNAs are required in controlling OL differentiation and myelination (Dugas et al., 2010; 
Letzen et al., 2010; Zhao et al., 2010). Specifically, a number of stage-specific miRNAs have 
been identified. Some of them are directly involved in the regulation of OPC proliferation, 
others promote the transition from OPCs to mature/myelinating OL, affecting both OPC 
differentiation and myelination.  
Concerning the control of the number of oligodendroglial cells, it has been shown that the 
miR-17-92 cluster, processed from common precursor transcripts, including miR-17, miR-
18a, miR-19a, miR-20a, miR19b, miR-92a (Lau et al., 2008), and especially miR-19b, play 
essential roles in this process. Both in vitro and in vivo experiments demonstrated that these 
miRNAs promote OPC proliferation through the inhibition of PTEN, a phosphatase involved 
in the regulation of the cell cycle (Budde et al., 2010). Besides miR-17-92, other miRNA are 
involved in the regulation of OPC proliferation. Among these, miR-219, miR-338 and miR-
138 take part to this regulation by targeting OPC-expressed genes, (e.g. PDGFRα, Hes-5 e 
Sox-6), whose expression is necessary to promote the cessation of proliferation coupled to OL 
differentiation (Zhao et al., 2010; Dugas et al., 2010). They also inhibit proliferation signaling 
molecules such as PDGFRα and FGFR, as well as neuronal differentiation factors (e.g. 
Zfp238 and FoxJ3) (Dugas et al., 2010; Zhao et al., 2010). MiR-219 may also regulate OL 
terminal maturation and myelin maintenance by targeting fatty acid elongases such as 
ELVOL7 (Shin et al., 2009). The only difference among miR-219, miR-338 and miR-138 is 
that, while miRNA 219 and miR-338 promote the expression of CNPase, MBP and MOG of 
both early and late OL differentiation stages, miR-138 promotes the expression of CNPase 
and MBP but not of MOG (Dugas et al., 2010; Zhao et al., 2010).  
Although the functional significance of these miRNAs is beginning to emerge, these 
results confirm the fact that the miRNA play multiple roles at various stages of OL 
development, including the initial production of fate-specified OPCs, the differentiation of 
mature OLs and generation of compact CNS myelin during development, and in the 
maintenance of functional myelin sheaths. New knowledge about these small regulatory 
molecules will offer novel therapeutic interventions by which disease-related miRNAs could 
be antagonized. 
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1.1.3 Structure and formation of myelin sheath 
The myelin sheath around most axons constitutes the most abundant membrane structure in 
the vertebrate nervous system. Its unique composition (richness in lipids and low water 
content allowing the electrical insulation of axons) and its unique segmental structure 
responsible for the saltatory conduction of nerve impulses allow the myelin sheath to support 
the fast nerve conduction in the thin fibers in the vertebrate system. High-speed conduction, 
fidelity of transfer signaling on long distances, and space economy are the three major 
advantages conferred to the vertebrate nervous system by the myelin sheath, in contrast to the 
invertebrate nervous system where rapid conduction is accompanied by increased axonal 
calibers. The importance of myelin in human development is highlighted by its involvement 
in an array of different neurological diseases such as leukodystrophies and MS in the CNS 
and peripheral neuropathies in the peripheral nervous system (PNS). Moreover, in recent 
years, myelin has also generated new interest for its involvement in normal cognitive 
function, learning and intelligence quotient and as an unexpected contributor to a wide range 
of psychiatric disorders, including depression and schizophrenia (Fields, 2008). 
Myelin is a spiral structure composed of extensions of the OL plasma membrane. 
Myelinating OLs send out sail-like extensions of their cytoplasmic membrane, each of which 
forms a segment of sheathing around an axon, the myelin sheath. This myelin sheath is made 
up of two different layers: the major dense line (dark layer) formed by the cytoplasmic 
surfaces of the expanding myelinating processes of the OL and the double intraperiodic line 
constituted by the overlapping of the outer leaflets of OL membranes (Baumann and Pham-
Dihn, 2001). 
 
1.1.3.1 Myelin sheath composition 
Myelin has a chemical composition very close to that of cellular plasmatic membranes but 
it has a peculiar lipid-to-protein ratio: it consists of 70% lipids and 30% proteins. The 
insulating properties of the myelin sheath, which favor rapid nerve conduction velocity, are 
largely due to its structure, its thickness, its low water content, and its richness in lipids. The 
specific constituents of myelin, glycolipids and proteins are formed in the OL. 
Concerning lipids, myelin contains cholesterol, phospholipids, and glycolipids in molar 
ratios ranging from 4:3:2 to 4:4:2. On the cytoplasmatic side of the membrane there are 
phospholipids and on the extracellular side there are glycolipids, cholesterol and among them 
long chain fatty acids. One of the major characteristics of the myelin lipids is their richness in 
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glycosphingolipids, in particular galactocerebrosides (i.e. galactosylceramides, GalC) and 
their sulfated derivatives, sulfatides (i.e., sulfogalactosylceramides). 
Myelin proteins comprise 30% dry weight of myelin. The major CNS myelin proteins 
MBP and PLP (and the immature isoform DM-20) are low-molecular-weight proteins and 
constitute 80% of the total proteins. MBP constitutes as much as 30% of the total proteins and 
is present in various isoforms of different molecular masses. The main role of MBP is to 
compact membrane during myelin maturation, whereas the proteolipid proteins PLP and 
DM20 are mainly myelin constituents.  
Another group of myelin proteins, insoluble after solubilization of purified myelin in 
chloroform-methanol 2:1, have been designated as the Wolfgram proteins, since their 
existence was suspected already in 1966 by Wolfgram (Wolfgram, 1966). One of these 
proteins is the CNPase. This is an enzyme representing the 4% of total myelin proteins and 
known to hydrolyzes artificial substrates 2’,3’-cyclic nucleotides into their 2’-derivatives.  
Finally, several glycoproteins are present in myelin, such as MAG and MOG. MAG is 
quantitatively a minor constituent, representing 1% of the total protein found in myelin 
isolated from the CNS and 0.1% in the PNS. In the adult rat CNS, MAG is confined to the 
periaxonal collar of the myelin sheath, whereas a larger distribution across different regions of 
PNS myelin has been reported. Interestingly, MAG function has been studied by generating 
MAG gene knock-out mice in which, surprisingly, CNS myelin forms almost normally even 
though the absence of MAG; however, a prominent defect of the mutant myelin sheaths is an 
abnormal formation of the periaxonal cytoplasmic collar that is lacking in most of the 
internodes; moreover, myelin sheaths contain cytoplasmic organelles between lamellae, 
indicating a delay or block of myelin compaction and 10% of axons, versus 3% in wild-type 
mice, received from two to four sheaths around a single axon, suggesting that MAG may have 
a role in helping OL processes to distinguish between myelinated and unmyelinated axons in 
the CNS (Li et al., 1994; Montag et al., 1994) 
MOG was first identified by a polyclonal antibody directed against an antigen called M2 
that induces autoimmune encephalomyelitis in the guinea pig. It was later identified as a 
minor glycoprotein specific for CNS myelin and further characterized by immunological 
methods, immunohistochemistry, and Western blot (WB), using a mouse monoclonal 
antibody against glycoproteins of rat cerebellum. MOG is only present in mammalian species 
and is highly conserved between species (Baumann and Pham-Dinh, 2001). 
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1.1.3.2 Myelination 
Myelination consists of the formation of a membrane with a fixed composition and specific 
lipid-protein interactions, allowing membrane compaction and the formation of the dense and 
intraperiodic lines of myelin. Therefore, myelination also needs activation of numerous 
enzymes of lipid metabolism necessary for the synthesis of myelin lipids, of synthesis and 
transport of specific protein components of myelin or their mRNAs to the OL processes. 
Individual OLs myelinate up to sixty axons by extending their cytoplasmic membrane and 
forming a compact wrapping in segments called internodes (Peters, 1964; Remahl and 
Hildebrand, 1990). Between two internodes there is a gap called the node of Ranvier. At these 
nodes, voltage-gated sodium channels are clustered to conduct action potentials, resulting in a 
conduction phenomenon called saltatory conduction. Myelination permits nerves to conduct 
action potentials faster and for longer distances, since the insulation provided by the myelin 
sheaths reduces the current flow across the axonal membrane and increases its transverse 
resistance. In addition, the saltatory conduction of action potentials from node to node reduces 
the metabolic requirements of the neurons and increases conduction velocity (Poliak and 
Peles, 2003). 
The following sequential steps characterize the myelination process: 1) the migration of 
OPCs to axons that are to be myelinated and their differentiation into highly ramified cells; 2) 
the adhesion of the OL processes to the axon, the spiraling of the process around the axon, 
with a predetermined number of myelin sheaths and the recognition of the space not to be 
myelinated, i.e., the nodes of Ranvier; 3) the compaction of the myelin layers resulting in the 
formation of the mature myelin sheath.  
During the first step, the preoligodendroglial multiprocessed cells settle along the fiber 
tracts of the future white matter, maintaining the ability to divide. Then, these 
preoligodendrocytes become immature OLs, characterized by the acquisition of specific 
markers (see paragraph 1.1.3) and, then, ready for myelination (Figure 1.4). 
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Figure 1.4 – Scheme representing the myelin sheath formation process 
Myelination process is characterized by three phases: (i) OLs differentiate and extend highly ramified 
processes; (ii) OLs take contact with neuronal axons and start wrapping them; (iii) the ensheathment 
becomes compact and myelin sheath is formed (adapted from Bauer et al., 2009). 
 
 
The exact mechanism through which axons are wrapped and myelinated by OLs has not 
been fully elucidated. Several theories have been put forward over the past few years to 
explain how myelination takes play. Two models have been proposed (Figure 1.5). In the 
first, the leading edge of the OL spreads along the axon in a sheet like manner, concludes an 
initial wrap, and then moves underneath the growing sheet. In the second, the process remains 
compact and, only when a sufficient number of wraps have been generated by turns around 
the axon, extends laterally into overlapping sheets. These two theories are clearly not 
mutually exclusive, and intermediate mechanisms might exist.  
The subsequent compaction phase is perhaps the most important part of the myelin sheath 
formation, because it involves the extrusion of the cytoplasm and both intracellular and 
extracellular sheet interconnection by specialized proteins, and is thus responsible for the 
highly specific insulating function of the sheath. 
Both models indicate that the formation of myelin requires important morphological 
changes of OLs which are mediated by alteration of the cytoskeleton (Bauer et a., 2009). In 
fact, during the first stage of myelination, the extension and the branching of OL processes 
need the reorganization of the cytoskeleton mediated by extracellular signals, such as bFGF 
and PDGF secreted by neurons and astrocytes and extracellular matrix molecules such as 
fibronectin, vitronectin, collagen and laminin.  
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Figure 1.5 – Scheme representing the two models of myelination. 
After contact formation of an OL process with an axon (A), the process could flatten into a broad 
sheet, wrap around the axon (B), and then move underneath itself (C) to form the multiple layers of the 
mature myelin sheath (G). Alternatively, the process could wrap around the axon-like twine around a 
post (D), and once the appropriate number of wraps has formed, flatten out and move laterally (E, F) 
to conclude sheath formation. From the images, it does become apparent that these models are not 
mutually exclusive, but that intermediate events might contribute to myelination. (H) depicts a 
longitudinal section through a myelinated axon, detailing the different layers of the compact myelin 
sheath, with cytoplasm-containing paranodal loops at either end (from Bauer et al., 2009). 
 
Besides the pronounced cytoskeletal remodeling, the process outgrowth requires the 
extension of the membrane surface and some alterations in membrane composition. Among 
these, one prominent feature is the emergence of specialized microdomains in the sheets, 
termed lipid rafts. Oligodendroglial lipid rafts consist of a tightly packed array cholesterol and 
glycosphingolipids and phospholipids with saturated acyl chains. The role of lipid rafts is not 
so clear. Two lines of evidence suggest that one role of rafts must be to direct cytoskeletal 
assembly for myelination after axo-glial contact; the second ones is to recruit myelin protein. 
Finally, important morphological changes are also observed in the last stage of myelination, 
the compaction of the myelin sheath, This step requires retraction, disassembly or 
reorganization of the cytoskeleton and, concomitantly, relocation of bulky cellular organelles 
located in the peripheral processes (Bauer et al., 2009). 
The development of OLs and myelination of individual axon is a highly regulated process 
controlled by a number of mechanisms. These include axonal surface ligands, secreted 
molecules and axonal activity (Emery, 2010). 
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Candidates for axonally derived soluble-factors include FGFs and thyroid hormone, while-
axonal cell surface molecules such as L1, MAG, NCAM and N-cadherin have been reported 
to regulate formation of the myelin sheath (Miller et al., 2002). As already mentioned in the 
paragraph 1.1.2.1, OL maturation is also influenced by neuregulins that are expressed on 
many axons and induces morphological changes in cultured OLs (Vartanian et al., 1994).  
Different signaling pathways have been also reported to regulate myelination. In this 
respect, Wnt signaling via the canonical pathway is transiently activated in OPCs concurrent 
with the initiation of terminal differentiation. Both β-catenin activity and the expression of 
Tcf4/Tcf7l2 (a transcription factor that mediates the transcriptional effects of the Wnt/β-
Catenin pathway) are subsequently down-regulated in mature OLs (Fancy et al., 2009; Fu et 
al., 2009). This down-regulation of Wnt signaling may be necessary for OL differentiation, as 
mutant mice with elevated Wnt/β-catenin signaling in the OL lineage display blocked 
differentiation and hypomyelination (Fancy et al., 2009). Paradoxically, however, deletion of 
the Wnt effector Tcf4 does not cause precocious OL differentiation as may be expected, but 
also blocks OL differentiation (Fu et al., 2002, Ye et al., 2009). Wnt signaling may, thus, 
exert complex roles in myelination, acting in conjunction with Tcf4 to promote the initial 
stages of OL differentiation, but preventing subsequent differentiation steps and myelination 
unless down-regulated (Emery et al., 2010)  
Two other signaling pathways have been shown to be involved in regulation of 
myelination: Notch-1 and LINGO-1. Notch-1 and its ligands are signaling molecules that are 
involved in gene regulation mechanisms including those that induce neuronal development. 
Non myelinating OLs express Notch1 receptors, and neurons/axons express its ligand, 
Jagged1 or contactin (Wang et al., 1998; Nakahara et al., 2009). Binding of Jagged1 to Notch 
induces expression of the transcription factor Hes5, which blocks the maturation of Notch1-
expressing cells, facilitating the migration of OPCs to white-matter tracts of the CNS. As 
development proceeds, down-regulation of Jagged1 is associated with the maturation of OPCs 
and myelination. These data suggest that Notch-1 may inhibit differentiation of OPCs in order 
to facilitate their migration to the white matter (Patel and Klein, 2011). LINGO-1 is a 
transmembrane protein that is abundantly expressed in the cortex of CNS and has been in 
implicated in the inhibition of axon regeneration (Mi et al., 2004). It also regulates 
remyelination in the adult CNS by inhibiting OL differentiation. In 2009, using three different 
animal models of de/remyelination: EAE, cuprizone induced demyelination, and 
lysophophatidylcholine (LPC) induced demyelination, Mi and coworkers demonstrated that 
LINGO-1 antagonism enhanced OPC differentiation and promoted remyelination of 
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demyelinated axons. Furthermore, LINGO-1 antagonism using monoclonal antibody 1A7 in 
the EAE model showed improvement in axonal integrity and the formation of new myelin 
sheath. In this respect, in a Phase I trial of BIIB033 (Biogen Idec), a LINGO-1 antagonist 
administered by infusion is currently recruiting (NCT01244139).  
Besides an axonal regulation of myelination process, it is believed that much of the 
regulation of OL behavior is intrinsic in nature, with mechanisms such as an internal “clock” 
limiting the number of cell divisions in OPC cultures grown in the absence of neurons. 
According to this, recent findings provide evidence for the involvement of transcriptional 
regulators. Some of them are reported below. 
 MRF (Myelin gene regulatory-factor) is a transcriptional factor that promotes the 
expression of many genes important in the production of myelin. It is therefore of 
critical importance in the development and maintenance of myelin sheaths. The 
expression of this transcriptional regulator is specific to mature, myelinating OLs. 
According to this, in vivo studies have shown that mice lacking-MRF in the 
oligodendroglial lineage continue to generate OLs but these cells do not fully 
mature and display defects in myelin gene-expression and myelin internode 
formation (Emery et al. 2009). 
 YY1 (Yin Yang 1) is a transcriptional factor multifunctional, ubiquitously 
expressed, zinc finger protein that can act as a transcriptional activator, repressor, 
or initiator element binding protein. Previous studies have shown that YY1 
modulates the activity of reporter genes driven by the myelin proteolipid protein 
(PLP1/Plp1) promoter and mice expressing a loss of function of YY1 generate OLs 
that do not fully mature to form proper myelin segments (He et al. 2007). YY1 is 
thought to repress transcriptional inhibitors by recruiting HDACs (He et al. 2007). 
HDACs normally remove acetyl groups from histones to allow for chromatin 
compaction, which subsequently silences transcription. Recent evidence suggests 
that this mechanism may be responsible for the repression of pathways that 
normally prevent OL differentiation (Li et al. 2010, Shen et al., 2005). 
 Sox10 is a transcriptional factor characterized by a high-mobility-group DNA-
binding domain (Wegner et al., 2001). Up to now, more than 20 different Sox 
proteins have been identified in mammals. In OPCs, Sox10 expression starts earlier 
than the expression of other commonly employed markers for these precursors such 
as PDGFRα and DM-20, but slightly later than Olig-2 (and possibly Olig-1). Once 
turned on, Sox10 remains expressed in OLs throughout the development and in the 
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adult. While the role of Sox10 in both development and differentiation of 
peripheral glia has been clearly established, its function in the OL lineage is still 
not known. So far, the best evidence for an essential role of Sox10 in OL 
development comes from the analysis of a human patient (Inoue et al., 1999). This 
patient carries a Sox10 allele in which deletion of a 12-bp segment at the end of the 
open reading frame has led to loss of the stop codon and elongation of the open 
reading frame by 82 additional amino acids. This mutation leads to severe myelin 
deficiencies in both the PNS and CNS, indicating that the mutant protein interferes 
with both Schwann cells and OPC development. Further studies are ongoing in 
order to clarify the role of this transcriptional factor. 
 Nkx2.2 is a transcriptional factor that is expressed by OPCs during development 
(Qi et al., 2001). Experiments carried on in in Nkx2.2 null mutants demonstrated 
that OPC differentiation is dramatically retarded in these animals suggesting that 
this transcriptional factor is involved in the regulation of this process. Interestingly, 
absence of Nkx2.2 expression also leads to a ventral expansion of the Olig1/Olig2 
expression in neuroepithelial cells with a consequent increase in the production of 
Olig1/Olig2
+
- and PDGFRα+-OPCs. These results strongly suggest that Nkx2.2 
regulates the differentiation and/or maturation, likely affecting MBP and PLP 
expression (Qi et al., 2001) but not the initial specification, of oligodendrocyte 
progenitors.  
 
1.1.3.3 Demyelination 
As previously described, myelin integrity plays a fundamental role in the transmission of 
electrical impulses and it is the result of the proper ensheathment of axons by myelinating 
cells. OL degeneration causes a pathological process called demyelination. Too little is, at 
present, known about the etiology of many demyelinating disorders to enable a precise 
pathological classification. The alteration and the loss of axonal ensheathment may have 
different origin and may be caused by genetic defects, infectious agents, autoimmune 
reactions, chemical agents exposure or unknown factors. 
Demyelination can be regarded as either primary or secondary. The primary form destroys 
or damages myelin or the myelin-forming cells, whereas the axons are relatively normal, at 
least in the early stages. On the other hand, secondary demyelination (also known as 
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Wallerian degeneration) involves damages to neurons or axons, followed by breakdown of 
myelin.  
From a clinical perspective there are two major causes of primary demyelination in the 
CNS: genetic abnormalities that affect glia (e.g. leukodystrophies), and inflammatory damage 
to myelin and OLs (e.g. MS). Concerning the genetic diseases, they usually present in 
childhood with generalized neurological symptoms, such as changes in gait, muscle tone and 
cognition, and can be subdivided into those that result from defects of lysosomal function (for 
example, metachromatic leukodystrophy and Krabbe’s disease) or perioxsomal function 
(adrenoleukodystrophy), those that result from abnormal OL myelinogenesis, that is due to 
deficiencies in or misfolding of key myelin proteins (hypomyelinating leukodystrophies, such 
as Pelizaeus–Merzbacher disease) and those that result from defects in the astrocytes that 
provide trophic support for myelinating OLs (Alexander’s disease and, probably, vanishing 
white matter disease).  
Another important myelin disease in the CNS is periventricular leukomalacia. This is a 
major cause of cerebral palsy and is thought to result from oligodendroglial loss or, at later 
stages of fetal development, damage secondary to ischemia or infection. However, it cannot 
be classified as a disease that causes primary demyelination for two reasons. First, the time of 
greatest risk (24–32 weeks of gestation) corresponds to the time of myelin formation, with a 
predominance of progenitor and pre-OLs seen in the CNS. Second, there may be significant 
axonal damage, with secondary rather than primary oligodendroglial defects resulting from 
abnormal axo–glial communication. It is more accurate therefore to classify it as a disease of 
hypomyelination.  
As previously described, during the initial phase of pathological demyelination, neurons 
remain intact and they can respond to the loss of myelin with the redistribution and the 
insertion Na
+
 channels along the denuded axolemma, to allow non saltatory conduction along 
the demyelinated segment. This compensatory mechanism allows the transmission of 
electrical impulse, even though it is less efficient than normal transmission, but impairs Na
+
-
K
+
 activity. This enzyme is responsible for rapidly correcting Na
+
 and K
+
 levels following an 
action potential but in these conditions it does not work properly because of a pathological 
increase in intra-axonal Na
+ 
concentrations. As a consequence there is the involvement of 
Na
+
-Ca
2+
 pompe that, eliminating Na
+
, increases intracellular Ca
2+
 levels which, in turn, 
causes severe damages (Franklin and Ffrench-Constant, 2008). 
Besides the formation of myelin sheath, OLs have an important role in maintaining axonal 
integrity and in promoting neuronal growth by synthetizing neurotrophic factors such as 
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CNTF, IGF and glial cell-derived neurotrophic factor (GNDF) (Dai et al., 2001; Du and 
Dreyfus, 2002). 
Since it seems clear that a damage to myelin and OLs has direct consequences on neurons 
and, in general, on the entire CNS, it is important to understand the causes of demyelination. 
One of the most frequent causes of OL death or dysfunction is oxidative injury. In the 
brain, the main source of reactive oxygen species (ROS) are mitochondria, nitroxide synthase, 
monoamine oxidase and P450 enzymes. The high metabolic rate of neurons requires a certain 
basal production of ROS since myelin production is an energy dependent process, which 
needs large amounts of ATP and oxygen. A toxic byproduct of ATP synthesis is hydrogen 
peroxide, which, if not metabolized, has been shown in vitro to cause DNA degradation and 
OL apoptosis. Hydrogen peroxide is also produced by peroxisomes, which are plentiful in 
OLs because of their need to produce large quantities of lipids. Cellular metabolism also 
creates reactive oxygen species, which are highly toxic and induce lipid peroxidation and 
DNA damage (McTigue and Tripathi, 2008). Another reason for OL susceptibility to 
oxidation is that many metabolic and myelin synthetic enzymes require iron as co-factor. Both 
OLs and OPCs have the largest stores of iron in the adult brain. While this metal is necessary 
for myelin production, it is also highly reactive and can evoke free radical formation and lipid 
peroxidation. This, together with high metabolism and numerous peroxisomes make OLs 
particularly vulnerable to oxidative damage. Moreover, paradoxically, OLs have low 
concentrations of glutathione (GSH), a robust antioxidative enzyme. This low glutathione 
concentration would allow intracellular iron levels rise. Thus, healthy cerebral cells need high 
levels of antioxidant defenses, both enzymatic (as the Cu
2+
/Zn
2+
 superoxide dismutase, 
glutathione peroxidase and the catalase) and non enzymatic (as glutathione, ascorbic acid and 
vitamin E). If these defenses are not able to keep ROS levels under the threshold of toxicity, 
there will be oxidative stress. The oxidative stress is a common feature of many pathological 
conditions as MS, Alzheimer’s disease, spinal cord injury, CNS hypoxia and ischemia 
(Stankiewicz et al., 2007; McTigue and Tripathi, 2008). 
Excitotoxicity is another important cause of OL death. It is the pathological process by 
which nerve cells are damaged and killed by excessive stimulation by neurotransmitters such 
as glutamate and similar substances. This occurs when receptors for the excitatory 
neurotransmitter glutamate (glutamate receptors) such as the NMDA receptor and AMPA 
receptor are over-activated by glutamatergic storm. Excitotoxins like NMDA and kainic acid, 
which bind to these receptors, as well as pathologically high levels of glutamate, can cause 
excitotoxicity by allowing high levels of Ca
2+
 ions to enter the cell. Ca
2+
 influx into cells 
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activates a number of enzymes, including phospholipases, endonucleases, and proteases such 
as calpain. These enzymes go on to damage cell structures, degrade cytoskeletal proteins and 
cause mitochondrial disruption leading to reactive oxygen species production and cytochrome 
c release. Glutamate release may be a consequence of a trauma or anoxia, which invert the 
direction of transporters or may be secreted by microglia and macrophages, exchanging 
glutamate with cysteine. It has also been demonstrated that immature OL can release 
glutamate via reverse glutamate transport, which can then feedback and damage the cells 
through calcium influx (McTigue and Tripathi, 2008). 
In addition to risks associated with myelin synthesis, certain constitutes of the myelin 
membranes can be damaging to OLs. Accordingly, the sphingomyelinase/ceramide pathway 
has been shown to be involved in the demyelination. These enzymes catalyze the breakdown 
of sphingomyelin to ceramide and phosphorylcholine. Once released into the cell, ceramide 
acts as a second messenger through intracellular signaling molecules in two different 
biological processes: cellular differentiation of tissues and programmed cell death. As 
previously described, brain is enriched in sphingolipids, which are the major lipid components 
of plasma membranes and comprise up to 20% of the dry weight of myelin. These molecules 
were long thought to be important for structural support but, now, it also clear that they play 
key roles in cellular signaling. Ceramide contained in sphingolipids can coalesce to form 
domain enriched in death receptor (DRs), so called because they can activate programmed 
cell death. Thus, OLs, having an high percentage of sphingolipids, are susceptible to DRs 
effects. Moreover, sphingomyelinase (SMase), which is normally inactive, gets activated by 
signals commonly involved in CNS injury such as irradiation, infectious agents, interleukin 
(IL)-1β, tumor necrosis factor α (TNFα), or nerve growth factor (NGF) (McTigue and 
Tripathi, 2008). 
 
1.1.3.4 Remyelination. 
As previously described, the loss of OLs and of the myelin sheath has dramatic 
consequences in the CNS. However, in some particular conditions, our organism is able to 
face this pathological process and plays out a reparative response called remyelination. 
During this process, the entire myelin sheaths are restored to demyelinated axons, salutatory 
conduction is reinstated and functional deficits are resolved (Figure 1.6). Remyelination is a 
spontaneous process to the myelin damage but, the new myelin sheath, although functional, is 
shorter and thinner than the original one. For this reason, it is believed that the mechanism of 
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remyelination is essentially different to that of myelination. One hypothesis of this difference 
is that, while the myelinating OL associates with a dynamically changing axon, that is yet to 
achieve its full length and diameter, the remyelinating OL engages an axon that is undergoing 
less change, having already reached its mature size. Therefore, the remyelinating OL is not 
subjected to the same degree of dynamic changes as the myelinating OL during development. 
Such changes may, by analogy with other cell types, regulate protein synthesis and a number 
of intracellular signaling pathways and make an essential contribution to the elaboration of the 
normal myelin sheath (Franklin and Ffrench-Constant, 2008). 
Remyelination follows the steps listed below: 
1. Generation of new OPCs 
2. Migration of OPCs in the demyelinated area 
3. Axon engagement and OPC differentiation  
4. Formation of a new myelin sheath 
The question of where new OLs come from has been a central theme of remyelination 
research over several decades. Now, it is believed that in most cases remyelination is 
mediated by new OLs derived from a population of adult OPCs. These proliferating cells are 
also known as NG2
+
-cells, based on the expression of the membrane chondroitin sulphate 
proteoglycan NG2 or polydendrocytes to reflect their multi-processed morphology and their 
lineal relationship to OLs. These cells represent 5-8% of the cell population and are dispersed 
in both white and grey matter in various CNS regions and in the subventricular zone (SVZ). 
These precursors remain in the adult brain in a quiescent state and are able to proliferate and 
migrate, even if less rapidly, towards demyelinated areas (Franklin and Ffrench-Constant, 
2008). 
Of note, during the first phases of demyelination, all the neural cells of the damaged area 
are involved in this process in particular microglia/macrophages and astrocytes which are 
immediately activated and start releasing different factors that are essential for the beginning 
of remyelination. Among these, PDGF and FGF have been found over-expressed after 
demyelination (Hinks and Franklin, 1999) and some others are the same involved in the 
embryonic OPC development. For example, FGF and IGF1 have an important role in the 
inhibition of OLs differentiation but they are responsible of OPC recruitment during 
remyelination and regulate their transition towards a mature phenotype. 
Following recruitment, the OPCs differentiate into remyelinating OLs. This differentiation 
phase encompasses three distinct steps: establishing contact with the axon that is to be 
remyelinated, expressing myelin genes and generating a myelin membrane, and finally 
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wrapping and compacting the membrane to form the sheath. Interestingly, in recent years, 
several studies have provide compelling evidence for a key role of neuroinflammation in 
remyelination. Microglia and macrophages, as said before, are present within the sclerotic 
plaques typical of the demyelinating diseases and within the inflammatory lesions of 
neurodegenerative diseases. Even though it is believed that inflammatory factors, proteases 
and chemical mediators released from these cells contribute to worsen the primary lesions by 
determining the onset of a secondary neuronal damage, now scientific community has 
accepted that the microglia activation does not have always a deleterious effect in CNS. In 
fact, their main function is to infiltrate the damaged area to phagocytize cellular debris, 
apoptotic cells and pathogens participating in this way to the reparative mechanisms. 
Furthermore, microglia and macrophages can counteract cerebral lesions by releasing 
inflammatory and neurotrophic cytokines and immunosuppressive factors which are able to 
promote neuronal tissue growth. 
 
Figure 1 6 - Events that occur in response to a demyelinating lesion in the corpus callosum. 
Following a demyelinating lesion (yellow oval), polydendrocytes that reside in the corpus callosum 
(dark green area) or those that are recruited from the subventricular zone (SVZ) proliferate around 
the lesion and differentiate into OLs, which myelinate demyelinated axons in the lesion (top panel). 
The extent of remyelination can therefore be affected by both the ability of the polydendrocytes to self-
renew and their ability to differentiate into myelinating OLs. Successful remyelination might occur 
when polydendrocytes proliferate and differentiate into OLs, and in this scenario the polydendrocyte 
population would be replenished (left-hand bottom panel). Successful remyelination might also occur 
in the absence of substantial proliferation, in which case the polydendrocytes would not be 
repopulated and a second demyelinating lesion would therefore not be successfully remyelinated 
(central bottom panel). In the other possible scenario, remyelination would not occur because 
proliferated polydendrocytes fail to differentiate into OLs, or newly differentiated OLs fail to ensheath 
axons (right-hand bottom panel) (from Nishiyama et al., 2009).  
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However, remyelination does not occur always properly. The efficiency of remyelination is 
affected by the non disease-related factors age, sex and genetic background. These generic 
factors will have a bearing on the efficiency of remyelination regardless of the disease process 
that is involved.  
Like all regenerative processes, the efficiency of remyelination decreases with age. This 
manifests as a decrease in the rate at which it occurs and is likely to have a profound bearing 
on disease progression (which, in the case of MS, can occur over many decades). The 
consequences of slow remyelination are compounded by an age-associated increase in the 
vulnerability of demyelinated axons to atrophy. The age-associated effects on remyelination 
are due to a decrease in the efficiency of both OPC recruitment and OPC differentiation. The 
basis of the aging effect is likely to lie in age-associated changes, in both the extrinsic 
environmental signals to which OPCs are exposed in remyelinating lesions, and intrinsic 
determinants of OPC behavior. Moreover, during aging the production of cytokines, 
chemokines and growth factors diminishes (Franklin and Ffrench-Constant, 2008; Franklin 
and Kotter, 2008). 
In addition to these generic factors, remyelination could also be incomplete or fail for 
disease specific reasons. This may be related to a primary deficiency in precursor cells or to a 
failure of precursor cell differentiation and maturation (Franklin and Ffrench-Constant, 2008).  
It is clear that, in order to stimulate remyelination, it would be important to depth the 
knowledge concerning this topic and try to answer many questions still unresolved.  
 
1.1.3.5 A deeper insight into the biological features of polydendrocytes 
Historically, it was believed that the mammalian CNS contains only three types of glial 
cells: astrocytes, OLs and microglia. However, observations made over the past two decades 
have revealed another major glial cell population that is distributed throughout the developing 
and mature CNS. As mentioned above, these cells are known as NG2
+
 or polydendrocytes to 
reflect the multi-processed morphology and the lineal relationship to OLs that characterize 
this type of glial cells. Polydendrocytes are defined as CNS parenchymal cells (non-vascular 
cells) that express the NG2 proteoglycan (Nishiyama et al., 2009). 
The NG2 chondroitin sulphate proteoglycan is a single membrane-spanning chondroitin 
sulphate proteoglycan with a large extracellular domain and a short cytoplasmic tail. It was 
first identified and characterized on the cellular membrane of rat neurons in the late 1970s 
(Stallcup, 1981) and, subsequently, it has also been identified in vascular mural cells, 
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including pericytes, cells of mesenchymal lineages, such as immature chondrocytes, 
osteoblasts and myoblasts and stem cells in the skin (Trotter et al., 2010). 
The first evidence that polydendrocytes are OPCs came from the observation that OPCs 
purified by immunopanning with A2B5 antibody were 95% positive for NG2. Moreover, 
these cells are positive for PDGFRα and, when cultured in differentiation media, these cells 
differentiate into OLs that express galactocerebroside (Levine and Stallcup, 1987; Stallcup 
and Beasley, 1987). On the other hand, polydendrocytes are antigenically distinct from 
astrocytes (they do not express glial fibrillary acidic protein -GFAP- or the glial glutamate-
aspartate transporter -GLAST-) and from resident microglia (They do not express the 
microglial antigens F4/80 and CD11b or bind GSA-IB4) (Nishiyama et al., 2009) 
Since NG2
+
 cells make up 5-10 % of all glia in the developing and adult CNS, the 
comprehension of the physiological role of these cells is crucial. Surely, as a mitotically 
active population, the capability of these cells to generate new OLs is a known function. 
However, these cells participate in homeostasis in the adult CNS. For example, numerous 
evidences indicate that these cells are involved in glutamate signaling, as NG2
+
 cell processes 
can interdigitate between pre- and post-synaptic terminals (Bergles et al., 2000; Ong and 
Levine, 1999). Furthermore, excitatory synapses mediated by AMPA receptors have been 
identified on NG2
+
 cells and such cells have been shown to respond to neuronally released 
glutamate (Bergles et al., 2000). In addition to the expression of glutamate receptors, cells of 
the OL lineage have been shown to transport glutamate actively (Reynolds and Herschkowitz, 
1987) and express glutamate transporter proteins (Kugler and Schmitt, 1999; Domercq et al., 
1999). Together these data indicate that NG2
+
 cells have a key role in glutamate 
neurotransmission (Polito and Reynolds, 2005). 
Besides the presence of glutamate receptors, NG2
+
 cells express functional GABA-A 
receptors (Lin and Bergles, 2004). These receptors alter the physiological properties of NG2
+
 
cells by modifying ion concentrations within these cells. Accordingly, in vitro experiments 
showed that activation of these receptors on developing progenitor cells induce Ca
2+
 influx, 
inhibiting their proliferation and progression along the OL lineage. 
High relevant is that NG2
+
-cells also react to many pathological conditions by active 
proliferation, hypertrophy, NG2 up-regulation and contribution to glial scar formation, 
suggesting that they actively participate in the neuroinflammatory events of the injured 
nervous system (Fumagalli et al., 2011).  
A growing interest toward the NG2
+
 cells comes from both in vitro and in vivo studies, 
showing their ability to give rise to neurons and astrocytes, thus highlighting their intrinsic 
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multipotent capacity, even though this concept is currently a highly debated topic (Raff et al., 
1983; Kondo and Raff, 2000; Guo et al., 2009; 2010).  
Concerning the astroglial fate of NG2
+
 cells, early cell-culture studies showed that OPCs 
purified from rat optic nerves by immunopanning with antibodies against A2B5 ganglioside 
differentiate not only into OLs but also into process-bearing “type-2 astrocytes” in the 
presence of serum factors, which led to the concept of bipotential oligodencrocyte-type-2 
astrocytes (O-2A) progenitors cells (Raff et al., 1983). More recently, A2B5
+
 cells from 
embryonic rat spinal cord were shown to differentiate into OLs, type-1 astrocytes and type-2 
astrocytes in culture and have been called glial restricted progenitor (GRP) cells (Rao and 
Mayer-Proschel, 1997). Conversely, the search for in vivo correlates of O-2A progenitor cells 
or GRP cells has not revealed a clearly defined cell population. These observations led to the 
currently widely accepted view that the generation of type-2 astrocytes from OPCs was an in 
vitro artefact. In contrast to this, recent observations have indicated that polydendrocytes 
might be bipotential glial progenitors that can generate both OLs and astrocytes when 
transplanted into a glia-depleted environment (Franklin et al., 1995). This suggest that 
polydendrocytes are inherently capable of differentiating into astrocytes bur are prevented 
from fulfilling their astroglial fate in the normal in vivo environment (Nishiyama et al., 2009). 
Concerning the neuronal fate of polydendrocytes, several observations suggest that 
polydendrocytes can also generate neurons. Accordingly, it has been demonstrated that 
neuron-like cells were generated in explant cultures of segments from neonatal rat optic 
nerves (Omlin and Waldmeyer, 1989) and that treatment of OPCs from postnatal rat optic 
nerves with bone morphogenetic protein2 (BMP2) and PDGFAA was shown to convert them 
into multipotent neural stem cell-like cells enabling the generation of neurons, astrocytes and 
OLs through epigenetic mechanisms (Kondo and Raff, 2004; Liu et al., 2007). As for the 
astroglial fate of polydendrocytes, also the in vivo capability to generate neurons is not so 
clear. This topic is currently studied by several laboratories through fate-mapping studies 
using transgenic animals in which Cre expression is driven by different promoters. Up to now, 
the results of these studies are not so clear. Some works claim that no neurons are generated 
from NG2 precursors (Dimou et al., 2008; Zhu et al., 2007); others demonstrated the 
neurogenic capability of these precursors (Rivers et al., 2008). The differences of these 
studies might be due to differences in the type of transgenic mice used. Surely, further studies 
will be addressed in order to clarify this debated topic 
Research aimed at clarifying the functional role of NG2
+
 cells in the CNS are currently 
active within the scientific community since, up to now, some interesting questions related to 
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their heterogeneity, their capability to intervene after a cerebral injury, their multipotency and 
their role in the neural network remain still open. 
 
1.1.4 Purinergic signaling and oligodendrogliogenesis 
Few and recent studies have revealed a role for purinergic signaling in OL development 
and death (Butt, 2006; Agresti et al., 2005; Fumagalli et al., 2011). Since the early ‘90s, ATP 
has been identified as an important activity-dependent axonal signal that is able to activate 
purinergic receptors, increasing Ca
2+
 concentrations in OPCs and differentiated OLs. These 
cells express several P2X (P2X1, P2X2, P2X3, P2X4, P2X7) and P2Y (P2Y1, P2Y2, P2Y6, 
P2Y12, P2Y13) receptors. Among these, P2X7 and the ADP-sensitive P2Y1 have been 
identified as the main ionotropic and metabotropic P2 receptor active in OPCs (Agresti et al., 
2005). In addition, OPCs have all four adenosine receptors (Fields and Burnstock, 2006). 
Recently, adenosine has been demonstrated to act as a potent neuron-glia transmitter, able 
to inhibit OPC proliferation, stimulate differentiation and promote the formation of myelin in 
both dissociated culture and cerebellar organotypic slice (Stevens et al., 2002). In fact, upon 
application of adenosine, the incorporation of BrdU or 
3
H-thymidine in NG2
+
-OPC nuclei 
decreases significantly, even in presence of potent mitogenic factors such as PDGF and 
bFGF. In parallel, OPCs start to show a more complex morphology and the expression of O4 
and O1 (Stevens et al., 2002). Similarly, Agresti and colleagues (2005) demonstrated that 
ATP and ADP are able to inhibit OPC proliferation in vitro, both in purified cultures and in 
cerebellar tissue slices. ATP and ADP, but not UTP have been shown also to induce OPC 
migration in vitro in dose-dependent manner. The effects of ATP and ADP on cell migration 
and proliferation are mediated by the ADP-sensitive P2Y1 receptor, as the P2Y1 antagonist 
MRS2179 completely prevents these changes (Agresti et al., 2005). More recently, purinergic 
signaling has been found to stimulate myelination at later stages of OL development, through 
an indirect mechanism involving astrocyte release of promyelination factors (Ishibashi et al., 
2006). In this respect, it has been demonstrated that upon treatment with ATP, 2-methylthio 
ATP and α,β-methylene ATP, astrocytes are induced to produce the leukemia inhibitory 
factor (LIF) (Yamakuni et al., 2002; Ishibashi et al., 2006), a cytokine belonging to the CNTF 
family, which has been shown to stimulate myelination in OPC/dorsal root ganglia (DRG) co-
cultures (Ishibashi et al., 2006; Stankoff et al., 2002). Collectively, these findings revealed an 
important and positive role for purinergic signaling in OL development. 
 Introduction 
 
32 
 
However, ATP signaling through P2X7 receptors has been demonstrated to mediate OL 
apoptosis (Matute et al., 2007; Neary and Zimmermann, 2009; Domercq et al., 2010). It has 
been shown that differentiated OLs of spinal cord and optic nerve have a robust expression of 
P2X7 (Matute et al., 2008). P2X7 channel opening causes rapid depolarization, Ca
2+
 influx and 
loss of Na
+
 and K
+
 gradients. Thus, its activation can amplify glutamate-receptor mediated 
excitoxicity. A recent report (Matute et al., 2007) has demonstrated that ATP signaling can 
trigger OL excitoxicity through the activation of P2X7 receptors. Moreover, it has also been 
showed that the OL death induced by the activation of P2X7 receptor may have a role in the 
pathogenesis of diseases characterized by demyelination, such MS. Accordingly, sustained 
activation of P2X7 receptor in vivo has been shown to cause white matter lesions that are 
reminiscent of the major features of MS plaques, as characterized by OL death, intense 
microgliosis, demyelination and axonal damage. These features indicate that excess of 
extracellular ATP as a consequence of progressive tissue damage in MS may in turn 
aggravate the development of the pathology. Indeed, administration of Brilliant blue G, a 
P2X7 antagonist, in EAE mouse model inhibits demyelination and restores axonal 
conductance (Matute et al., 2007; 2008). This finding can be highly relevant for 
understanding the etiology of MS, since an increased P2X7 expression has been detected also 
in normal appearing axonal tracts in post-mortem tissues from MS patients, suggesting that 
the elevated expression of this purinergic receptor may be a risk factor associated with early 
lesion formation in this disease (Matute et al., 2007). 
Also the four adenosine receptors take part to OPC differentiation are involved in some OL 
diseases. For example, the deletion of A1 receptor induces a severe demyelination and causes 
a progressive form of the experimental autoimmune encephalomyelitis (EAE), a model of MS 
(Tsutsui et al., 2004). Similarly, the continuous activation of A1 receptor in the brain reduces 
the MBP expression and induces a damage in the white matter (Turner et al., 2003). 
Besides the role of purines in OL development and differentiation, a number of very recent 
studies have demonstrated the existence of a pyrimidinergic signaling mediated by uracil 
nucleotides (i.e. UDP and UTP) and their sugar conjugates (i.e. UDP-glucose and UDP-
galactose) which has been also reported to modulate OPC proliferation and differentiation 
(Lecca and Ceruti, 2008). In this respect, UDP, UDP-glucose and UDP-galactose have been 
shown to act as endogenous agonists at the P2Y-like receptor GPR17 (Ciana et al., 2006; 
Benned-Jensen and Rosenkilde, 2010) recently identified as an important regulator of OL 
maturation (Lecca et al., 2008; Ceruti et al., 2011; Fumagalli et al., 2011).The role of this 
receptor in OL development will be described in detail in the paragraph 1.2.5. 
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In conclusion, the current date suggest that ATP and other nucleotides, that are released in 
high concentrations during inflammatory events and after cell death, may take part to the 
reparative processes in the diseases characterized by demyelination (Lecca et al., 2012).  
1.2 The G protein coupled receptor GPR17 
GPR17 is a G protein coupled receptor (GPCR) that was first identified thanks to a 
screening of a human cDNA library for P2Y-receptor homologous sequences (Blasius et al, 
1998). Two distinct transcripts of the human GPR17 receptor (hGPR17) were identified to be 
generated by alternative polyadenylation, resulting in the generation of two different isoforms 
lately named short (hGPR17-S) and long isoform (hGPR17-L) (Pugliese et al., 2009; Benned-
Jensen and Rosenkilde, 2010). Subsequently also the rat and mouse GPR17 orthologues were 
identified and cloned, showing a 80% homology in the amino acid sequence to the hGPR17, 
(Figure 1.7) (Ciana et al, 2006; Lecca et al, 2008). 
The expression pattern and functional characterization of GPR17 have been studied since 
few years, and our knowledge is therefore based on few in vitro studies on the hGPR17, and 
several in vitro and in vivo studies for the rGPR17 and mGPR17 (rat and mouse GPRI7). 
Here we aim at reporting the main structural, pharmacological, functional characteristics 
and expression profiles of GPR17 receptor so far known. 
 
Figure 1.7 – Alignment of the human, the mouse and rat amino acidic sequence. 
Note the highly conserved transmembrane domains (TM) and the H-X-X-R motif in T6 conserved in all 
GPCR receptors (from Ciana et al., 2006). 
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1.2.1 GPR17 receptor: structure and pharmacological characteristic 
Although GPR17 amino acidic sequence is conserved among species, the gene structure is 
pretty different. The hGprl7 gene is indeed located on chromosome 2 and it is composed of 
four exons, of which only two contain coding sequences. The rat and mouse Gprl7 gene are 
both located on chromosome 18. rat Gpr17 (rGpr17) is composed only by one exon, whereas 
the mGpr17 (mouse Gprl7) has two different exons and only a small portion of the second 
exon encodes for the GPR17 protein. So far nothing is known about mGpr17 promoter or 
regulatory sequence, neither for the human gene nor for the rat one. The majority of the 
studies have so far focused on GPR17 protein and its function.  
The receptor is named GPR17, because before its endogenous ligands were described, it 
was classified as an orphan GPCR, since it displayed the same structure of G protein coupled 
receptors, with 399 amino acids including 7 transmembrane domains, an N- and a C-terminus 
(Ciana et al, 2006; Lecca et al, 2008). As already mentioned, GPR17 structure is 
phylogenetically related to two classes of GPCR receptors: P2Y receptors and CysLT 
receptors (Figure 1.8). The former class of receptors (P2Y receptors) includes P2Y1, 2, 4, 6, 
11,12,13,14, that respond to adenine nucleotides (ATP adenosine-5 '-triphosphate and ADP 
adenosine monophoshate), uracil nucleotides (UTP uridine triphosphate and UDP uridine 
diphosphate) and sugar nucleotides (UDP-glucose and UDP-galactose). CysLT receptors, 
namely CysLT1 and CysLT2, are also a class of GPCRs responding solely to cystenil-
leukotrienes such as LTD4, LTC4 and LTE4. GPR17 shows pharmacological responses to both 
classes of ligands, therefore it has been one of the first GPCRs to be classified as a "hybrid" or 
"dual" receptor (Ciana et al, 2006; Parravicini et al, 2008). 
 
 
Figure 1.8 – Phylogenetic tree. 
The figure represents the relationships between GPR17 and P2Y and CysLT receptors (from Ciana et 
al., 2006). 
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1.2.1.1 GPR17 agonists 
In the last few years, many studies have been performed in order to clarify the 
pharmacological profile of this receptor. To find the natural ligands of GPR17, the cDNA of 
the short form of the human receptor was cloned in an expression vector pcDNA3.1, that was 
transfected in 1321N1 cells, COS-7 and HEK-293. [
35
S]GTPγS binding studies showed that in 
1321N1 cells, which do not express functional P2Y receptors (Communi et al., 1999), the 
expression of GPR17 induces concentration-dependent responses to LTC4 and LTD4 (with 
LTC4>>LTD4) and UDP, UDP-glucose and UDP-galactose (with UDP-
galactose=UDP>UDP-glucose ), whereas no responses were identified for ligands as ATP, 
ADP, 2-methyl-thio-ADP, UTP, α,β-methylene-ATP and guanosine (Ciana et al., 2006) . 
Moreover, additional studies conducted in 1321N1 cells expressing the GPR17 receptor 
demonstrated that prolonged exposure of these cells to agonists UDP-glucose and LTD4 
determines the desensitization of the receptor, followed by a process of resensitization 
consequent to the removal of agonists (Daniele et al., 2011). 
Pharmacological studies were conducted also on the rodent GPR17 receptor. The 
pharmacology of the rat GPR17 (rGPR17) is identical to that of human as regards the type of 
agonists, but shows variations in the order of the potency (LTD4>LTC4; UDP -glucose>UDP, 
and UDP-galactose has no effect). On the contrary, from the pharmacological studies 
conducted on the murine receptor emerges that the mouse GPR17 (mGPR17) has a 
pharmacological profile more similar to that of the human receptor (UDP>UDP -
galactose>UDP-glucose; LTE4>LTD4>LTC4) (Lecca et al., 2008). Transfection of GPR17 in 
other cell lines such as COS-7 , HEK-293 and CHO confirmed the results obtained in 1321N1 
cells (Ciana et al., 2006). 
It is interesting to emphasize that the EC50 values of the tested agonists are in agreement 
with the known characteristics of the P2Y receptors (micromolar (μM)) and for cystenyl-
leukotrienes; in fact, for the first , the EC50 is comprised in a range while for the cysteinyl-
leukotrienes (nanomolar (nM)). 
The long form of the human GPR17 receptor (hGPR17) was characterized 
pharmacologically too. Similarly to the short form, treatment with both uracil and cysteinyl-
leukotrienes agonists induces the appearance of concentration-dependent responses to LTC4 
and LTD4 (with LTC4 >LTD4) and also to UDP, UDP-glucose (UDP-glucose) and UDP-
galactose (with UDP-galactose=UDP>UDP-glucose). However, while the values found for 
the cysteinyl-leukotrienes not show significant differences with those described for the short 
form, UDP-glucose appears to be slightly more potent on the long form (Pugliese et al., 
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2009). One explanation for these differences has been given by recent studies of molecular 
dynamics simulation on the short form of the receptor. These studies suggest that, in addition 
to an inner pocket for the binding of the nucleotides, GPR17 has an accessory site in a region 
formed by three extracellular domains (EL): EL2, EL3, and the N-terminal sequence. This 
binding site could drive small extracellular agonists towards the main inner binding site, 
leading to receptor activation (Parravicini et al., 2008; 2010). Even though, modeling studies 
on the long form of the receptor have not yet been described, it is thought that the N-terminal 
sequence longer 28 amino acids than the long ones, might change the conformation of this 
accessory binding site, influencing the affinity of nucleotide agonists (Pugliese et al., 2009), 
thus explaining the observed differences between the two isoforms. 
Similar to these studies, the group of Benned-Jensen has performed experiments in 
transfected HEK293 cells, demonstrating that the ligands UDP, UDP-glucose and UDP-
galactose activate the two isoforms of the receptor GPR17, with more power on the long ones. 
Contrary to the above mentioned studies, they did not find receptor activation by cystenil-
leukotrienes, LTD4 and LTE4 (Benned-Jensen and Rosenkilde, 2010; Nörregaard et al., 2011). 
However, recent results in recombinant in vitro systems suggest that the GPR17 receptor 
may also act through a ligand-independent way. It appears that GPR17 behaves as a negative 
allosteric modulator of the CysLT1 receptor, that is able to respond to LTD4, through the 
formation of a dimer receptor-receptor. This action of GPR17 does not seem to be due to its 
activation by endogenous ligands (Maekawa et al., 2009) . 
In contrast with these results, the group of Qi demonstrated that, in C6 and CHO cells 
stabling expressing GPR17, neither UDP, UDP sugars, nor cysteinyl-leukotrienes activate 
GPR17 (Qi et al., 2013). The reasons for the discrepancies between the results obtained by 
different laboratories still remain to be clarified. 
 
1.2.1.2 GPR17 antagonists 
In the studies aimed at characterizing GPR17 pharmacological profile, the activity of some 
known purinergic and cysteinyl-leukotrienes antagonists was also assayed. As for agonists 
also for the antagonists the [
35
S]GTPγS binding assay was performed in 1321N1 cells 
expressing the receptor (long or short isoform of the human receptor, mouse and rat receptor). 
As nucleotide antagonists both cangrelor (N(6)-(2-methyl-tioetil)-2-(3,3,3-trifluoropropiltio)-
beta,gamma-diclorometilene-ATP), which is known to antagonize P2Y12 and P2Y13 (Ingall et 
al., 1999; Marteau et al., 2003; Fumagalli et al., 2004) and MRS2179 (2'-deoxy-N6-
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metiladenosina3',5'-bisphosphate) which antagonizes P2Y1 (Jacobson et al. 2002) were 
assayed; both molecules inhibit in a concentration-dependent the binding of the [
35
S]GTPγS 
stimulated by UDP -glucose, with nanomolar IC50 values. 
It was also demonstrated that a non-hydrolyzable analog of ATP, ATPβS, which does not 
act as an agonist neither on the short nor on the long form of the human receptor (Ciana et al., 
2006), may act as an antagonist in blocking in a concentration-dependent manner the 
activation of GPR17 induced by UDP-glucose and LTD4. The fact that this compound 
behaves as an antagonist is in agreement with the capacity of cangrelor and MRS2179, two 
derivatives of ATP (Abbracchio et al., 2006), to act as antagonists of GPR17. 
As cysteinyl-leukotriene antagonists, montelukast and pranlukast were assayed (Brink et 
al., 2003; Capra et al., 2006). Both these two compounds inhibit the activation induced by 
LTD4 of human, rat and mouse receptor, with values nanomolar IC50 typical of CysLT1. 
Due to the dual nature of this receptor, it was therefore hypothesized the existence of two 
distinct binding sites on the receptor: one for nucleotides and one for the cysteinyl-
leukotrienes. 
 
1.2.1.3 Identification of new GPR17 ligands 
In the last years, the importance of GPR17 as a promising therapeutic target for the 
treatment of neurodegenerative diseases characterized by demyelination and other human 
diseases has gradually consolidated. The need to have new molecules able to modulate the 
activity of this receptor is an important starting point for improving the atomic and molecular 
knowledge of GPR17. In this respect, the approach of the "drug discovery" is a good strategy. 
In the case of receptors such as GPR17 whose molecular structure is not yet known, the 
“Homology modeling” is a powerful approach to study ligand-receptor interactions. 
Moreover, in several cases this technique allowed to successfully predict the ligand-receptor 
interaction. 
Currently, there are two homology models of hGPR17. The first model is entirely based on 
the crystal structure of bovine rhodopsin (bRh), the only high-resolution crystal structure of a 
GPCR available at time of publication of the model, and then the only useful "template" for 
the homology modeling. This model allowed to successfully predict and characterize the 
binding site of endogenous ligands and various derivatives of GPR17 (Parravicini et al., 2008; 
2010; Calleri et al., 2010). Recently, thanks to protein engineering, a new GPR17 structure 
has been built (Figure 1.9) This is based on different templates: the human adenosine A2A 
 Introduction 
 
38 
 
receptor (hA2AR), the human β2-adrenergic receptor (hβ2AR), the turkey β1-adrenergic 
receptor (t β1AR) and squid Rh (Eberini et al., 2011). 
The availability of a more accurate model of the receptor, allowed the identification of five 
candidate agonist or partial agonist molecules, belonging to very different chemical classes, 
able to modulate GPR17 activity with higher potency and efficacy than the endogenous 
reference compounds. This represents the first step towards the rational identification of 
candidate molecules for the development of entirely novel drugs for demyelinating and 
ischemic diseases, for which no effective therapy is yet available (Eberini et al., 2011, see also 
below). 
 
Figure 1.9 – Tridimensional model of human GPR17 receptor. 
The color spheres represent the binding site predicted for extracellular nucleotides on the receptor. 
 
Recently another molecule has been proposed as potential modulators of this receptor, the 
MDL29,951 (Hennen et al., 2013). Specifically, using different targeted pharmacological 
assays (measurement of cAMP accumulation, [
35
S]GTPγS incorporation, inositol phosphate 
accumulation, Ca
2+
 release, label-free DMR and bioimpedance, and BRET assays), Hennen 
and co-workers demonstrated that in cell transfected with GPR17, stimulus with MDL29,951 
is able to activate the entire set of intracellular II messengers and their reciprocal cooperation. 
Specifically, through cAMP assay, they showed a dual modulation of the adenylyl cyclase, 
suggesting an engagement of either the Gs and Gi mediated pathways. The coupling to Gi 
subunit after treatment with MDL29,951 was further demonstrated blocking the inhibition of 
forskolin-induced cAMP increase with the pertussis toxin (PTX). Moreover, functional 
GPR17-mediated Gαq activity was confirmed by a specific inhibition of Ca
2+
 flux induced by 
the agonist. The same effects/responses were not found in control cells, suggesting that the 
activation of the various intracellular cascades is a consequence of the modulation of GPR17 
induced by the ligand MDL29,951 (Hennen et al., 2013). 
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1.2.2 Transduction signaling pathways activated by GPR17 
Studies on the system of signal transduction showed that, in cells transfected with GPR17, 
the receptor is mainly coupled to Gi protein that inhibits the activity of the enzyme adenylate 
cyclase and consequently the formation of cAMP (Ciana et al., 2006). It was also 
demonstrated the activation of Gq protein which, in turn, induce the activation of 
phospholipase C (PLC) and the increase of intracellular calcium levels. However, this 
transduction system does not seem to represent the main signaling pathway used by the 
receptor, as only 30% of the cells transfected with GPR17 is able to couple to PLC (Ciana et 
al., 2006). 
Similarly, studies carry on in rat primary OPCs, which express physiologically GPR17 
during a specific temporal window of their differentiation process (see paragraph 1.5.2), 
confirmed that this receptor is coupled to Gi and that its activation after the exposure to 
GPR17 agonists reduces cAMP levels (Fumagalli et al., 2011). Furthermore, the siRNA-
induced GPR17 knock-down supports the hypothesis that the effects on cAMP levels 
observed after treatment with GPR17 agonists are specifically mediated by this receptor: in 
fact, they are completely obliterated in GPR17-silenced cells. No effect on the calcium 
intracellular levels was observed after GPR17 agonists exposure in primary OPCs, suggesting 
that, in this native system, GPR17 is not associated with protein-Gq (Fumagalli et al., 2011). 
It has also been demonstrated by electrophysiological studies in 1321N1 cells stably 
expressing the hGPR17 that the activation of the receptor with micromolar concentrations of 
UDP, UDP-glucose and UDP-galactose and with nanomolar of LTD4 leads to an increase of 
the outward potassium currents while the treatment with MRS2179, specific antagonist for 
P2Y1, but also active on GPR17, blocks this effect (Pugliese et al., 2009). It seems that the 
effect observed is due to the activation of large-conductance, Ca
2+-
activated BK (or maxi-K) 
potassium channels widely expressed in human glioma cells (Basrai et al., 2002). These ion 
channels react to increases in intracellular Ca
2+
 and membrane depolarization, which follow 
an acute ischemic stroke, by increasing K
+
 efflux, rapidly hyperpolarizing the membrane and 
reducing further voltage-dependent Ca
2+
 influx (Gribkoff et al., 2001).  
 
1.2.3 GPR17 expression profile 
So far the majority of the studies on GPR17 have been performed in rodent models (rats 
and mice). However, the receptor was first identified in a cDNA library from human 
hippocampus (Blasius et al, 1998). The expression of GPR17 in the human brain was lately 
confirmed by mRNA analysis from different human tissues (Ciana et al, 2006). hGPR17 is 
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expressed at high levels in organs or tissues that can undergo ischemic damage, namely brain, 
heart and kidney (Ciana et al., 2006). The long form is, instead, expressed exclusively in the 
brain, especially in the cortex and striatum (Pugliese et al., 2009; Benned-Jensen and 
Rosenkilde, 2010).  
Other studies showed GPR17 expression on human and mouse mastocysts and bone 
marrow derived monocytes (Maekawa et al, 2009; Maekawa et al, 2010), where the receptor 
seems to tightly co-localize with CysLTRl. Finally, and most interesting, a trascriptome 
analysis performed on human and mouse adult neural stem cells and fetal embryonic tissue 
revealed expression of the receptor specifically in adult neuroprogenitors (Maisel et al, 2007).  
Concerning the GPR17 expression in the brain, the same pattern of expression observed in 
human has also been confirmed in rats and mice (Ciana et al, 2006; Lecca et al, 2008). In fact, 
immunohistochemistry experiments carried on in our laboratory demonstrated that, in rat and 
mouse brain cortex, GPR17 is expressed by two distinct cell types: 
• neurons: where it co-localizes with typical neuronal proteins, SMI-311 (neurofilament 
marker), β-tubulin (neuronal specific tubulin) and NeuN (neuronal nuclear protein) 
• numerous cells dispersed in both grey and white matter, displaying small cell bodies 
with fine radiating processes and expressing typical OPC markers, such as NG2 and 
Olig2. 
No co-localization of GPR17 was found with more mature myelinating oligodendroglial 
markers, such as CNPase, myelin-associated glycoprotein (MAG) and myelin basic protein 
(MBP) suggesting that GPR17 may be expressed at a specific stage of oligodendroglial 
differentiation.  
In mice and rats, GPR17 was never found in astrocytes (no co-localization with GFAP, 
glial fibrillary acidic protein), and in non-activated microglia (no co-localization with Iba) 
assuming therefore that the receptor is not localized in these cell types (Lecca et al., 2008). 
GPR17 is instead co-expressed with the marker IB4 in activated microglia (Lecca et al., 
2008). 
Recently, the first characterization of GPR17 expression in neurosurgical and autoptic 
samples from patients with traumatic brain injury (TBI) has been published. In this study 
through immunohistochemistry analysis it has been demonstrated that GPR17 co-localizes 
with various specific markers of brain cells. Specifically, it has been shown that, in the 
damaged area, the receptor is expressed by injured neurons (NeuN
+
 in post-surgical samples; 
MAP2
+
 in autoptic samples), by a subpopulation of hypertrophic astrocytes (GFAP
+
) with a 
stellate morphology, by infiltrating cells that participate in the processes of repair engulfing 
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the dead cells, microglia/macrophages (IB4
+
 tissues in post-surgical samples, Iba1
+
 in autoptic 
samples), and OPCs (CNPase
+
 and O4
+
 in autoptic samples). Furthermore, through a spatio-
temporal gradient analysis, it was shown that GPR17 expression is very strong in cells inside 
and at the borders of the necrotic core. These cells are activated microglia/macrophages; more 
externally GPR17 is expressed by activated astrocytes. Concerning neurons, a reduction of 
GPR17 expression has been observed as the distance from the injured area increased; finally, 
in the most distal areas, GPR17 is also found in ramified cells expressing O4 and CNPase, 
thus confirming that they are OPCs (Figure 1.10). These results confirm the findings from the 
studies in rodents concerning the distribution of the receptor in the damaged brain and its 
involvement in repair processes (Franke et al., 2013).  
 
 
Figure 1.10 - Spatial gradient of GPR17 expression in various types of neural cells in autoptic 
specimens from TBI patients. 
GPR17 expression was very strong in cells inside and at the borders of the necrotic core (zones I and 
II, also indicated as PCZ in the central drawing) and then gradually declined in zones (III) and (IV). 
Dense immunoreactive red spots in zones (I) and (II) of the central drawing likely represent shrunk 
dying or already dead cells, or fragments of necrotized cells. Green circles in zone (II) represent cells 
costaining for both GPR17 and the microglial marker Iba1 (a), thus representing activated globose 
microglia. In zone (III), stellate GPR17/GFAP double-positive reactive astrocytes were found (yellow 
cells indicated by arrows in b). GFAPpositive, GPR17-negative astrocytes (red cells in b; see also 
cells indicated by thick short arrows in d) were also present. Starting from zone (III) and throughout 
zone (IV), many pyramidal cells costaining for GPR17 and the neuronal marker MAP2 were present 
(c). In these zones, several GPR17-expressing cells that, however, did not stain for anyone of the 
previously mentioned markers (including GFAP) were also detected (green fluorescent cells indicated 
by long thin arrows in d and e). The morphology of these cells was reminiscent of that of OPCs. 
Nuclei are labeled with Hoechst 33258 dye (Hoe, blue fluorescence). Scale bars=10 μm (a, b, d, e) 
and 20 μm (c) (from Hanke et al., 2013). 
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1.2.4 GPR17 function 
Studies aimed at understanding GPR17 function have been performed in two tissues: the 
CNS (brain and spinal cord) and the immune-system (Ceruti et al, 2011; Ciana et al, 2006; 
Lecca et al, 2008; Maekawa et al, 2010; Mao et al., 2013). Only one study has been published 
on the modulation of the immune response to allergenes by GPR17 activation (Maekawa et al, 
2010). As previously mentioned GPR17 is co-expressed on dendritic cells together with 
CysLTR1. In case of forced allergene (dust) exposure, GPR17 seems to negatively modulate 
the response of CysLTR1-mediated inflammatory cell accumulation. This observation opens 
the possibility to use GPR17 ligands to positively modulate the immune reaction to 
allergenes. 
On the other hand, more numerous are the studies aimed at understanding GPR17 function 
in the CNS. GPRl7 therapeutic potential was first assessed in a rat model, and subsequently in 
a mouse model, of ischemia (MCAo, medial cerebral artery occlusion) (Ciana et al, 2006; 
Lecca et al, 2008). rGPR17 was shown to be expressed in neurons, OPCs and in microglial 
cells upon pathological condition. The application of a P2Y antagonist and more specifically 
the use of anti-sense oligonucleotide targeting GPR17 are sufficient to reduce the penumbra 
area of the ischemic damage. It is not clear, however, if the ischemic damage reduction is due 
mainly to the effect on a specific cell type or if it was more general. Therefore, in this case 
GPR17 appears to be pro-inflammatory and its blockage, with the antagonist and anti-sense 
oligonucleotide, improves functional recovery (Ciana et al, 2006; Lecca et al, 2008).  
Use of the anti-sense oligonucleotide, gave positive results in terms of damage reduction 
and functional recovery also in a model of spinal cord injury (SCI), again suggesting an active 
role of GPR17 in damage propagation (Ceruti et al, 2009). In this scenario the function of 
GPR17 was described to be temporal and cellular specific; the first response to injury 
provokes neuronal and OL death through GPR17 activation; later, the recruitment of 
microglia and GPR17
+
-macrophages seems to shed the first steps of tissue remodeling and 
repair, that was followed by the up-regulation of GFAP, as a marker of stem-cell like 
properties, on GPR17 positive ependymal cells. The multiplicity of roles exploited by GPR17 
in the SCI model can be explained by the diverse actions that its endogenous ligands, 
abundantly released during injury, may play. 
The fact that GPR17 may act as sensor for white matter damage has also been confirmed in 
a recent work in which, an animal model of periventricular leukomalacia (PVL), that is the 
most common ischemic brain injury in premature infants, has been used. In this work, it has 
been shown that GPR17
+
-glial progenitor cells, within the white matter, together with the 
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progenitors cells of the SVZ, are significantly increased after an ischemic event and migrate 
towards the lesion to support its repair. However, the endogenous self-repair capacity of these 
cells appear to be limited, since the more mature OLs do not completely recover from 
experimental ischemia. This limitation is likely associated with cerebral microenvironmental 
factors, such as ischemia-induced intracellular calcium overload, excitotoxicity caused by 
overstimulation or secondary effects from over-expression of certain immediate-early genes 
(Mao et al., 2013). 
Taken together the data described above suggest that GPR17 represents an interesting 
target to develop new approaches to foster tissue repair in different pathological conditions. 
 
1.2.5 Role of GPR17 in OL differentiation 
In vitro studies in rat postnatal OPC cultures, showed that GPR17 expression labels a 
specific temporal window of OL differentiation process. Specifically, during the early stages 
of differentiation, GPR17 receptor decorates two subsets of slowly proliferating cells. The 
first one corresponds to early, morphologically immature slowly proliferating NG2
+
 precursor 
cells that also express Olig2, PDGFRα, and the immature PLP isoform DM-20; the second 
one corresponds to more ramified, still immature pre-oligodendrocytes that are losing NG2 
and PDGFRα immunoreactivity and already express O4, O1, and the two splicing variants of 
the myelin protein PLP (Figure 1.11). After this differentiation stage, GPR17 expression is 
progressively turned down, and the GPR17 protein is never found in fully mature MAG
+
 or 
MBP
+
 OLs (Fumagalli et al., 2011).  
In this cells, it has been demonstrated that GPR17 receptor has a functional role during the 
differentiation process; in fact, its activation by UDP-glucose (100 μM) or LTD4 (100 nM) for 
72 hours, induces a significant increase in the number of MBP
+
-cells (Lecca et al., 2008; 
Fumagalli et al., 2011). Additional in vitro data also show that, GPR17 antagonists (for 
example, cangrelor) or knock-down by siRNAs impaires the normal differentiation program 
of OPCs (Fumagalli et al., 2011). These data suggest that GPR17 may be involved in the 
control of the transition from OPCs to mature myelinating OLs enabling the repair or 
damaged myelin. 
In support to these data, recent studies have also shown that GPR17 activation by UDP-
glucose enhances delayed rectifier K
+
 currents without affecting transient K
+
 conductances. 
This effect was observed in a subpopulation of OPCs (NG2
+
) and immature pre-OL (O4
+
) 
whereas it was absent in mature OLGs, in line with GPR17 expression, that peaks at 
intermediate phases of OL differentiation and is thereafter down-regulated to allow terminal 
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maturation. The effect of UDP-glucose on K
+
 currents is concentration-dependent, blocked by 
the GPR17 antagonists MRS2179 and cangrelor, and sensitive to the K
+
 channel blocker 
tetraethyl-ammonium (TEA), which also inhibits OL maturation. Moreover, the effect 
observed parallels the expression of distinct voltage-dependent currents during OPC 
differentiation. In fact, while in OPC progenitors most currents are represented by outward 
rectifying conductances (Ik), in mature OL inwardly rectifying currents (Kir) prevail. 
Altogether these data suggest the enhancement of IK currents after UDP-glucose exposure is 
responsible for the GPR17-mediated facilitating effect in OPC maturation (Coppi et al., 
2013). 
 
 
Figure 1.11 - Cangrelor delays and UDP-glucose accelerates OPC differentiation in vitro. 
After GPR17 agonists treatment, cells were fixed and immunostained with anti-GPR17, anti-MBP, and 
anti-CNPase antibodies. A, histograms show quantification of the percentage of cells expressing the 
indicated OL markers in control and treated cells (with vehicle-treated control cells set to 100%). 
Hoechst 33258 was used to label cell nuclei. Data are the mean ± S.E. (**, p<0.001; *, p<0.05 
compared with control, one-way ANOVA, followed by Bonferroni’s multiple comparison test. #, 
p<0.01 compared with control, Student’s t test). B, representative images of control, cangrelor-, or 
UDP-glucose-treated cells show double immunostaining with anti-GPR17 and anti-MBP antibodies. 
Nuclei were labeled with Hoechst 33258. Scale bars, 15μm. (from Fumagalli et al., 2011). 
 
 
It was also observed that the receptor has a different intracellular localization depending on 
the differentiation stage: during the first day in culture, it is present within the compartments 
of synthesis of OPCs, while in more advanced differentiation stages it is found on the cell 
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surface and within the endosomal compartments. This observation suggests the hypothesis of 
a possible link between the subcellular distribution of GPR17 and the maturation process of 
these cells. In this regard, a recent in vitro study in Oli-neu cells, an immortalized OPC cell 
line, showed that the exposure to UDP-glucose and LTD4 induces GPR17 internalization, 
which is delivered into early endosomes and sorted either to lysosomes for degradation or 
recycled to the cell surface via small G-protein Rab4-dependent pathway. GPR17 down-
regulation is the results of these two processes. It has been propose that this is a key event 
necessary to allow OPCs to proceed to myelination (Fratangeli et al., 2013).  
Recently, in astrocytes-OPCs mixed cultures, it has been demonstrated that the expression 
of GPR17 receptor is markedly influenced by culturing conditions (Ceruti et al., 2011). In the 
presence of growth factors (GFs), no significant GPR17 expression is found. On the contrary, 
when cultures are shifted to a differentiating medium, a dramatic, time-dependent increase in 
the number of highly branched GPR17
+
-cells is observed. Under these conditions, GPR17 is 
induced in the totality of O4
+
-immature OLs. In the same work, it was also shown that the 
addition of ATP to the culture medium without GFs induces cell death, suggesting that 
GPR17 act as danger signal in the presence of high extracellular ATP concentrations. The 
influence of culturing conditions on GPR17 receptor was also demonstrated in Oli-neu cells 
line, in which the expression of the receptor is increased by factors released from neurons and 
astrocytes (Fratangeli et al, 2013). 
A recent work has also demonstrated through a chromatin immunoprecipitation (ChIP), 
that the transcription factor Olig1 can directly bind to the promoter of GPR17 and regulates it 
negatively. Accordingly, GPR17 was also identified as one of the genes down-regulated in 
Olig1 mutant mice (Chen et al., 2009). In this work, GPR17 has been proposed as a negative 
regulator of the OPC differentiation. Both in vitro and in vivo (using a mouse model) it has 
been demonstrated that GPR17 over-expression blocks OPC maturation and, in some cases, 
induces death. In fact, although the precursors are properly generated, they are not able to 
proceed in the differentiation process and, as a consequence, there is a defective 
myelinogenesis and hypomyelination (Chen et al., 2009).  
An in vivo study has shown that, in cerebral cortex, during ontogeny, GPR17 expression in 
the oligodendroglial lineage precedes the production of myelin. Immediately after birth, the 
receptor is not expressed, but it progressively appears in an increasing fraction of OPCs which 
stop proliferating and start differentiating up to covering the majority of immature OLs (Boda 
et al., 2011). Similarly to what observed during the development in the rodent cerebral cortex, 
GPR17 expression begins to be detectable soon after birth within the spines and gradually 
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increases until P14. Subsequently, it undergoes a strong decline, in parallel with the beginning 
of myelinogenesis (Figure 1.12). Finally, according to Chen and co-workers, GPR17 prevents 
OPC differentiation allowing the translocation into the nucleus of two potent repressors: ID2 
and ID4. They belong to the family of transcription factors bHLH (basic proteins HLH) and 
they block OPC differentiation. Accordingly, in vitro studies showed that there is an over-
expression of ID2 in the proliferating OPCs, in which the differentiation is slowed or stopped; 
the levels of this repressor are instead reduced during OPC maturation towards mature 
myelinating OLs. It is known that these repressors are able to go into the nucleus by passive 
diffusion thanks to their small size, but during OPC differentiation, they are internalized in 
this compartment through an active transport mechanism. Once inside the nucleus, they form 
a complex with Olig1/2 and E47, so that they prevent these factors to bind DNA. As a result 
OPC differentiation is inhibited. On the contrary, during OPC differentiation, ID2 is found in 
the cytoplasm associated with Enigma Homolog (ENH), a cytoskeletal protein, thus allowing 
Olig1/2 and E47 to bind DNA and to induce the transcription of myelin genes. Specifically 
Olig1 represses GPR17 thus promoting OPC maturation (Kondo and Raff, 2000; Wang et al., 
2001; Chen et al., 2009; 2012). It has to be highlighted that, in the GPR17 over-expressing 
mice used in this work, GPR17 expression is under the control of an OL-expressing CNP1 
promoter. It means that, when CNPase is produced, GPR17 is transcribed (Chen et al., 2009). 
As mentioned above, our studies suggest that, GPR17 levels are strongly reduced when 
CNPase starts appearing in immature OLs. Thus, GPR17 forced expression at this stage of 
differentiation, could seriously affect and compromise the oligodendrogliogenesis, making 
this animal model highly contestable. 
However, these data demonstrate a close relationship between GPR17 and the myelination 
process, suggesting a possible role of this receptor in demyelinating diseases. In fact, it was 
also observed that, both in patients with MS and in animal models of EAE (Experimental 
Autoimmune Encephalomyelitis), that is a well established model of MS, GPR17 levels are 
higher compared to controls, and this alteration may explained the failure of remyelination 
observed in this pathological conditions (Chen et al., 2009). Furthermore, as described in the 
previous paragraphs, after a traumatic, ischemic or demyelinating injury GPR17
+
-OPCs 
accumulate within the damaged area in order to take part to the reparative processes (Lecca et 
al., 2008; Ceruti et al., 2009; Boda et al., 2011).  
 
 Introduction 
 
47 
 
 
Figure 1.12 - Maturation pattern of postnatal GPR17 positive cells. 
(A–D’): Changes in GPR17 and MBP expression from birth to adult stages. GPR17-positive cells 
were already present at birth (A). GPR17 expression increased over time (B and C) and declined in 
the adult cortex (D). MBP protein was instead not detectable until P7 (A’ and B’), whereas its 
expression level augmented at later time points (C’ and D’). (E) Western blot analysis of GPR17 and 
MAG proteins revealed the presence of GPR17 before MAG production has started. Furthermore, 
GPR17 protein appeared down-regulated before massive MAG protein production (modified from 
Boda et al., 2011). 
 
In contrast with the data described above, in a recent paper, Hennen and co-workers 
proposed GPR17 as a negative regulator of myelinogenesis (Hennen et al., 2013). In this 
paper this group sustained that the receptor should be block in order to promote OPC 
maturation. Specifically, they showed that in OPC cultures from heterozygous (GPR17
+/−
), 
but not homozygous (GPR17
−/−
) mice, MDL29,951 markedly attenuate the capacity of OLs to 
differentiate suggesting that the addition of GPR17 antagonists to anti-inflammatory drug 
cocktails that are already used in the management of MS may be an innovative strategy to 
promote remyelination (Hennen et al., 2013). 
Although the conflicting results obtained by different groups within the scientific 
community, GPR17 remains an attractive candidate for the developing of new 
pharmacological compounds. Further studies will clarify whether it will be more useful to 
obtain molecules enabling the activation or the block of this receptor. 
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1.3 The mammalian target of rapamycin (mTOR) 
The mammalian target of rapamycin (mTOR) was identified and cloned (Brown et al. 
1994; Chiu et al. 1994; Sabatini et al. 1995) shortly after the discovery of the two yeast genes, 
TOR1 and TOR2, in the budding yeast Saccharomyces cerevisiae during a screen for 
resistance to the immunosuppressant drug rapamycin (Kunz et al. 1993; Helliwell et al. 1994). 
Rapamycin was originally identified as an antifungal compound derived from Streptomyces 
hygroscopicus, present in soil samples collected from Easter Island (Dennis et al., 1999). It 
acts by forming an inhibitory complex with its intracellular receptor, the FK506-binding 
protein, FKBP12, which binds a region in the C terminus of TOR proteins termed FRB 
(FKB12–rapamycin binding), thereby inhibiting TOR activity (Chen et al. 1995; Choi et al. 
1996).  
mTOR is a highly evolutionarily conserved serine/threonine protein kinase belonging to 
the phosphoinositide 3-kinase (PI3K) family. It is ubiquitously expressed in cells and it 
regulates multiple cellular functions including survival, proliferation, organogenesis and 
differentiation of numerous cell types (Hwang et al., 2008). Mammalian genomes encode a 
single TOR protein with a similar structure exhibiting ∼42% amino acid sequence identity to 
the yeast TOR proteins. TORs are high molecular weight proteins that contain several distinct 
and conserved structural domains. mTOR contains 2549 amino acids and comprises several 
conserved structural domains (Figure 1.13). The N-terminus possesses 20 tandem HEAT (for 
Huntignton, EF3, A subunit of PP2A, TOR1) repeats. Each HEAT repeat consists of two 
helices of ∼40 amino acids, each with a specific pattern of hydrophobic and hydrophilic 
residues. The C-terminal half of mTOR contains the kinase domain. Immediately upstream of 
the catalytic domain is the FRB domain, which is involved in the interaction with FKBP12, 
the intracellular receptor of rapamycin. In addition, mTOR contains a relatively large FAT 
(for FRAP, ATM, TRAP) domain, which is also present in other PIKK proteins (Bosotti et al. 
2000). The C-terminal end contains another FAT domain, designated FATC that is absolutely 
necessary for mTOR activity, and the deletion of even a single amino acid from this domain 
abrogates its activity (Peterson et al. 2000; Takahashi et al. 2000). mTOR also contains a 
putative negative regulatory domain (NRD) between the catalytic and FATC domains.  
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Figure 1.13 – Scheme representing the structural domains of mTOR kinase. 
mTOR is a highly evolutionarily conserved serine/threonine protein kinase whose structure contains: 
the HEAT domain consisting of a flexible structure found in several cytoplasmic proteins; the FAT 
(for FRAP-ATM-TRAPP kinases) domain that is a homology region found in PI3-Kinase-related 
kinases; the FATC (FAT COOH-terminal) domain that is a highly conserved COOH-terminal domain, 
which regulates the function of mTOR; the FRB (FKBP12-rapamycin binding) domain that is the 
region recognized by the immunosuppressant drug rapamycin bound to immunophylin FK506 binding 
protein 12 (FKBP12) (from Hay and Sonenberg, 2004). 
 
 
mTOR is linked to diverse cellular physiological functions that ultimately control cell and 
body growth. In the whole organism, mTOR plays a role in development, metabolism, 
memory and aging. At the cellular level, this kinase responds to the presence of nutrients and 
other growth cues (see below for details). It functions to regulate translation initiation, 
ribosome biogenesis and autophagy through mTORC1 and actin cytoskeleton reorganization 
through mTORC2 (see paragraph 1.3.1). Recently, evidence has indicated that mTOR is also 
involved in transcriptional regulation and RNA processing (Hannan et al., 2003; Cunningham 
et al., 2007; Willis and Moir, 2007; Kantidakis et al., 2010; Shor et al., 2010). Deregulation of 
mTOR signaling pathway is associated with the onset of pathological conditions including 
cancer, immune-related diseases, diabetes, cardiovascular and neurological disorders. 
1.3.1 mTORC1 and mTORC2 
mTOR exists in two functionally distinct complexes, the mTORC1 (raptor–mTOR 
complex) and the mTORC2 (rictor–mTOR complex). mTORC1 (Figure 1.14) is a 
heterotrimeric protein complex that functions as a nutrient/energy/redox sensor and controls 
protein synthesis (Hay and Sonenberg, 2004). mTORC1 is composed of mTOR itself, 
regulatory-associated protein of mTOR (Raptor), which positively regulates mTOR activity 
and acts as a scaffold for the recruitment of mTORC1 substrates (Hara et al., 2002; Kim et al., 
2002), mammalian lethal with SEC13 protein 8 (MLST8), whose role remains unclear at 
present and the recently identified PRAS40 and DEPTOR (Kim et al., 2002; 2003; 
Wullschleger et al., 2006). The activity of this complex is controlled by hormones, growth 
factors, cytokines and oxidative stress (Kim et al., 2002; Fang et al., 2001). In addition to 
extracellular stimuli, mTORC1 is responsive to internal signals. For example, when cellular 
 Introduction 
 
50 
 
energy is low, the AMP kinase (AMPK) blocks mTORC1 activity, via activation of the 
inhibitory protein TSC (tuberous sclerosis complex) 2. Moreover, the activity of mTORC1 is 
also sensitive to nutrient availability. Increasing the cellular concentration of amino acids, 
such as leucine, activates mTORC1, although the molecular mechanisms are not fully 
elucidated (Garelick and Kennedy, 2011).  
 
 
Figure 1.14 - Scheme representing the molecular partners of mTORC1 and its main intracellular 
targets. 
The complex is critically involved in the regulation of protein translation. Phosphorylation of the 
eukaryotic initiation factor 4E-binding protein 1, 4E-BP1, by mTORC1 enables the elongation 
initiation factor, (eIF)-4E to associate with eIF-4G leading to the formation of eIF-4F, which 
facilitates the loading of ribosomes onto the mRNA. Phosphorylation of the ribosomal S6 protein 
kinase 1, p70S6K, by mTORC1, is followed by the phosphorylation of eIF-4B and the eukaryotic 
elongation factor 2 (eEF2) kinase, which facilitate protein synthesis (from Dello Russo et al., 2013). 
 
 
The activation of mTORC1 generally increases the cellular capacity of protein generation. 
The two main downstream targets on mTORC1, the eukaryotic initiation factor 4E-binding 
protein 1 (4E-BP1) and the ribosomal S6 protein kinase 1 (p70S6K), are key components of 
the protein translation machinery (Ma and Blenis, 2009). In fact, the regulation of the 
initiation process of protein translation is the most well characterized action regulated by the 
mTORC1 pathway. Phosphorylation of 4E-BP1 by mTORC1 induces the dissociation of 4E-
BP1 from the eukaryotic translation initiation factor (eIF)-4E. This allows eIF-4E to associate 
with eIF-4G leading to the formation of eIF-4F, which facilitates the loading of ribosomes 
onto the mRNA. Phosphorylation of the p70S6K by mTORC1 also promotes the initiation of 
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protein translation by the phosphorylation of eIF-4B and regulates protein elongation through 
the phosphorylation of the eukaryotic elongation factor 2 (eEF2) kinase. The activation of 
p70S6K facilitates the role of the eEF2 kinase in the elongation process (Proud, 2007). 
Finally, the cellular capacity of protein generation is also controlled by mTORC1-mediated 
suppression of macroautophagy (autophagy).  
mTORC2 complex is composed of mTOR, rapamycin-insensitive companion of mTOR 
(Rictor), GβL, and mammalian stress-activated protein kinase interacting protein 1 (mSIN1) 
(Weichhart and Sӓemann, 2009) (Figure 1.15). It appears to be regulated by insulin, growth 
factors, serum, and nutrient levels (Frias et al., 2006). Originally, mTORC2 was identified as 
a rapamycin-insensitive entity, as acute exposure to rapamycin did not affect mTORC2 
activity or Akt phosphorylation (Sarbassov et al., 2005). However, subsequent studies have 
shown that, at least in some cell lines, chronic exposure to rapamycin, while not affecting pre-
existing mTORC2, promotes rapamycin inhibition of free mTOR molecules, thus inhibiting 
the formation of new mTORC2 (Sarbassov et al., 2006). 
 
 
Figure 1.15 - Scheme representing the molecular partners of mTORC2 and its main intracellular 
targets. 
The complex is involved in the regulation of cell proliferation through the activation of Akt signaling 
pathway and cytoskeleton modification through the activation of PKC (from Dello Russo et al., 2013). 
 
 
In comparison with mTORC1, the biological function of mTORC2 is less well understood. 
It is known that its main target is Akt kinase that is phosphorylated by this protein complex at 
Ser
473
 (Hresko and Mueckler, 2005). Phosphorylation of this serine stimulates Akt 
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phosphorylation at a threonine T308 residue by PDK1 and leads to full Akt activation. As 
consequences, nutrient uptake and cell survival are promoted (Sarbassov et al., 2005). Every 
components of mTORC2 are essential; deletion or knock-down of rictor, Sin1, or 
mLST8/GbL has a dramatic effect on mTORC2 assembly and activation of Akt (Guertin et 
al., 2006). Interestingly, mTORC2 provides a quality control in the process of protein 
production by phosphorylating amino acid residues in nascent polypeptide chains, as it occurs 
during Akt protein translation (Oh et al., 2010). This complex is also involved in the 
regulation of actin cytoskeleton dynamics (Jacinto et al., 2004), by promoting the 
phosphorylation of protein kinase C and paxillin (Sarbassov et al., 2004). In conclusion, 
mTORC1 and mTORC2 contribute to integrate signals from growth factors, nutrients and 
stress, with the final effect of promoting anabolic and inhibiting catabolic intracellular 
processes (Foster and Fingar, 2010).  
 
1.3.2 mTOR in OL differentiation 
In the past three years, different in vivo and in vitro studies have demonstrated that the 
kinase Akt plays an important role in the regulation of OL differentiation and myelin 
formation in the CNS. Specifically, it has been shown that in transgenic mice over-expressing 
constitutively active Akt in OLs have increased expression of mTOR and increased 
myelination (Flores et al., 2008). In this mice, long-term exposure to rapamycin prevents the 
hypermyelinating phenotype, but has no effect on myelin maintenance in the normal adult 
CNS (Narayanan et al., 2009). The involvement of mTOR signaling in the regulation of OL 
functions was confirmed by in vitro studies. Tyler and co-workers demonstrated that 
inhibition of mTOR by rapamycin interferes with the development of GalC positive immature 
OLs in purified OPC cultures. They also proposed different functions for the two mTOR 
complexes during OL differentiation. While mTORC1 regulates myelin protein synthesis by 
interfering with protein translation, mTORC2 interferes with mRNA transcription of several 
myelin genes. Interestingly, intense mTOR activation was found during postnatal rat brain 
development, particularly in the white matter as myelination peaked in the forebrain. The 
involvement of mTOR in OL differentiation, albeit in a later stage of this process, was 
demonstrated also by Guardiola-Diaz et al., (2012). However, this group demonstrates that the 
mTOR inhibition by rapamycin does not impair the differentiation from late progenitors 
O4
+
/GalC
-
 to immature OL O4
+
/GalC
+
, but that this pathway blocks only the late stage of 
differentiation, from immature to mature OLs (Guardiola-Diaz et al., 2012). This different 
observation is likely due to the in vitro conditions used in the experiments. Moreover, 
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activation of mTOR signaling was found to be critical for cytoskeletal organization and the 
expression of normal levels of major myelin proteins in vitro, and for the onset of myelination 
in the postnatal mouse brain. 
Thus, both in vivo and in vitro works underlie the importance of the mTOR signaling in 
driving terminal differentiation of OLs and myelination. However, the specific targets of 
mTOR in differentiating OLs remain to be defined. Some aspects of the differentiation and 
myelination programs have been proposed to be regulated by the mTOR signaling. These 
include nuclear regulation of differentiation, cytoskeletal rearrangements involved in 
morphological maturation and processes necessary for myelin synthesis (Wood et al., 2013). 
Concerning the nuclear regulation, it is known that the initial stages of OPC differentiation 
require chromatin remodeling and transcriptional regulation. During these events, inhibitors 
of differentiation are down-regulated and, then, factors necessary for myelin gene 
transcription are up-regulated (Li et al., 2009). Several negative regulators of OL 
differentiation have been identified including the ID (inhibitor of DNA binding/ 
differentiation) helix–loop–helix members ID2 and ID4 and TCF4/TCF7L2 (T cell factor 4). 
It has been demonstrated that rapamycin-treated cultures have elevated levels of ID2, ID4 and 
TCF4/TCF7L2 RNA expression, which correlate with a block in OPC differentiation (Tyler et 
al., 2009). Based on these data, it has been proposed that the mTOR signaling has a role in 
transcriptional regulation of OL differentiation, specifically by directly decreasing these 
negative transcriptional regulators or indirectly suppressing BMP signaling which is able to 
increase mRNA and protein levels of ID2 and ID4 (Wood et al., 2013; Samanta and Kessler, 
2004; Cheng et al., 2007).  
Concerning the cytoskeleton modification, it is known that the OPC differentiation implies 
profound morphological changes which are the consequences of continuous cytoskeleton 
rearrangements. A recent report supports the hypothesis that mTOR signaling underlies this 
event. Proteins identified and confirmed in the mTOR-regulated proteome with known roles 
in cytoskeleton include Fyn tyrosine kinase, Sirt2, βIV-tubulin, Gap43 and BASP-1 (Tyler et 
al., 2011). As discussed previously, a major mechanism for mTOR regulation of cytoskeleton 
in developing OLs is likely via mTORC2 (Tyler et al., 2009; 2011).  
Finally, it is believed that the mTOR pathway regulates numerous processes necessary for 
myelin synthesis. For example, mTOR induces expression of multiple lipogenesis proteins as 
OLs differentiate (Tyler et al., 2011). According to this, it has been demonstrated that Fasn 
(fatty acid synthase) is expressed in OLs late in brain development and is dramatically 
decreased in mTOR-inhibited OLs (Saito et al., 2009; Tyler et al., 2011). Similarly, fdft1 
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(farnesyl-diphosphate farnesyltransferase 1), a cholesterol synthetic enzyme essential for 
myelin production (Saher et al., 2005), is also part of the mTOR-regulated proteome (Tyler et 
al., 2011). Several other lipid biosynthetic proteins including the cholesterol biosynthesis 
proteins Idi1 (isopentyenyl-diphosphate d-isomerase), Fdps (farnesyl pyrophosphate 
synthetase) and Hmgcs1 (hydroxymethylglutaryl-CoA synthase) and the Acsl3 and Acsl4 
(fatty acid biosynthesis enzymes long-chain-fattyacid- CoA ligase 3 and 4) (Tyler et al., 2011) 
were also identified in the mTOR proteome screen. Taken together, these studies support an 
essential role for mTOR signaling in lipogenesis in maturing OLs initiating myelin production 
(Wood et al., 2013). 
To conclude, altogether these data indicate the existence of a link between mTOR and OL 
differentiation and myelination. Further studies, also the ones described in this thesis, will 
help to better understand the physiological role of this interaction and to clarify whether this 
pathway could be a new pharmacological target for remyelination strategies. 
1.4 G protein-coupled receptor desensitization 
G protein-coupled receptors (GPCRs) constitute a superfamily of seven transmembrane 
spanning proteins that respond to a huge variety of stimuli (both sensory and chemical). Once 
activated, they transduce the information provided by these stimuli into intracellular second 
messengers that are interpreted as meaningful signals by the cell. This process involves the 
coupling of agonist-activated GPCRs to different effector systems via their interaction with 
heterotrimeric guanine nucleotide binding proteins (G proteins). The binding of agonist to a 
GPCR, selects for a receptor conformation state that promotes the exchange of GDP for GTP 
on the G protein α-subunit and is presumed to allow the dissociation of the G protein Gα- and 
Gβγ-subunits (Neer, 1995; Surya et al., 1998). Subsequently, the activated Gα- and Gβγ-
subunits positively and/or negatively regulate the activity of effector enzymes and ion 
channels (Neer et al., 1995; Gautam et al., 1998).  
GPCR activity represents a coordinated balance between molecular mechanisms governing 
receptor signaling, desensitization, and resensitization. Receptor desensitization, represents an 
important physiological “feedback” mechanism that protects against both acute and chronic 
receptor overstimulation. This process is the result of the activation and of the recruitment of 
three families of regulatory molecules: second messenger-dependent protein kinases, G 
protein-coupled receptor kinases (GRKs) and arrestins (Ferguson, 2001). 
GPCRs desensitization involves different mechanisms: (i) the uncoupling of the receptor 
from heterotrimeric G proteins in response to receptor phosphorylation, (ii) the internalization 
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of cell surface receptors to intracellular membranous compartments and (iii) the down-
regulation of the total cellular complement of receptors due to reduced receptor mRNA and 
protein synthesis, as well as both the lysosomal and plasma membrane degradation of pre-
existing receptors (Ferguson, 2001) (Figure 1.16). 
The uncoupling of GPCRs from heterotrimeric G proteins is the consequence of a covalent 
modification of the receptor (phosphorylation) mediated by intracellular kinases. It is 
generally accepted that both second messenger-dependent protein kinases (cAMP-dependent 
protein kinase (PKA) and protein kinase C (PKC)) and GRKs phosphorylate serine and 
threonine residues within the intracellular loop and carboxyl-terminal tail domains of GPCRs.  
 
Figure 1.16 - Molecular mechanisms involved in the GRK- and β-arrestin dependent desensitization 
and internalization of GPCRs. 
As shown in the scheme, desensitization, internalization and recycling of GPCRs are intimately 
connected. The whole process is initiated by binding of an agonist to the receptor, which triggers a 
signal (usually via heterotrimeric G-proteins). However, agonist binding also converts the receptor 
into a substrate for a family of kinases, the G-protein-coupled receptor kinases (GRKs). These kinases 
phosphorylate only agonist-activated receptors. Subsequently, the phosphorylated receptor becomes a 
binding partner for arrestins. Arrestins are normally cytosolic proteins, but they recognise agonist-
activated, phosphorylated receptors and bind them. This binding makes the receptor inacessible for G-
proteins and it targets the receptor for internalisation. This is because arrestins do not only bind 
receptors, but they also bind components of clathrin-coated pits. Thus, arrestin-bound receptors move 
into clathrin-coated pits and are then internalised. 
 
The GRK family of kinases is comprised of seven family members that share significant 
sequence homology (see paragraph 1.5). Each of the GRKs shares a similar functional 
organization with a central catalytic domain, an amino-terminal domain that is thought to be 
important for substrate recognition and that contains an RGS-like domain, and a carboxyl-
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terminal domain that contributes to the plasma membrane targeting of the kinase. GRKs 
phosphorylate agonist-activated receptors, thereby promoting the binding of cytosolic 
cofactor proteins called arrestins, which sterically uncouple the receptor from heterotrimeric 
G protein (Benovic et al., 1987; Lohse et al., 1990, Pippig et al., 1993).  
The second messenger-dependent protein kinases, PKA and PKC, are phosphotransferases 
that catalyze the transfer of the γ-phosphate group of ATP to serine and threonine residues 
contained within specific amino acid consensus sequences of proteins. Second messenger-
dependent protein kinase are activated in response to GPCR-stimulated increases in 
intracellular second messengers such as cAMP, Ca
2+
, and diacyglycerol and participate in 
GPCR signaling by mediating the phosphorylation of downstream target proteins. However, 
these kinases also feedback phosphorylate GPCRs at phosphorylation consensus sites within 
their intracellular loops and carboxyl-terminal tail domains. In contrast to GRKs, second 
messenger-dependent protein kinases not only phosphorylate agonist-activated GPCRs, but 
also indiscriminately phosphorylate receptors that have not been exposed to agonist 
(Hausdorff et al., 1989; Lohse et al., 1990). Thus, agonist-independent phosphorylation is a 
property that has generally been ascribed only to second messenger-dependent protein kinases 
and not GRKs (Lefkowitz, 1993). Nevertheless, it is now recognized that GPCRs 
spontaneously isomerize to an activated conformation in the absence of agonist, which 
suggests that GRKs may also contribute to the regulation of basal GPCR activity (Pei et al., 
1994; Rim and Oprian, 1995).  
After the association with the phosphorylated GPCRs, β-arrestins undergo a 
conformational change which allows them to bind clathrin and the adaptor protein complex 
AP-2, both of which are critical components of receptor-mediated endocytosis. The binding 
occurs between the amino terminal region of the clathrin heavy chain and the carboxyl 
terminal region of β-arrestins, and between the β2 subunit of AP-2 and the extreme carboxyl 
terminal region of β-arrestins. This interaction facilitates the entry of desensitized receptors 
into clathrin-coated pits for subsequent internalization (Goodman et al. 1996, Laporte et al. 
1999). The destiny of the internalized GPCRs is different according to the type of the 
receptor. Studies have revealed that specific determinants within the cytoplasmatic tails of 
GPCRs determine whether GPCRs are either recycled back to the plasma membrane or are 
retained within the intracellular compartment of the cell and/or targeted to lysosomes 
(Innamorati et al., 1998; Trejo and Coughlin, 1999; Oakley et al., 1999; Anborgh et al., 2000). 
Many GPCRs are internalized, but are not recycled back to the cell surface (Hermans et al., 
1997; Trejo and Coughlin, 1999; Groarke et al., 1999; Oakley et al., 1999; Zhang et al., 1999; 
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Anborgh et al., 2000; Bremnes et al., 2000). These internalized GPCRs, are predominantly 
targeted to lysosomes for degradation (Trejo and Coughlin, 1999; Bremnes et al., 2000). 
Other internalized GPCRs are not necessarily sorted to lysosomes, but may be retained within 
the endosomal compartment (Zhang et al., 1999; Anborgh et al., 2000). As a consequence, by 
virtue of the fact that some receptors do not recycle, they will mediate transient responses to 
agonist. Finally, some internalized GPCRs can be resensitized. The physiological importance 
of receptor resensitization in the maintenance of normal tissue homeostasis is obvious since 
prolonged or irreversible receptor desensitization would leave a cell unable to respond 
appropriately to extracellular stimuli. Just as GPCR desensitization provides a mechanism 
protecting cells against receptor overstimulation, GPCR resensitization protects cells against 
prolonged receptor desensitization. The mechanism by which the resensitization of many 
GPCRs is achieved is thought to be the agonist-stimulated internalization of receptors to an 
intracellular membrane compartment (endosomes) enriched in a GPCR-specific phosphatase 
activity. During this process the receptor is released from β-arrestin, becomes 
dephosphorylated, is sorted and recycled back to the cell surface. 
Taken together, the information summarized in this paragraph highlights the complex 
inter-relationship between mechanisms involved in GPCR desensitization, internalization an 
resensitization. The activation of distinct GPCR subtypes is translated into diverse receptor-
specific patterns for GPCR desensitization and resensitization. This diversity may be 
exploited for the development of strategies to therapeutically manipulate GPCR function in 
diseases associated with altered GPCR signaling. 
1.5  G protein-coupled receptor kinases  
G protein-coupled receptor kinase (GRKs) are serine/threonine kinases that mediate the 
process of GPCR desensitization, the physical uncoupling of the G protein from the cognate 
receptor. These kinases phosphorylate intracellular domains of activated receptors, leading to 
the recruitment of the multifunctional adaptor proteins, arrestins, to the receptors and the 
attenuation of intracellular G protein-dependent signaling (Lefkowitz and Shenoy, 2005). 
Based on sequence similarity and gene structure, vertebrate GRKs are classified into three 
subfamilies: visual GRK subfamily (GRK1, rhodopsin kinase and GRK7, cone kinase), the β-
adrenergic receptor kinase subfamily (GRK2/GRK3) and the GRK4 subfamily (GRK4, 
GRK5 and GRK6). All GRKs are multi-domain proteins which share a common structural 
architecture (Figure 1.17) comprising a highly conserved, centrally located catalytic domain 
of approximately 270 residues, similar to that of other serine-threonine kinases, flanked by an 
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N-terminal domain of approximately 185 amino acids and a variable-length carboxyl-terminal 
domain (105-230 amino acids). Both the N-terminal and the C-terminal domains are involved 
in the regulation of GRK targeting to the membrane and activity. The N-terminal domain, 
which has been proposed to be important for receptor recognition and intracellular membrane 
anchoring, harbors several regulatory motifs, including a regulator of G protein signaling 
homology (RH) domain. The C-terminus of GRKs contains structural elements responsible 
for their membrane targeting, for the interactions with lipids and membrane proteins and for 
the control of the subcellular distribution of these kinases (Pitcher et al., 1998; Penela et al., 
2010). 
 
 
Figure 1.17 - Domain structure of GRKs. 
All GRKs share a common structure comprising a highly conserved, centrally located catalytic 
domain of approximately 270 residues, similar to that of other serine-threonine kinases, flanked by an 
N-terminal domain of approximately 185 amino acids and a variable-length carboxyl-terminal domain 
(105-230 amino acids) (from Gurevich et al., 2012). 
 
Subcellular localization of GRKs has mainly been described in cultured cells, focusing on 
mechanisms of their membrane recruitment. However in vivo, cells are highly 
compartmentalized and contain multiple types of specialized membranes absent in cultured 
cells. This is particularly obvious in neurons, which arguably have complex morphology and 
perform more signaling than any other cell type (Bisegna et al., 2008; Caruso et al., 2011). It 
is therefore important to investigate how the various isoforms of GRKs are addressed in the 
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various compartments of the cell membrane as the different subcellular localization could 
contribute to the various cellular functions even independently from their receptors  
As previously described, the ability to phosphorylate activated GPCRs was the first GRK 
function to be discovered. Receptor phosphorylation by itself can decrease G protein coupling 
(Wilden, 1995) and enables high-affinity binding of arrestin, which stops G protein-mediated 
signaling by blocking the cytoplasmic surface of the receptors and preventing further binding 
and activation of the same receptors and inducing their desensitization (Krupnick et al., 1997; 
Ferguson et al., 2001). After the binding to β-arrestins, the phosphorylated receptors are 
endocyteted through a specific process which involved proteins called clathrins. This 
mechanisms allows the receptor resensibilization and their recycle in the membrane (Reiter 
and Lefkowitz, 2006; Moore et al., 2007). The mechanism of GRKs’ action is shown in 
Figure 1.18. 
 
 
Figure 1.18 – Representative scheme of GPCR desensitization induced by GRKs. 
In the figure it is shown the agonist-induced GPCR desensitization. After the agonist-induced receptor 
activation (A) the intracellular C-terminal domain of the receptor is phosphorylated by a GRK. This 
phosphorylation increases the receptor affinity for the arrestins which, then recruit clathrins inducing 
receptor internalization (from Lymperopoulos et al., 2013). 
 
The most striking feature distinguishing GRKs from other kinases is that their activity 
depends on the functional state of the target: GRKs effectively phosphorylate active GPCRs. 
However, they are clearly capable of phosphorylating other targets at the membrane in 
response to receptor activation. An increase of the availability of receptor phosphorylation 
sites upon their activation does not appear to play a role, because active GPCRs can enhance 
GRK phosphorylation of exogenous peptide substrates, indicating that docking with the active 
receptor directly activates the GRK (Palczewski et al., 1991; Chen et al., 1993). This receptor- 
dependent activation functions with non-cognate pairs, as demonstrated by the fact that GRK2 
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robustly phosphorylates rhodopsin in strictly light-dependent fashion (Benovic et al., 1986). A 
shared activation mechanism of GRKs relying on common structural features presented by 
active GPCRs thus seems to allow relatively few GRKs to phosphorylate hundreds of 
structurally different receptors (Palczewski, 1997). Interestingly, GRK4 is the only GRK 
isoforms (GRK4α splice variant) reported to be constitutively active and capable of 
phosphorylating unstimulated GPCRs (Ménard et al., 1996; Rankin et al., 2006). 
Most GRKs require the presence of negatively charged lipids to phosphorylate GPCRs 
efficiently, and they also require the cytoplasmic surface of the active receptor to form a 
pocket that is not accessible in the inactive state (Choe et al., 2011; Rasmussen et al., 2011; 
Standfuss et al., 2011) into which the GRK will dock. The size and physical properties of this 
pocket are expected to be highly conserved among receptors, while the size and sequence of 
the more exposed cytoplasmic loops of the receptor are clearly not. According to this model 
of GPCR-mediated GRK activation is one that involves the activated receptor in its native 
lipid environment forming a surface that is complimentary in shape and charge to that of 
GRKs in their active and closed conformation. Such a mechanism would allow GRKs to 
recognize many GPCR substrates. Once docked, the kinase adopts a closed conformation that 
allows it to phosphorylate any substrate in close proximity. The molecular details of how 
GRKs initially recognize receptors remain still unclear, but one hypothesis is that their 
intrinsically disordered N-termini form an initial low-affinity interaction in what has been 
termed “fly-casting”, which is believed to kinetically favor complex formation (Shoemaker et 
al., 2000; Cortese et al., 2008).  
In recent years it has been demonstrated that GRKs can also interact with a variety of 
proteins other than GPCRs and that in many cases they are able to phosphorylate them. Up to 
now, the list of non-GPCR substrates includes single transmembrane domain tyrosine kinases 
(PDGFRβ), single transmembrane domain serine/threonine kinases, death receptors, toll-like 
receptors, transcription factors and adapter proteins. It remains unclear whether this mode of 
GRKs acting on non-GPCR-linked signaling pathways is an exception or a rule. If indeed 
GRKs participate not only in desensitization, but also in signaling via such a huge variety of 
targets, they might play a role in processes such as cell growth and proliferation, cell death 
and motility, immunity, cancer, and development.  
GRKs have also been reported to phosphorylate a diverse collection of receptor-associated 
proteins, changing their binding to the receptor and/or their activity, which might lead to 
desensitization of G protein dependent or independent signaling pathways (Gurevich et al., 
2012). Other known targets of GRKs are nuclear proteins, such as class II HDACs (Martini et 
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al., 2008), multiple transcription factors and cytoskeleton proteins, such as tubulin that was 
the first non-GPCR substrate described (Gurevich et al., 2012). 
As many other enzymes in the cell, the expression of GRKs is tightly regulated by various 
factors and is altered in pathological conditions. For example, chronic or even acute 
administration of GPCR agonists can increase the level of GRKs in the brain, which may lead 
to tolerance to drugs (Hurle, 2001; Diaz et al., 2002; Fan et al., 2002; Rubino et al., 2006; 
Schroeder et al., 2009). Administration of GPCR antagonists or removal of endogenous 
agonists also can affect the GRK concentration too (Hurle, 2001; Diaz et al., 2002; Bezard et 
al., 2005; Ahmed et al., 2008, 2010). In some cases, transcriptional regulation is involved, 
whereas in others alterations in the protein concentration are not accompanied by changes in 
the mRNA levels, suggesting the regulation at post-transcriptional levels. 
Insufficient or excessive activity of GRKs was implicated in a variety of human disorders, 
which include heart failure, depression, Parkinson's disease and pain. As key regulators of 
GPCR-dependent and -independent signaling pathways, GRKs are emerging drug targets and 
promising molecular tools for therapy (Gurevich et al., 2012). 
 
1.5.1 GRK2 
Among all isoforms of GRKs, GRK2 is one of the most studied member. It is known that 
cells of the immune system express particularly high levels of GRK2 protein and its 
expression level is precisely regulated (De Blasi et al., 1995; Chuang et al., 1992). In vivo, the 
expression of GRK2 protein in cells of the immune system is altered in a number of disease 
states, including hypertension, cardiac failure, and the chronic inflammatory disease 
rheumatoid arthritis (Gros et al., 2000; Penela et al., 2001) and, recently, reduced levels of 
GRK2 have been found in leukocytes of patients with multiple sclerosis (MS), a 
demyelinating chronic inflammatory disease of the CNS (Vroon et al., 2005). The 
pathogenesis of this disease is characterized by the infiltration of activated T lymphocytes and 
macrophages into the brain and spinal cord and the family of G protein-coupled receptors 
(GPCR) plays an important role in regulation of inflammation by a variety of ligands, 
including chemokines, leukotrienes, prostaglandins, neurotransmitters, and adrenergic 
agonists (Lombardi et al., 2002). As described in the previous paragraph, the agonist-induced 
activation of these receptors triggers a series of signals that are rapidly attenuated by a 
phenomenon called homologous receptor desensitization. This phenomenon occurs as a 
consequence of receptor phosphorylation by GPCR kinases (GRK) and results in the 
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uncoupling of the receptor from the G protein, which abrogates receptor signaling. In 
addition, GRK-mediated receptor phosphorylation facilitates subsequent binding of arrestins, 
which promotes GPCR internalization (Ferguson 2001). 
Since GRK2 can modulate the activity of multiple GPCR involved in regulation of 
inflammation and that chronic inflammation can reduce GRK2 levels, Vroon and co-workers 
hypothesize that changes in GRK2 expression will contribute to the pathogenesis of MS, 
suggesting the important role of this kinase in the disease (Vroon et al., 2005). 
Apart from the recruitment of β-arrestin to the activated GPCR, it has been demonstrated 
that GRK2 also utilizes β-arrestin-independent mechanisms to mediate receptor 
internalization. Recent studies have shown that GRK2 associates with a growing number of 
protein partners with known roles in receptor internalization and signaling. In some cases, this 
interaction interferes with normal receptor down-regulation by blocking the kinase activity of 
GRK2. However, in other reported cases, the interaction between GRK2 and its protein 
partner directly affects receptor endocytosis or internalization.  
Evidence suggests that GRK2, as other GRKs, can also regulate signaling mediated by 
other membrane receptor families such as tyrosine kinase receptors for IGF1, Insulin, PDGF 
or EGF (Hupfeld and Olefsky, 2007; Cipolletta et al., 2009). Other substrates of GRK2 are 
non-GPCR and non-plasma membrane receptor substrates such as tubulin, synucleins, 
phosducin, ribosomal protein P2, the inhibitory g subunit of the type 6 retinal cyclic 
guanosine monophosphate (cGMP) phosphodiesterase, a subunit of the epithelial Na
+
 
channel, the ERM family protein ezrin, the calcium-binding protein DREAM, IKappaBalpha 
or the p38 MAPK (Peregrin et al., 2006; Ribas et al., 2007; Patial et al., 2010). These data 
suggest that GRK2 may act as “effector”, participating in the regulation of diverse cellular 
phenomena through the phosphorylation of substrates (Figure 1.19). 
GRK2 may also contribute to modulate cellular responses in a phosphorylation-
independent manner thanks to its ability to interact with a plethora of proteins involved in 
signaling and trafficking. In fact, this kinase has been reported to associate with PI3K, 
clathrin, GIT, caveolin, MEK, Akt, and RKIP (Ferguson 2007; Ribas et al., 2007). Very 
recent reports have identified novel interactions of GRK2 with the RalA GTPase in HEK293 
cells (Aziziyeh et al., 2009) and with the APC protein in osteoblasts (Wang et al., 2009). 
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Figure 1.19- The complex GRK2 interactome. 
The complex GRK2 interactome. In addition to its ‘classical’ role triggering GPCR phosphorylation 
and β-arrestin binding, GRK2 can modulate cell signaling by interacting with Gαq and Gβγ subunits. 
Furthermore, emerging evidence indicate that GRK2 phosphorylates diverse non-GPCR substrates 
and displays a complex network of functional interactions with proteins involved in signal 
transduction. The P symbol denotes that GRK2 has been shown to phosphorylate the indicated 
proteins (from Penela et al., 2010).  
 
 
Other functional interactions have been shown to be involved in the regulation of GRK 
expression levels, localization, and activity (Penela et al., 2003; Reiter and Lefkowitz, 2006; 
Premont and Gainetdinov, 2007). The association of GRK2 with α-actinin, clathrin, 
calmodulin, caveolin or RKIP participates in controlling GRK2 activity and in determining 
the complex subcellular distribution of the kinase. It has been demonstrated that the 
phosphorylation by different kinases enhances (PKA, PKC, Src) or decreases (ERK) 
membrane targeting and/or the catalytic activity of GRK2 (Sarnago et al., 1999; Elorza et al., 
2000; Penela et al., 2003), thus opening the possibility of transmodulation by different 
signaling pathways. A recent work has put forward S-nitrosylation of GRK2 as a novel 
mechanism to inhibit its activity (Whalen et al., 2007). Phosphorylation of GRK2 at given 
tyrosine or serine residues is also emerging as a key mechanism to dynamically modulate its 
interaction with cellular partners. Tyrosine phosphorylation by c-Src appears to enhance the 
interaction of GRK2 with Gαq (Ribas et al., 2007) and with the GIT1 scaffold protein. On the 
other hand, ERK1/2 phosphorylates GRK2 on S670, strongly impairing the GRK2/Gβγ 
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interaction (Pitcher et al., 1999) and inhibiting kinase translocation and catalytic activity 
towards receptor membrane substrates, while also modulating GRK2 interaction with GIT1 
(Penela et al., 2008). 
Regarding the regulation of GRK2 expression little has been reported about the 
mechanisms governing GRK transcription. For example, in aortic smooth muscle cells it has 
been shown that agents inducing physiological vasoconstriction and hypertrophy enhance 
GRK2 promoter activity, whereas inflammatory cytokines have the opposite effect (Ramos-
Ruiz et al., 2000). 
Probably, regulation of GRK2 stability may provide an important mechanism for 
modulating its expression levels. According to this, it has been demonstrated that GRK2 is 
rapidly degraded by the proteasome pathway after β2-adrenergic receptor (β2-AR) or of the 
chemokine receptor CXCR4 (Penela et al., 1998, 2001). This degradation is a complex 
process that is the result of phosphorylation of GRK2 by c-Src and MAPK (Penela et al., 
1998; 2001; Elorza et al. 2003). More recently, Mdm2, an E3-ubiquitin ligase involved in the 
control of cell growth and apoptosis, has been shown to play a key role in GRK2 degradation 
(Salcedo et al., 2006). Mdm2 and GRK2 association and subsequent proteolysis are facilitated 
by the β-arrestin scaffold function upon β2-adrenergic receptor stimulation. On the contrary, 
activation of the PI3K/Akt pathway by agonists such as IGF1 alters Mdm2 phosphorylation 
and triggers its nuclear localization thus hampering Mdm2-mediated GRK2 degradation and 
leading to enhanced GRK2 stability and increased kinase levels (Salcedo et al., 2006).  
Recently, studies carried on by Cobelens and co-workers (2007) have shown that the 
treatment with hydrogen peroxide in C6 rat glioma cells alters GRK2 translation by a novel 
mechanism involving the activity of calpain and the cyclin-dependent kinase, Cdk1 and the 
mTOR signaling. These studies suggest that H2O2-induced Cdk1 activation triggers 
inactivation of a translational component which results in inhibition of GRK2 protein 
synthesis. In this work, a number of Cdk1 targets involved in the silencing of gene expression 
have been identified including RNA polymerase II, elongation factor 1γ (Gottesfeld et al., 
1997) and 70-kDa ribosomal protein S6 kinase (S6K1) (Shah et al., 2003). S6K1 is an 
important regulator of translation that is under the control of the rapamycin-sensitive mTOR 
pathway, which is considered a master modulator of protein synthesis. Indeed, the mTOR 
complex controls the activity of other translational factors, as the eukaryotic initiation factor 
4E-binding protein-1 (4E-BP1) and the elongation kinase (Tee and Blenis, 2005). Moreover, 
Cdk1 not only modulates the mTOR downstream factor S6K1 as mentioned, but also the 
initiation factor 4E-BP1 (Heesom et al., 2001). It has been hypothesized that the mTOR 
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pathway is impaired after oxidative stress via Cdk1-induced modulation of molecules 
downstream from mTOR. Moreover, rapamycin treatment resulted in a time-dependent 
decrease of GRK2 expression (Cobelens et al., 2007). 
The increasingly complex GRK2 “interactome” puts forward this kinase as a relevant 
signaling node of the cellular transduction network. The intricacy of this network of 
functional interactions and the participation of this protein in basic cellular processes as 
migration and cell cycle progression or cardiovascular cell functionality predicts that 
alterations in GRK2 levels and/or activity, as those reported in several relevant 
cardiovascular, inflammatory or cancer pathologies, may have important effects in human 
disease. For this reason a better comprehension of the mechanisms involved in the regulation 
of GRK2 levels and activity may represent a promising strategy for the development of new 
pharmacological tools. 
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In the adult central nervous system (CNS), OLs play a role of paramount importance in 
allowing saltatory conduction of nerve impulses and in maintaining neuronal function and 
survival (McTigue and Triphati, 2008). In spite of this, they are remarkably vulnerable to a 
number of damaging conditions, including excitotoxicity, oxidative stress and the presence of 
pro-inflammatory cytokines. A plethora of acute CNS injuries (including trauma, ischemia, 
infections and intoxications) and chronic degenerative and psychiatric diseases (such as 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, schizophrenia) are 
characterized by oligodendrocytes (OL) loss and myelin breakdown (McTigue and Triphati, 
2008).  
In the adult intact and injured CNS, OL turn-over is guaranteed by a subset of NG2
+
 called 
oligodendrocyte precursor cells (OPCs) (Polito and Reynolds, 2005), that are able to 
spontaneously differentiate into mature OL. However, this process is efficient only under 
specific conditions, but often, such as in MS, remyelination fails. An uncontrolled 
environmental inflammatory response may, indeed, cause a profound impairment on the 
extent of repair (Fumagalli et al., 2011). On this basis, the identification of signals/molecules 
that block or promote OPC differentiation represents an important starting point for the 
development of new therapeutic strategies able to exploit the intrinsic reparative potential of 
these precursors. 
In this scenario, the GPR17 receptor emerges as a new and promising therapeutic target to 
promote myelin repair (Lecca et al., 2008; Chen et al., 2009; Boda et al., 2011). Since its 
discovery, the receptor has proven to be interesting both concerning the possibility to exploit 
it pharmacologically and for its role in the pathogenesis of demyelinating diseases. 
GPR17 is a G protein-coupled receptor that can be activated by two distinct classes of 
endogenous ligands, the uracil nucleotides (UDP, UDP-glucose and UDP-galactose) and the 
cysLTs (LTC4, LTD4 and LTE4) (Ciana et al., 2006). Both these two types of molecules are 
released in large quantities after CNS injury (Ciceri et al., 2001; Melani et al., 2005). It has 
been proposed that, under pathological conditions, these factors may act as danger signals, 
promoting reparative mechanisms aimed at restoring damaged neuronal circuits through the 
activation of specific membrane receptors (Di Virgilio et al., 2009). GPR17 is involved in 
these mechanisms and acts as a molecular sensor of damage (Lecca et al., 2008). In fact, this 
receptor is expressed by a subpopulation of OPCs dispersed both in the white and grey matter 
of the CNS and, similarly, in vitro, this receptor specifically identifies the stages of transition 
at which the OPCs exit the cell cycle and are directed towards differentiation, while the 
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receptor is never expressed by mature myelinating OL (Fumagalli et al., 2011; Boda et al., 
2011). 
It has also been reported that both the pharmacological and biotechnological manipulation 
of this receptor modifies the normal differentiation program of OPCs by either promoting or 
inhibiting cell terminal maturation (Fumagalli et al., 2011). Moreover, both in vivo and in 
vitro data showed that, to complete OPC maturation, the receptor has to be turned off, thus 
highlighting the existence of a precise time window at which GPR17 must be expressed 
during the differentiation of these cells (Chen et al., 2009; Fumagalli et al., 2011; Fratangeli et 
al., 2013). Together with the demonstration of persistent aberrant expression of GPR17 in 
OPCs under demyelinating conditions (Chen et al., 2009; Boda et al. , 2011), these findings 
raise the hypothesis that alterations leading to excessive/prolonged functional expression of 
GPR17 in OPCs may contribute to the failure of precursors to efficaciously remyelinate. 
Since the factors that take part to the regulation of GPR17 expression throughout OPC 
differentiation are only partially understood, the experiments carried on in this thesis were 
designed to investigate (i) the consequences of GPR17 agonists activation at early stages of 
the differentiation process; (ii) the physiological meaning of GPR17 down-regulation at late 
differentiation stages and (iii) the mechanisms underlying this down-regulation. 
Concerning the first aim, based on the fact that previous experiments demonstrated that, in 
OPCs, GPR17 activation by UDP-glucose is able to promote cell differentiation towards a 
mature phenotype (Fumagalli et al., 2011), specific experiments were designed in order to 
evaluate the pro-differentiating effects of other known GPR17 agonists (UDP, LTD4 and 
LTE4) in the same cellular model. Then, since OPC differentiation and the subsequent 
myelination are strictly correlated, we decided to also assess the effects of some GPR17 
agonists (UDP and UDP-glucose) on the formation of myelin segments. To this purpose, we 
set up another in vitro model, the OPC/DRG co-cultures, which gave us the possibility to 
direct quantify myelination. 
Concerning the second aim, previous data also clearly showed that GPR17 is not present in 
morphologically mature MBP
+
-cells, suggesting that the receptor has to be turned down at 
critical stage of maturation. To better understand the consequences of this physiological 
down-regulation, we specifically designed an experiment aimed at interfering with this 
process through the receptor over-expression. In this respect, we took advantage of 
fluorescent reporter plasmids for GPR17 over-expression that allowed us to trace the cells by 
fluorescent microscopy throughout all OPC differentiation process.  
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Finally, we investigated the mechanisms underlying GPR17 down-regulation. In general, it 
is known that GPCRs are down-regulated either through the homologous desensitization 
induced by its own agonists and/or by the intracellular kinases. In this respect, we first tested 
the capability of two GPR17 agonists (UDP-glucose and LTD4) to induce GPR17 
desensitization and, then, we evaluated the involvement of GRK2, a G-protein coupled 
receptor kinase highly expressed in the CNS, that usually actively participates in GPCRs 
homologous desensitization. Finally, since recent data have shown that the mTOR signaling 
pathway plays an important role in regulating the process of OPC maturation (Tyler et al., 
2009; Guardiola-Diaz et al., 2012), by also modulating GPR17 (Tyler et al., 2011), we 
performed specific experiments to investigate this hypothesis. Specifically, we treated OPCs 
with rapamycin, an immunosuppressant drug that inhibits the activity of this kinase. 
Moreover, to assess whether the two mechanisms described above are interconnected to each 
other, we measured GRK2 protein levels after rapamycin treatment and, through a cAMP 
assay, examined the capability of GPR17 agonists to induce receptor desensitization after 
mTOR inhibition by rapamycin. 
Altogether these experiments will help us to better understand the role of GPR17 in OL 
maturation, shedding light on the mechanisms underlying its physiological regulation in order 
to develop new pharmacological and biotechnological strategies to promote/implement the 
reparative potential of the OPC precursors, that are still present in the adult brain. 
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3.1 Primary rat oligodendrocyte precursor cells (OPC) cultures 
3.1.1 Dissection and plating of rat cortical cortices 
Primary mixed glial cultures were obtained from postnatal day 2 Sprague Dawley rats 
(Charles River). In a laminar flow hood, pups were anesthetized with ether, decapitated and, 
then, brains were extracted from the skull. Olfactory bulbs and cerebellum were cut off and 
the two cerebral hemispheres were divided along the midline for the cerebral cortex isolation. 
After the removal of meninges, cortical tissues were diced with a sterilized razor blade and 
transferred into a 50 ml sterile centrifuge tube (Euroclone) containing ice-cold Hanks 
balanced salt solution with calcium and magnesium (HBSS, Euroclone). Afterwards, HBSS 
was aspired and tissues were washed with HBSS without calcium and magnesium and 
incubated with 10 ml trypsin-EDTA solution (final concentration 0.5%, 0.2% in HBSS 
without calcium and magnesium) containing 1% DNAse I (final concentration 0.01 mg/ml) 
(Sigma-Aldrich) for 30 minutes in a water bath at 37°C for tissue disaggregation. After the 
incubation, trypsin was inactivated with HBSS containing 10% of fetal bovine serum (FBS, 
Euroclone) and tissues were further triturated mechanically with a Pasteur pipet. The cellular 
suspension was passed through a 100 μm cell strainer (BD) in order to eliminate 
undissociated tissue residues, collected into a 50 ml sterile centrifuge tube and centrifuged at 
1200 rpm for 10 minutes. The supernatant was discarded and the pellet was resuspended in 
the medium for cortical astrocytes containing: 
 DMEM high glucose (Euroclone) 
 2 mM L-glutamine (Sigma-Aldrich) 
 1 mM Sodium pyruvate (Sigma-Aldrich) 
 Penicillin 100 U/ml-Streptomycin 100 μg/ml (Euroclone) 
 2,5 μg/ml Fungizon (Euroclone) 
 20% FBS 
The cellular suspension was spread over the entire T75 poly-D-lysine (final concentration 
10 μg/ml, Sigma-Aldrich) -coated flask surface. Then, flasks were put in a tissue culture 
incubator (Steri Cult 200) at 37°C, 5% CO2 and 95% relative humidity. The medium was 
changed every 2-3 days until cell confluence (about 8 days after the plating). 
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3.1.2 Isolation and culture of rat OPCs 
Eight days after the plating, mixed glial cultures reached the confluence and phase-dark, 
process-bearing OPCs and microglial cells started appearing on the top of phase grey bed 
layers of astrocytes (Figure 3.1). At this time point the cultures were ready to be shaken to 
obtain OPCs. For OPC isolation we followed the protocol described by Chen and co-workers 
(Chen et al., 2007) with some modifications.  
 
 
Figure 3.1 - Mixed glial cultures from rat cerebral cortex. 
The picture shows the oligodendrocyte precursor cells and the microglia attached on the monolayer of 
cortical astrocytes (40x magnification; scale bar 15 μm). As described in the paragraph, 8 days after 
the seeding, mixed glial cultures reach the confluence and phase-dark, process-bearing OPCs and 
microglial cells started appearing on the top of phase grey bed layers of astrocytes. OPCs have a 
polygonal soma with some small ramifications (see yellow arrows). 
 
 
Culture flasks were removed from the incubator, well fixed with the plug-seal cap tightly 
screwed on a horizontal orbital shaker and shaken for 20 minutes at 200 rpm at room 
temperature to remove microglial cells. The medium containing microglial cells was 
discarded from the flasks by aspiration and 12 ml of fresh DMEM containing 10% of FBS 
were added to each flask. The flasks were put again on the shaker for further 3-4 hours to 
isolate OPCs. The cell suspension from each flask was then collected by a pipette, transferred 
to an untreated Petri-dish and incubated for 20 minutes in tissue culture incubator at 37 °C for 
differential adhesion of contaminating microglia and astrocytes. At the same time, 12 ml of 
fresh DMEM containing 10% of FBS were added to each flask and returned to the incubator. 
The culture medium was completely changed every 2-3 days to allow more OPCs to grow on 
the astrocyte layer so that they could be shaken a second time after 3-4 days using the same 
procedure. 
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The cell suspension was transferred into a 50 ml tube and centrifuged at 1200 rpm for 15 
minutes. The supernatant was carefully discarded and the pellet was resuspended and 
dissociated in a small amount of Neurobasal (Life Technologies) containing 2 mM L-
Glutamine, 1% of Penicillin 100 U/ml-Streptomycin 100 μg/ml and 2% of B27 (Life 
Technologies). Living cells were counted using the Trypan blue which allows the exclusion of 
death cells. The OPC suspension was diluted to the desired concentration with the same 
medium used for the pellet resuspension and plated onto poly-D,L-ornithine-coated plates 
(final concentration 50 μg/ml, Sigma-Aldrich) to a specific density according to the 
subsequent experiments (see successive paragraphs) in the presence of PDGF-BB (final 
concentration 10 ng/ml, Sigma-Aldrich) and bFGF (final concentration 10 ng/ml, Space 
import-Export) to allow cell proliferation. OPCs were maintained in this medium for 2-3 days 
and, then, switched to a differentiation medium lacking growth factors and containing the 
thyroid hormone T3 (final concentration 10 ng/ml, Sigma-Aldrich) to allow cell differentiation 
to a mature OL phenotype. 
 
3.2 Myelinating co-cultures 
3.2.1 Dissection and isolation of mouse dorsal root ganglia (DRG) 
Mouse DRG were isolated from E14.5 embryos using the protocol as described in 
Taveggia et al., 2005. Mouse mother was sacrificed by dislocation and placed in a supine 
position. Abdominal skin was cut using medium-size scissors (2 Biological) in an “I” pattern 
to expose abdominal muscles; uterus was removed from abdominal cavity and embryos were 
isolated from uterus by cutting through tissue surrounding amniotic fluid. All embryos were 
put in a 10 cm Petri dish containing L-15 (Life Technologies) and individual embryo were 
transferred to a 6 cm Petri dish with a thin layer of L-15 to isolate DRG. Under a dissecting 
microscope, the head of each embryo was cut off at the cervical flexure and the tail was cut 
off just caudal to the hind-limbs; the ventral portion was removed in order to isolate the dorsal 
structures containing the spinal cord. Using micro-dissecting scissors (2 Biological), vertebral 
column was cut proceeding caudally in order to expose spinal cord and DRG. The same 
procedure was repeated for all embryos. After isolating all spinal cords, DRG were plucked 
off using dissecting forceps (2 Biological) and deposited onto the center of collagen-coated 
(final concentration 0.5 mg/ml diluted with glacial acetic acid diluted 1:1000 in sterile dH20, 
Cultrex Trevigen) glass coverslips previously covered with 180 μl of C-media composed by: 
 MEM (Life Technologies) 
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 4 mg/ml Glucose (Sigma-Aldrich) 
 10% FBS 
 2 mM L-Glutamine 
 Penicillin 100 U/ml-Streptomycin 100 μg/ml 
 50 ng/ml NGF (Harlan). 
 
3.2.2 Generation of DRG explant cultures 
DRG cultures were obtained using the same protocol described in Taveggia et al., 2007. 
The following day, C-media was removed and neuronal cells were cycled with 250 μl of two 
different media, NBF and NB (see respective composition below), for 20 days following a 
specific scheme (Figure 3.2) to allow DRG growth and to eliminate all non-neuronal cells.  
 
NBF NB 
 Neurobasal 
 2% B27 
 4 mg/ml Glucose 
 2 mM L-Glutamine 
 Penicillin 100 U/ml-Streptomycin 100 
μg/ml 
 50 ng/ml NGF 
 Fluorodeoxyuridine (FUDR): 12,3 mg 
fluorodeoxyuridine (FdU, Sigma-
Aldrich) + 12,2 mg uridine (Sigma-
Aldrich) dissolved in 0.5 ml MEM 
 Neurobasal 
 2% B27 
 4 mg/ml Glucose 
 2 mM L-Glutamine 
 Penicillin 100 U/ml-Streptomycin 100 
μg/ml 
 50 ng/ml NGF 
 
 
 Monday Wedensday Friday 
Week 1  NBF NB 
Week 2 NBF NB NBF 
Week 3 NB NB NB 
 
Figure 3.2 – Protocol of scheme for the generation of DRG cultures 
The day after the plating, DRG were cycled with two different media: NBF (containing 
fluorodeoxyuridine ) which allows the elimination of non neuronal cells and NB (without 
fluorodeoxyuridine). Both media were supplemented with NGF which promotes the neuritis 
outgrowth. 
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After 20 days, neuritis were well extended radially from DRG explants and they were 
ready to be myelinated by OPCs. Purified OPCs, separated by orbital shaking (as described in 
paragraph 3.1.2) and immunopanned using Ran-2 (see paragraph 3.2.3), were added to each 
DRG in culture (35000 cells/DRG) and kept in M1 medium containing: 
 MEM 
 10% FBS 
 4 g/L Glucose 
 2 mM L-Glutamine 
 100 U/ml Penicillin-100 μg/ml Streptomycin  
The following day myelination was induced by the addition of 1 μg/ml recombinant 
chimeric TrkA-Fc (Space Import-Export) which binds to NGF, that has been shown to inhibit 
myelination by OLs, to the culture medium. The myelinated segments started appearing 8 
days after OPCs seeding and became more consistent at day 11. 
 
3.2.3 Immunopanning 
The immunopanning technique was used to eliminate non-oligodendroglial cells from the 
cell population obtained after the mixed glial cell cultures shaking. This procedure was 
essential to prevent astrocytes and microglia contamination in OPC-DRG co-cultures 
according to the protocol described in Taveggia et al. 2007. 
The day before the shaking, two 10 cm Petri dish were incubated overnight with 10 ml 
goat anti-mouse IgG (final concentration 0.5 μg/ml, Cappel) diluted in 50 mM Tris HCl pH 
9.5 (Sigma-Aldrich). The following day, dishes were rinsed 3 times with sterile PBS 
(Euroclone) and incubated at room temperature for 3 hours with primary antibody Ran-2 
hybridoma supernatants (kind gift of dr. Taveggia) diluted in BSA Medium containing: 
 MEM 
 0.1% BSA (Sigma-Aldrich) 
 2.5 % Hepes 1N (Sigma-Aldrich) 
The cell suspension, obtained after shaking of mixed glial cell cultures for 3 hours, was 
transferred into a 50 ml tube and centrifuged at 1200 rpm for 7 minutes. The supernatant was 
carefully discarded and the pellet was resuspended and dissociated in 6.5 ml of NM15 
containing: 
 MEM 
 15% FBS 
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 2 mM L-Glutamine 
 6 mg/ml Glucose 
 Insulin (Sigma-Aldrich) 
 Penicillin 100 U/ml-Streptomycin 100 μg/ml 
The cell suspension was incubated for 20 minutes at room temperature with one of Ran-2 
coated-dishes which were previously rinsed 3 times with sterile PBS. Non-attached cells were 
collected and re-incubated for further 20 minutes with a second Ran-2 coated-dish. After 
incubation the cell suspension was centrifuged at 1200 rpm for 10 minutes. Finally, the 
supernatant was discarded and the pellet was resuspended in a small amount of M1 medium 
for cell counting. 
 
3.3 OPCs transient transfection 
3.3.1 GPR17 over-expression 
OPCs were seeded on 13 mm poly-D,L-ornithine-coated coverslips (2 x 10
4
 cells/well) and 
maintained for 2 days in Neurobasal supplemented with B27 and proliferative factors (PDGF-
BB and bFGF) as described in paragraph 3.1.2. Afterwards, OPC differentiation was induced 
by removing proliferative factors and by adding T3. After 3 days in differentiation medium, 
cells were transfected with two different fluorescent plasmids previously generated in the lab: 
 pEGFP-N1 (an empty vector which allows the identification of cells incorporating 
the plasmids since they become fluorescent); 
 pEGFP-GPR17-N1 (a vector in which GPR17 receptor coding sequence was cloned 
in frame with EGFP so that all cells incorporating the plasmids over-expressed 
GPR17). 
The transfection was performed by using the transfection reagent NeuroFECT
TM
 
(Genlantis), a biodegradable cationic polymer indicated for transfection of neuronal cells, 
according the manufacturer’s protocol. NeuroFECT and DNA were prepared in separate 
tubes. Briefly, 4 μg of NeuroFECT and 1 μg of DNA (both pEGFP-N1 and pEGFP-GPR17-
N1) were diluted respectively in 50 μl of Neurobasal. Then, the diluted NeuroFECT was 
added to diluted DNA in a drop wise fashion for the formation of NeuroFECT/DNA complex. 
The complex was incubated for 15 minutes at room temperature. During this time, culture 
medium was replaced with 400 μl of fresh Neurobasal supplemented with 2% of B27 and 
with 10 ng/ml of T3. After 15 minutes, the NeuroFECT/DNA complexes (100 μl/ well) were 
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added to the cells. Cells were, finally, incubated at 37°C in 5% CO2 for 48 hours and fixed 
with 4% paraformaldehyde (Sigma-Aldrich) for immunocytochemistry (see paragraph 3.5). 
 
3.3.2 GPR17 knock-down 
OPCs were seeded on poly-D,L-ornithine-coated 6-well plates (10 x 10
4
 cells/well) and 
maintained for 3 days in Neurobasal supplemented with B27 and proliferative factors (PDGF-
BB and bFGF) as described in paragraph 3.1.2. After 3 days in proliferating medium, 
differentiation was induced by adding T3 and cells were transfected with a siRNA specifically 
designed for silencing rat GPR17 (Qiagen): CCGTATAGAGAAGCACCTCAA (target 
sequence). The sequence was designed to minimize homology to any known vertebrate 
transcript. This sequence has already been successfully utilized to knock-down GPR17 
(Fumagalli et al., 2011). In parallel, an ineffective randomly designed RNA sequence was 
used as negative control (Qiagen). In the present study, siRNAs were transfected with 
Lipofectamine RNAiMAX reagent (Invitrogen) as described in Fumagalli et al., 2011 to a 
final concentration of 100 nM/well following the manufacturer’s protocol. After 2 days from 
the transfection, cells were treated with UDP (100 μM) for 48 hours. Cells were, then, lysed 
for Western blot analysis (see paragraph 3.6). 
 
3.3.3 GRK2 knock-down 
OPCs were seeded on poly-D,L-ornithine-coated 6-well plates (15 x 10
4
 cells/well) and 
maintained for 3 days in Neurobasal supplemented with B27 and proliferative factors (PDGF-
BB and bFGF) as described in paragraph 3.1.2. After 3 days in proliferating medium, 
differentiation was induced by adding T3 and cells were transfected with a pool of four siRNA 
specifically designed for silencing rat GRK2 (Thermo Scientific). In parallel, an ineffective 
randomly designed RNA sequence was used as negative control (Thermo Scientific). Both 
siRNA were resuspended in 1X siRNA Buffer (Thermo Scientific) at a final concentration of 
20 μM. siRNA were transfected with Lipofectamine RNAiMAX reagent (Life Technologies) 
to a final concentration of 50 nM (6-well cell culture plate) following the manufacturer’s 
protocol. siRNAs (5 μl) and lipofectamine (6 ul) were diluted respectively in 195 μl of 
Optimem (Life Technologies). Then, the diluted siRNA was added to diluted lipofectamine 
and incubated at room temperature for 15 minutes. After 15 minutes, 400 ul of the mix was 
added to each well and cells were incubated at 37°C in 5% CO2 for 48 or 96 hours in order to 
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evaluate the efficiency and the consequences of GRK2 silencing at two different time points 
of OPC differentiation. Finally, cells were lysed for Western blot analysis (see paragraph 3.6) 
3.4 Pharmacological treatments 
3.4.1 GPR17 endogenous ligands 
GPR17 endogenous ligands were tested both in primary OPCs culture and in OPC-DRG 
co-cultures to assess their pro-differentiation and pro-myelination effect respectively. 
 According to the type of culture, a specific protocol of treatment was set up (Figure 3.3). 
For primary OPCs, cells were seeded on 13 mm poly-D,L-ornithine-coated coverslips (2 x 10
4
 
cells/well) or on poly-D,L-ornithine-coated 6 cm dishes (35 x 10
4
 cells/dish) and maintained 
for 2 days in Neurobasal supplemented with B27 and proliferative factors (PDGF-BB and 
bFGF) as described in paragraph 3.1.2. Afterwards, OPC differentiation was induced by 
removing proliferative factors and by adding T3 (day 0) and pharmacological treatments with 
GPR17 agonists UDP (100 μM, Sigma-Aldrich), LTE4 (10 nM, Cayman Chemical) and LTD4 
(100 nM, Cayman Chemical) was performed the following day. After 48 hours, cells were 
fixed for immunocytochemistry (see paragraph 3.5) or lysed for Western blot analysis (see 
paragraph 3.6). 
 
Figure 3.3 - Schematic representation of the experimental protocol followed for the 
pharmacological treatment of OPC cultures with GPR17 agonists. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding the thyroid hormone T3 in the medium (“day 0”). After 
two/three days in the differentiating medium, when the majority of cells expresses GPR17 (stage 3), 
cells were treated with GPR17 agonists (UDP μM; LTE4 10 nM; LTD4 100 nM). After 48 hours cells 
were lysed for WB analysis or fixed for ICC. 
 
For OPC-DRG co-cultures (Figure 3.4), UDP-glucose (100 μM, Sigma-Aldrich) and UDP 
(100 μM) were added to cultures at day 4. The pharmacological treatment was repeated every 
2 days up to day 11, when cells were fixed for immunocytochemistry (see paragraph 3.5). 
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Figure 3.4 - Schematic representation of the experimental protocol followed for the 
pharmacological treatment of OPC-DRG co-cultures with GPR17 agonists. 
Dorsal Root Ganglia (DRG) from E14.5 mouse embryos were plucked off from spinal cord, put in 
culture in Neurobasal supplemented with B27 in the presence of NGF (100 ng/ml) and cycled with 
fluorodeoxyuridine to eliminate all non-neuronal cells. After 20 days, when neuritis were well 
extended radially from DRG explants, purified OPCs were added to each DRG (day “0” in co-
culture) and kept in M1 medium. Myelination was induced the following day by the addition of 
recombinant chimeric TrkA-Fc to the culture medium. GPR17 agonists were added starting from day 
4 (stage 3). At day 11 all cells were fixed for ICC analysis. 
 
3.4.2 GRK2 inhibitor 
To verify the involvement of GRK2 in the LTD4-induced pro-OPC maturation, primary 
OPCs, cultured in differentiating medium, were treated with LTD4 (100 nM) in the absence 
(control) or in the presence of 1 μM of the specific GRK2 inhibitor (KRX29, Gomez–
Monterrey et al, 2013) as shown in Figure 3.5. After 48 hours, cells were fixed for 
immunocytochemistry (see paragraph 3.5). 
 
Figure 3.5 - Schematic representation of the experimental protocol followed for the 
pharmacological treatment of OPC cultures with GRK2 inhibitor. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding the thyroid hormone T3 in the medium (“day 0”). At day 0, the 
GRK2 inhibitor KRX29 (1μM) was added in the medium. At day 1 and day 3 in the differentiating 
medium, cells were treated with LTD4 (100 nM). At day 4 and at day 6, cells were fixed for ICC. 
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3.4.3 mTOR inhibitor 
To test the effect of mTOR pathway inhibition on OPC differentiation, cells were treated 
with rapamycin (15 nM, Sigma-Aldrich), an immunosuppressant drug which is able to inhibit 
mTOR (Brown et al., 1994). The concentration of rapamycin was chosen on the basis of 
already published data and cell treatment was performed according to the protocol shown in 
Figure 3.6. 
To assess the consequences of rapamycin on OPC terminal maturation, cells were 
maintained for 2 days in Neurobasal supplemented with B27 and proliferative factors (PDGF-
BB and bFGF) as described in paragraph 3.1.2. Afterwards, OPC differentiation was induced 
by removing proliferative factors and by adding T3 (day 0). At day 1, cells were treated with 
rapamacyn and at day 3 the pharmacological agent was re-added in the medium. At day 6, 
cells were fixed for immunocytochemistry (see paragraph 3.5) or lysed for western blot 
analysis (see paragraph 3.6). 
 
Figure 3.6 - Schematic representation of the experimental protocol followed for the 
pharmacological treatment of OPC cultures with rapamycin. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding the thyroid hormone T3 in the medium (“day 0”). At day 1 and 
day 3 in the differentiating medium, cells were treated with rapamycin (15 nM). To investigate the 
consequences of rapamycin on the transition from immature (stage 4) to mature stage (stage 5), cells 
were lysed for WB analysis or fixed for ICC at day 6. 
 
 
To evaluate the effects of rapamycin on the transition from pre-oligodendrocytes to 
immature OLs, cells were also lysed and fixed at day 4 (Figure 3.7). 
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Figure 3.7 - Schematic representation of the experimental protocol followed for the 
pharmacological treatments of OPC cultures with rapamycin. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding the thyroid hormone T3 in the medium (“day 0”). At day 1 and 
day 3 in the differentiating medium, cells were treated with rapamycin (15 nM). To investigate the 
consequences of rapamycin on the transition from pre-oligodendrocyte (stage 3) to immature stage 
(stage 4), cells were lysed for WB analysis at day 4. 
 
 
3.5 Immunocytochemistry 
Both primary OPCs and OPC-DRG co-cultures were fixed at room temperature with 4% 
paraformaldehyde in 0.1 M PBS (Euroclone) containing 0.12 M sucrose (Sigma-Aldrich). 
Cells were subsequently incubated for 20 min at room temperature with Goat Serum Dilution 
Buffer (GSDB; 450 mM sodium chloride and 20 mM sodium phosphate buffer, pH 7.4, 15% 
goat serum, and 0.3% Triton X-100), before exposure to the primary antibodies diluted in 
GSDB (see Table 3.1). After an overnight incubation at 4°C or 2.5 hours incubation at room 
temperature, cells were rinsed three times for 10 min in a high salt buffer solution (500 mM 
sodium chloride and 20 mM sodium phosphate buffer, pH 7.4), and then incubated (1 hour, 
room temperature) with secondary goat anti-rabbit and goat anti-mouse antibodies conjugated 
to AlexaFluor
®
488 or AlexaFluor
®
555 (Life Technologies) diluted 1:600 in GSDB 
Subsequently, nuclei were labeled with the fluorescent dye Hoechst-33258 (Life 
Technologies) diluted 1:10,000 in high salt buffer solution. Cells were rinsed three times in 
high salt buffer, three times in low salt buffer and, finally, once in 5 mM sodium phosphate 
buffer, pH 7.4. Coverslips were mounted with Fluorescent Mounting Medium (Dako), and 
analyzed using an inverted fluorescence microscope (200M; Zeiss) connected to a PC 
computer equipped with the Axiovision software (Zeiss) or a confocal microscope (LSM510 
META, Zeiss).  
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Table 3.1 – Primary antibody used in ICC 
ANTIBODY COMPANY DILUTION INCUBATION 
Rabbit anti-GPR17 Home-made 1:100 
o/n (4°C) or 2,5 hours 
(RT) 
Rat anti-MBP Millipore 1:200 o/n (4°C) or 2,5 hours 
(RT) 
Rabbit anti-GRK2 Santa Cruz 1:50 o/n (4°C) 
Mouse anti-SMI 31 Cell Signalling 1:500 2.5 hours (RT) 
Mouse anti-SMI 32 Cell Signalling 1:500 2.5 hours (RT) 
Rabbit anti-NG2 Millipore 1:200 o/n (4°C) 
Mouse anti β-
Tubulin III 
Promega 1:500 o/n (4°C) 
 
For OPC cultures, the quantitative analysis was done with ImageJ software, counting the 
total number of positive cells in 20 fields under 20X magnification (3 coverslips for each 
experimental condition. Depending on the experiment and on the parameters to be estimated, 
at least 700 cells/condition were counted. 
For OPC-DRG co-cultures, the quantification of myelin segments was performed with 
ZEISS LSM Image Browser in 6 random fields of 3-6 coverslips for each experimental 
condition. Briefly, stacks of images of MBP and Smi31/Smi32 positive cells were taken at 
40X magnification; images in the stack were merged at each level and pixels overlapping in 
the red and green fields above a predefined threshold intensity value were highlighted in 
white. The amount of myelin per axon (myelination index), was calculated as the ratio 
between the white pixels area and the green pixels area.  
 
3.6 Western blot  
Cells were lysed with 50 μl of lysis buffer (20 mM Tris pH=7.2, 0.5% DOC, 1% Triton, 
0.1% SDS, 150 mM NaCl, 1 mM EDTA and 1% proteases inhibitors Sigma-Aldrich) and, 
then, approximately 25-30 g aliquots from each protein sample were loaded on 12.5 
sodium-dodecylsulphate polyacrylamide gels (for MBP and CNPase) or on 8.5% sodium-
dodecylsulphate polyacrylamide gels (for GPR17, NG2 and GRK2), and blotted onto 
nitrocellulose membranes (MBP and CNPase) or PVDF membranes (GPR17, GRK2 and 
NG2) (Bio-Rad Laboratories). Membranes were saturated with 10 non-fat dry milk in Tris-
buffered saline (TBS; 1 mM Tris-HCl, 15 mM NaCl, pH 8) for 1 h at room temperature and 
incubated overnight at 4°C with primary antibodies diluted in 5% non-fat dry milk in TBS 
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(Table 3.2). The following day, membranes were washed in TBS-T (TBS plus 0.1 
Tween20®), incubated for 1 h with goat anti-rabbit or goat anti-mouse or goat anti-rat 
secondary antibodies conjugated to horseradish peroxidase (1:4000, 1:2000 and 1:2000 in 5% 
non-fat dry milk in TBS respectively; Sigma-Aldrich). Detection of proteins was performed by 
enhanced chemiluminescence (ECL, Thermo Scientific) and autoradiography. Non-specific 
reactions were evaluated in the presence of the secondary antibodies alone. 
The quantification of protein bands was done with ImageJ software. Films were scanned 
and a horizontal rectangular was drawn around the bands. To each band corresponds a 
specific peak and the area under the peak represents the density of Western blot band. α-
Tubulin expression was analyzed from the same sample as an internal control and it was used 
for data normalization. 
 
Table 3.2 – Primary antibody used in WB 
ANTIBODY COMPANY DILUTION 
Rabbit anti-GPR17 Home-made 1:1000 
Rat anti-MBP Millipore 1:500 
Rabbit anti-GRK2 Santa Cruz 1:200 
Mouse anti-NG2 Millipore 1:1000 
Rabbit anti-CNPase Santa Cruz 1:250 
Mouse anti-Tubulin Sigma Aldrich 1:1500 
 
3.7 Total RNA isolation and Real time PCR 
A semiquantitative analysis of RNA was done with real-time PCR (TaqMan® Gene 
Expression Assays, Applied Biosystem). This technology exploits the 5´–3´ exonuclease 
activity of Taq polymerase to cleave a dual-labeled probe during hybridization to the 
complementary target sequence and fluorophore-based detection. As in other quantitative 
PCR methods, the resulting fluorescence signal permits quantitative measurements of the 
accumulation of the product during the exponential stages of the PCR. In the TaqMan
®
 
system, three oligonucleotides are used for quantifying each sequence. Two of them are the 
primers for the PCR amplification. The third oligonucleotide (the probe) is designed to 
hybridize specifically to the amplified sequence. It has a reporter fluorescent dye (R) at the 5’-
end and a quencher dye (Q) at the 3’-end. When the probe is intact, it is non-fluorescent, due 
to fluorescence quenching by Q when it is close to R. Q acts in this way as a free resonance 
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energy transfer (FRET) across the space. During the process of primer extension of PCR, the 
DNA polymerase displaces and cleaves the probe using its 5’ to 3’ exonuclease activity. 
Cleavage separates the dye and the quencher so that the dye becomes now fluorescent. The 
increase in fluorescence is thus directly correlated to the accumulation of the PCR product, 
and can be used to monitor the formation of the PCR product in real time. For every sample, 
an amplification plot is generated, showing the increase in the reporter dye fluorescence 
(ΔRn) with each cycle of PCR. From each amplification plot, a threshold cycle (Ct) value is 
calculated, representing the PCR cycle number at which the fluorescence becomes detectable 
above a threshold value, based on the variability of base line data in the first 15 cycles. The Ct 
values were elaborated with the Comparative CT method (ΔΔCT) which allows the relative 
quantification of template comparing the expression levels of the interested gene with the 
ones of the housekeeping gene. 
Total RNA was extracted using the TRIZOL® reagent (Life Technologies) according to the 
manufacturer's instructions. RNA was then pre-treated with RQ1 DNase (Promega) for 
eliminating genomic DNA contamination. Retrotranscription of 1 μg RNA was performed 
with Superscript II RNaseH Reverse Transcriptase (200 U per sample; Life Technologies) 
using 100 pmoles of OligodT (Life Technologies), as primers. The quality of RNA sample 
was assessed with amplification reaction (PCR). 
For real time PCR, several mix were prepared according to the number of interested genes. 
The housekeeping gene GAPDH was used as control. Each mix included: 
 Master mix (2X) 
 250 nM Probe (specific for each gene, Life Technologies) (Table 3.3) 
 Sterile H2O 
 50 ng of cDNA 
 
Table 3.3 – Probes used in Real time PCR 
TATGET cDNA PROBE 
NG2 Rn00578849_m1  
GPR17 Rn03020713_s1 
MBP Rn01399619_m1 
SIRT2 Rn01457502_m1 
GAPDH Rn01775763_g1 
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3.8 Immunoprecipitation 
OPCs were treated with medium alone (basal) or with UDP-glucose (5 μM) or LTD4 (50 
nM) for 5 minutes, and then lysed for 60 min at 4 °C by the addition of 200 μl RIPA buffer 
(9.1 mM NaH2PO4, 1.7 mM Na2HPO4, 150 mM NaCl, pH 7.4, 0.5% sodium deoxycholate, 
1% Nonidet P-40, and 0.1% SDS, protease inhibitor cocktail). 1 mg of cell lysate was 
incubated with anti-GPR17 antibody overnight at 4 °C under constant rotation. Probes were 
then immunoprecipitated with protein A-Sepharose (2-3 h at 4 °C). Immunocomplexes, after 
being washed, were resuspended in Laemmli solution and boiled for 5 min, resolved by SDS-
PAGE (8.5%), transferred to PVDF membranes and probed overnight at 4°C with the specific 
primary antibodies: anti-GRK2 (1:100); anti-GPR17 (1:1000). The primary antibodies were 
detected using anti-rabbit or anti-mouse IgG light chains conjugated to peroxidase (diluted 
1:10000 and 1:5000, respectively). 
 
3.9 Receptor phosphorylation 
OPCs were treated with medium alone (control) or with 100 μM UDP-glucose or 100 nM 
LTD4 for different times (5, 30 or 90 min), and then lysed for 60 min at 4 °C by the addition 
of 200 μl RIPA buffer (see paragraph 3.8). Extracts were then quantified by protein assay, and 
1 mg of cell lysate was precleared with protein A-Sepharose (1 h at 4 °C) to precipitate and 
eliminate IgG. Samples were then centrifuged for 10 min at 4 °C (14,000 g). The supernatants 
were incubated with anti-GPR17 antibody overnight at 4 °C under constant rotation and then, 
immunoprecipitated with protein A-Sepharose (2 h at 4 °C). Immunocomplexes, after being 
washed, were resuspended in Laemmli solution and boiled for 5 min, resolved by SDS-PAGE 
(8.5%), transferred to PVDF membranes and probed overnight at 4 °C with primary antibody 
anti-Phosphothreonine (Millipore, 1:750) or anti-Phosphoserine (Millipore, 1:750). The 
primary antibodies were detected using anti-rabbit IgG light chains conjugated to peroxidase 
(diluted 1:10.000). The peroxidase was detected using a chemiluminescent substrate (ECL, 
Perkin Elmer).  
 
3.10 Measurement of cyclic AMP levels 
The intracellular cAMP assay was performed to test the ability of GPR17 agonists to 
induce homologous desensitization. Intracellular cAMP levels were measured using a 
competitive protein binding method as reported (Daniele et al, 2011 Fumagalli et al, 2011). 
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Briefly, purified OPCs were seeded on poly-D,L-ornithine 24-well plates (1.5 x 10
4
 
cells/well) in 0.5 ml of medium (Neurobasal + B27) and maintained in culture for 5–6 days 
(peak of GPR17 expression). For the assay, the entire medium was removed, and cells were 
incubated at 37°C for 15 min with 0.4 mL of DMEM in the presence of the phosphodiesterase 
inhibitor, Ro20-1724 (20 μM). Cells were pre-treated with high concentration of UDP-
glucose (5 μM) or LTD4 (50 nM) for different times (5-120 min) and then, cells were washed 
with 400 μl of saline and stimulated with the same agonists but at low concentration (UDP-
glucose 500 nM; LTD4 5 nM) and their ability to inhibit cAMP accumulation stimulated by 
10 μM forskolin was assessed. Reactions were terminated by medium removal and addition of 
200 μl of 0.4 N HCl. After 30 min, lysates were neutralized with 50 μl of 4 N KOH, and the 
suspension was centrifuged at 800 rcf for 5 min. For determination of cAMP, cAMP-binding 
protein isolated from bovine adrenal glands was incubated with [
3
H]cAMP (2 nM), 50 μl of 
cell lysate or cAMP standard (0–16 pmol) at 4 °C for 150 min, in a total volume of 300 μl. 
Bound radioactivity was separated by rapid filtration through GF/C glass fiber filters and 
washed twice with 4 ml of 50 mM Tris-HCl, pH 7.4. Radioactivity was measured by liquid 
scintillation spectrometry. 
To assess the involvement of GRK2and of mTOR pathway in GPR17 homologous 
desensitization, the same experiment was repeated, in the absence (control cells) or in the 
presence of 1 μM of the specific GRK2 inhibitor or of 15 nM of rapamycin. 
 
3.11 Statistical analysis 
All results were expressed as mean ± s.e. of at least three independent experiments. 
Statistical analysis was done with non-lineat multipurpose curve-fitting Graph-Pad Prism 
program (Graph-Pad). The statistical test used was chosen according to the type of experiment 
performed and was indicated in the legend of the figure. Three degrees of significance were 
considered: P < 0.05 (*), P < 0.01 (**), P < 0.001 (***). 
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4.1 Effects of GPR17 activation by its endogenous ligands on 
oligodendrocyte precursor cell (OPC) maturation and myelination 
4.1.1 GPR17 agonists regulate myelin proteins expression during OPC differentiation in 
vitro 
As described in detail in the “Introduction”, OPCs are widely distributed in the grey and in 
the white matter of the adult brain and spinal cord, constituting about the 5% of all cells in the 
CNS (Pringle et al., 1992). These precursors are extremely important within the adult nervous 
system, since they represent an endogenous source of remyelinating oligodendrocytes (OLs) 
in diseases characterized by demyelinated lesions.  
OPC differentiation into mature OL is a complex process that requires cell cycle exit and 
the coordinate expression of specific genes and proteins required for maturation and 
myelination. During this spontaneous process, OPCs progress through distinct morphological 
and antigenic stages that have been characterized extensively both in vitro and in vivo 
(Warrington et al., 1993; Pfeiffer et al., 1993; Miller, 2002; Emery, 2010). In this respect, 
recent studies carried on in our laboratory have proposed GPR17 as a new functional OL 
marker (Lecca et al., 2008; Fumagalli et al., 2011, Boda et al., 2011). Both in vivo and in vitro 
experiments have shown that this receptor (both its transcript and protein) is natively 
expressed by OPCs with a precise spatio-temporal pattern. Indeed, as depicted in Figure 4.1, 
despite the presence of GPR17 transcript in early bipolar NG2
+
-progenitors of stage 1, the 
protein starts to appear in more mature precursors of stage 2, reaching a plateau in pre-
oligodendrocytes of stage 3, then gradually decreasing in post-mitotic immature OL of stage 
4. After the O4/O1 differentiation stage, GPR17 is progressively turned down and never 
found in fully mature myelinating OL of stage 5. Moreover, by means of pharmacological and 
biotechnological approaches, it has been previously demonstrated that OPC exposure to the 
GPR17 endogenous agonist UDP-glucose (100 μM) promotes their differentiation towards 
more mature cells, as indicated by the increased number of MBP
+
-OL in culture. Of note, the 
pro-differentiation effect of this endogenous ligand was specifically mediated by GPR17 since 
the receptor knock-down completely abrogates this effect (Fumagalli et al., 2011).  
To widen these data, we first evaluated the pro-differentiating properties of other known 
endogenous GPR17 agonists (i.e. UDP, LTD4 and LTE4) (Fumagalli et al., 2011) in purified 
primary OPCs. The ability of these compounds to act as agonists on GPR17 has been 
previously established by cAMP assay (see “Introduction”), but their effects on OPC 
maturation have not been evaluated yet. 
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Figure 4.1 - Schematic representation of the OPC differentiation process 
The drawing shows the different stages of OPC differentiation process, starting from immature NG2
+
-
precursors to mature OL of stage 5. Specific stage markers and some representative brightfield 
microscope images of cell morphology at each maturation step are reported. As indicated by the 
yellow/orange triangle, GPR17 expression is restricted to a specific temporal window, with a peak in 
the pre-oligodendrocytes of stage 3 (image modified from Fumagalli et al., 2011) 
 
To this purpose, OPCs were cultured for 2 days in presence of PDGF and bFGF in order to 
promote proliferation and, then, after 3/4 days in differentiating medium (stage 2/3) cells were 
treated with UDP (100 μM), LTE4 (10 nM) and LTD4 (100 nM). After 48 hours, cells were 
fixed for ICC analysis or lysed for WB analysis. As shown in Figure 4.2 (E), UDP, LTE4 and 
LTD4 strongly increased the percentage of MBP
+
-cells compare to vehicle-treated control 
(CTRL: 100 ± 6.83%; UDP: 158.4 ± 11.49%; LTE4: 165.2 ± 8.80%; LTD4: 171 ± 21.70%), 
indicating an acceleration in OPC maturation, as also confirmed by appearance of a 
myelinating phenotype in culture (Figure 4.2 B, C and D). No changes in the total number of 
cells in culture were observed in all experimental conditions, indicating that these ligands did 
not affect cell proliferation and/or survival (data not show). In line with these data, also WB 
analysis confirms the pro-differentiating effects of UDP and LTE4 on OPC differentiation 
(Figure 4.2 F and G). Indeed, quantitative analysis of CNPase protein showed that both these 
ligands significantly increased CNPase expression with respect to control (CTRL: 100 ± 
5.06%; UDP: 137.2 ± 6.47%; LTE4: 126.1 ± 5.79%).  
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Figure 4.2 - Activation of GPR17 by its endogenous ligands accelerates OPC maturation. 
Primary purified OPCs were cultured in differentiating medium containing T3. At day 3/4, GPR17 
endogenous ligands UDP (100 μM), LTE4 (10 nM) and LTD4 (100 nM) were added to cultures. After 
48 h, cells were fixed and immunostained with anti-GPR17 (green) and anti-MBP (red) antibodies or 
lysed for WB analysis. (A-D) Representative images of CTRL (A), UDP (B), LTE4 (C) and LTD4 (D) 
treated cell. (E) Histograms show quantification of the percentage of MBP positive cells in control 
and treated cells (with vehicle-treated control cells set to 100%). Hoechst 33258 was used to label cell 
nuclei. The number of positive cells was counted in 10 optical fields under a 10X magnification. Data 
are the mean ± S.E. of cell counts from a total of 10 coverslips/condition from three independent 
experiments (CTRL: 100 ± 6.83%; UDP: 158.4 ± 11.49%; LTE4: 165.2 ± 8.80%; LTD4: 171 ± 
21.70%). ***, p<0.001; *, p<0.05 compared to control; one-way ANOVA, followed by Bonferroni’s 
multiple comparison test. Scale bars: 15 μm. (F) CNPase expression was assessed by western blot 
after UDP and LTE4 treatment. (G) Histograms show the quantification of CNPase protein levels in 
CTRL and in UDP or LTE4-treated cultures. Scanning densitometry was quantified and normalized to 
control (set to 100%) on the same WB. α-tubulin expression was analyzed from the same samples as 
an internal control. Data are expressed as mean + S.E. of three independent experiments (CTRL: 100 
± 5.06%; UDP: 137.2 ± 6.47%; LTE4: 126.1 ± 5.79%). *, p<0.05; ***, p<0.001 compared to CTRL, 
non parametric Mann-Whitney test. 
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To univocally confirm that the pro-differentiating effect of these ligands was due to 
GPR17 activation, we took advantage of siRNAs specifically designed for silencing rat 
GPR17. Both the efficiency and the efficacy of these siRNAs to specifically act against rat 
GPR17 were already tested in the same experimental model of purified OPC cultures 
(Fumagalli et al., 2011). Using the same protocol of transfection described in this publication, 
we repeated the knock-down experiments. Based on these premises, OPCs were cultured in 
differentiating medium and transfected with either an ineffective randomly designed siRNA 
(negative control, “Neg”) or with siRNAs specifically designed against rat GPR17 (siRNA) as 
described in Fumagalli et al., 2011. 48 hours after transfection, cells were cultured in 
differentiation medium in the absence or presence of UDP (100 μM) for another 2 days and, 
then, lysed for WB analysis. As shown in Figure 4.3 A and B, WB analysis confirmed the 
remarkable decrease of GPR17 in cells transfected with GPR17 siRNAs with respect to cells 
transfected with ineffective siRNAs (Neg: 100 ± 3.62%; siRNA: 43.10 ± 0.91%).  
 
Figure 4.3 - GPR17 knock-down abolishes the UDP pro-differentiating effect. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for 2 or 3 days and, then, 
cell differentiation was induced by adding T3 in the medium. Concomitantly, cells were treated with 
either siRNAs (50 nM) specifically designed against rat GPR17 (siRNA) or ineffective randomly 
designed siRNA utilized as a negative control (Neg). For 48 hours after transfection, UDP (100 μM) 
was added in the culture medium and was left for another 48 hours. (A, C) GPR17 and MBP 
expression was assessed by WB analysis. (B) Histograms show the quantification of GPR17 protein 
levels in cells transfected with the ineffective siRNA and in siRNA GPR17-treated cultures. Scanning 
densitometry was quantified and normalized to CTRL (set to 100%) on the same WB. α-tubulin 
expression was analyzed from the same samples as an internal control. Data are expressed as mean + 
S.E. of two independent experiments (Neg: 100 ± 3.62%; siRNA: 43.10 ± 0.91%). *, p<0.05 compared 
to Neg, unpaired T-test. (D) Histograms show the quantification of MBP protein levels in cells 
transfected with the ineffective siRNA and in siRNA GPR17-treated culture in presence or absence of 
UDP. Scanning densitometry was quantified and normalized to CTRL (set to 100%) on the same 
western blot. α-tubulin expression was analyzed from the same samples as an internal control. Data 
are expressed as mean + S.E. (siRNA: 1.98 ± 0.13%; siRNA+UDP: 10.81 ± 1.10%). **, p<0.01 
compared to Neg; *, p<0.05 compared to Neg; ##, p<0.01 compared to siRNA+UDP, unpaired T-
test. 
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Moreover, as expected, UDP treatment increased MBP protein levels compared to non-
treated cultures (Neg: 100 ± 1.21%; Neg+UDP: 127.6 ± 1.10%). In contrast, GPR17 knock-
down in siRNA-transfected cultures blocked OPC maturation (siRNA: 1.98 ± 0.13%) and, in 
these cultures, the pro-differentiation effect of UDP was completely lost (siRNA+UDP: 10.81 
± 1.10%), indicating that, as for UDP-glucose, also in this case the effect was specifically 
mediated by GPR17. These data confirm that GPR17 plays a functional role in OPCs 
differentiation and its activation at early differentiation stages induces OPCs to undertake 
their differentiation program towards a mature phenotype. 
 
4.1.2 Characterization of OPC/DRG co-cultures 
To evaluate whether, besides favouring the acquisition of a myelinating phenotype, GPR17 
ligands can influence the formation of myelin segments, purified OPCs were cultured with 
DRG. Different protocols for this in vitro model have been described in literature and they 
mainly differ for the time length for which DRG are maintained in cultures before adding 
OPCs. Indeed, DRG can be cultured as dissociated or undissociated neurons (Jarjour et al., 
2012). Both models are largely accepted within the scientific community, but we decided to 
follow the second approach, since our preliminary data indicate that the dense neurite beds 
extending from intact ganglia favours myelin sheath formation. 
As described in detail in the paragraph 3.2.1, DRG explants from E14.5 mice were directly 
put in culture after being plucked off from embryo spinal cords. Then, they were grown in 
presence of NGF, a neurotrophic factor which is known to promote neuritis outgrowth and in 
presence of FUDR in order to remove all non-neuronal cells. After 20 days, when neuritis 
were well extended radially from DRG explants, OPCs were seeded onto DRG and 
myelination was induced by the adding of TrkA-Fc which is a recombinant factor able to 
sequestrate NGF that has been demonstrated to inhibit OPC myelination (Chan et al., 2004). 
To fully characterize how OPC differentiation proceeds in this in vitro model, also in relation 
to GPR17 expression, cells were fixed at different times and immunostained with specific 
differentiation stage markers. As shown in Figure 4.4, after 4 days in co-culture (A), the 
majority of OPCs expressed NG2 and they were distributed along neuronal filaments; after 6 
days (B), all the cells expressing GPR17, displayed an highly ramified morphology and some 
of them started taking contact with axons; after 8 days in co-culture (C), cells started 
expressing MBP and establishing contacts with neurofilaments, wrapped them and forming 
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the myelin sheath. The number of myelinating OL progressively increased during the 
following days. 
 
 
Figure 4.4 - Characterization of OPC/DRG co-cultures. 
DRG were maintained in culture in presence of NGF for 20 days. When neuritis were well extended 
radially from DRG explants, purified OPCs were added to each DRG in culture. In order to 
characterize how OPC differentiation proceeds in this in vitro model, cells were fixed and 
immunolstained with different stage-specific markers at different times. (A) After 4 days in co-culture, 
the majority of OPCs expressed NG2 (in red); neurofilaments (NF) are immunolabelled with SMI 31, 
which specifically recognized the phosphorylated neurofilament H and with SMI 32, which recognized 
the non-phosphorylated neurofilament H (in green). (B) After 6 days in co-culture, the majority of 
OPCs expressed GPR17 (in green); neurofilaments are immunolabeled with anti-β-tubulin III (in red). 
(C) After 8 days in co-culture, cells started expressing MBP (in red) and some of them started 
myelinating neuronal axons (NF, in green). The number of myelinating OL progressively increases 
during the following days (data no shown). Images were taken under a confocal microscope at 40X 
magnification. Scale bars: 20 μm. 
 
 
Since this type of culture is extremely complex and variable, in the last decade several 
strategies have been proposed for setting a reliable method for the quantification of the 
myelination process. These approaches include the measurement of CNPase activity 
(Birgbauer et al., 2004; Roth et al., 1995) or of the immunofluorescence staining for MBP 
(Ghoumari et al., 2003; Mi et al., 2009; Miron et al., 2010). However, it has to be highlighted 
that both these two methods do not allow a direct quantification of myelination. In fact the 
former is based on the measurement of a marker of OL differentiation, rather than the 
presence of myelin sheaths; the latter allows only the quantification of MBP which is present 
in OL processes and cell bodies as well as in myelin sheaths. Moreover, neither approach 
considers the number of axons present in the culture that is a prerequisite for myelination. The 
need of a fast, accurate, objective and automatic quantification of the amount of myelin is 
crucial for the study of factors influencing myelination and remyelination. In this respect, 
Zhang and co-workers have recently developed a new method for myelin quantification which 
is based on the possibility to directly quantify the myelin amount in an ex vivo slice culture 
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system using the immunohistochemistry approach and a confocal microscope. Through this 
method, the structural myelin protein (MBP) and the axonal protein neurofilaments (NF) are 
stained with two different fluorophores and, then, only the overlapping between these two 
staining, which represents the myelin sheath, is measured. This approach allows the exclusion 
of OL cell bodies and of non-myelinating processes which are also stained for MBP (Zhang et 
al., 2011).  
We took advantage of this new method of analysis and we adapted this approach to the 
quantification of myelination in our in vitro system (Figure 4.5). The OPC/DRG co-cultures 
were maintained in culture for 11 days and, then, cells were fixed and immunostained for NF 
and for myelin. NF (in green) were immunolabelled with two different antibodies: anti-Smi 
31, which specifically recognized the phosphorylated neurofilament H and anti-Smi 32, which 
recognized the non-phosphorylated neurofilament H; myelin was immunolabelled with anti-
MBP antibody (in red).  
,  
Figure 4.5 - Automatic quantification of myelination in OPC/DRG co-cultures. 
(A) OPC-DRG co-cultures were maintained in culture for 8 days and then fixed and immunostained 
for neurofilaments with anti-Smi 31 and anti-Smi 32 antibodies (in green), and (B) for myelin with an 
anti-MBP antibody (in red). (C) To perform the quantification of myelination, stacks of images of 
MBP and NF positive cells were taken under confocal microscope Zeiss LSM 510 META at 40X 
magnification. The ZEISS LSM Image Browser was utilized to automate quantification of the 
myelination index. Images in the stack were merged at each level and pixels overlapping in the red 
and green fields above a predefined threshold intensity value were highlighted in white. The 
myelination index, which represents the amount of myelin per axon, is the ratio between the white 
pixels area and the green pixels area. 
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Quantification of myelination was performed under the confocal microscope. Stacks of 
images of MBP and NF positive cells were taken at 40X magnification and, then, images 
within the stack were merged at each level. The ZEISS LSM Image Browser was utilized to 
automate quantification of the myelination: pixels overlapping in the red and green fields 
above a predefined threshold intensity value were counted (white pixels area) and divided by 
the number of green pixels (NF). This ratio is the “Myelination Index” and represents the 
amount of myelin per axon. 
 
4.1.3 GPR17 agonists promote the myelination in OPC/DRG co-culture system 
To determine whether GPR17 activation can also affect the myelination process, we 
performed a series of experiments using the OPC/DRG co-culture system. As described in the 
previous paragraph, OPCs co-cultured with DRG spontaneously differentiate reaching a 
mature phenotype starting from day 8. UDP-glucose (100 μM) and UDP (100 μM) were 
added to OPC/DRG co-cultures at day 4 when OPCs started expressing GPR17 and the 
pharmacological treatment was continued up to 11 days in order to have a high number of 
myelinating OL. After this time, DRG displayed a general “suffering” state due to a huge 
increased number of OPCs which made the system unsuitable for the automatic 
quantification. After fixation, cells were immunostained for MBP and NF and myelin 
segments were quantified as previously described. 
As shown in Figure 4.6 (D), GPR17 activation mediated by both UDP-glucose and UDP 
significantly promoted the formation of myelinated segments as shown by the increased value 
of the “Myelination Index” (CTRL: 0.011 ± 0.0015%; UDP-glucose: 0.026 ± 0.008%; UDP: 
0.027 ± 0.007%). This increase was due to the presence of more MBP
+
-myelinated axons in 
treated-cultures (Figure 4.6 B and C) with respect to vehicle-treated cells (Figure 4.6 A). 
This result clearly demonstrated that, besides regulating the spontaneous OPC 
differentiation program as shown above, agonists-mediated GPR17 activation also enhanced 
OPC myelination. 
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Figure 4.6 - The GPR17 agonists UDP-glucose and UDP increase myelination in OPC/DRG co-
cultures. 
OPC/DRG co-cultures were exposed for 96 h to UDP-glucose (100 μM) or UDP (100 μM). 
Representative images of control (CTRL, A), UDP-glucose (UDPglu, B) or UDP (C) treated cells 
show double immunostaining for anti-MBP antobody (red) and anti-neurofilament antibody (NF, 
green), scale bar: 20 μm. (D) Histograms show the quantification of the myelin segments (Myelination 
index). Both UDP-glucose and UDP increase myelination with respect to control. Data are the mean 
± S.E. of the myelin index obtained from the analysis of 6 random fields of 3 coverslips for each 
experimental condition from two independent experiments (CTRL: 0.011 ± 0.0015%; UDP-glucose: 
0.026 ± 0.008%; UDP: 0.027 ± 0.007%). *, p < 0.0,5 Student’s T-test.  
 
 
4.2 Down-regulation of GPR17 at late OPC differentiation stages is needed 
to complete cell maturation 
Our previous in vitro data demonstrated that GPR17 transiently labels specific early OPC 
differentiation stages, reaching a maximal expression in cells that exit the cell cycle and 
become irreversibly committed to differentiation. On the contrary, mature OLs expressing the 
myelin proteins PLP, MAG and MBP do no longer express the receptor (see paragraph 1.2.5 
for details) (Fumagalli et al., 2011). Accordingly, a detailed in vivo study also showed that, in 
rodents, during postnatal development, GPR17-expressing OPCs are already present at birth; 
receptor expression increases over time during postnatal development clearly preceding the 
peak of myelination, and then declines in the adult brain while myelination proceeds (Boda et 
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al., 2011). Altogether these results suggest that the down-regulation of GPR17 at an advanced 
differentiation stage is a prerequisite to allow cells to proceed to terminal maturation.  
On this basis, to verify this hypothesis, OPCs were transfected with a fluorescent plasmid 
in which the coding sequence for GPR17 has been cloned in frame with the sequence coding 
for GFP (GPR17-GFP). In parallel, as a control we used the same empty vector (GFP). These 
plasmids gave us the possibility to follow the destiny of the cells thanks to the green 
fluorescence, in order to compare OPC maturation of control cells, with cells in which GPR17 
has been over-expressed. As shown in figure 4.7, we demonstrated that most cells 
incorporating a GFP-GPR17 fusion vector for GPR17 over-expression did not express the 
mature marker CNPase (B). Conversely, the majority of cells transfected with the control 
plasmid (containing only GFP) normally underwent in vitro maturation and expressed 
CNPase (A).  
 
Figure 4.7 – Forced GPR17 expression at late OPC differentiation stages impairs cell terminal 
maturation. 
(A) shows representative culture transfected with an empty GFP-fluorescent plasmid. The majority of 
these GFP-positive cells (in green) normally undergoes in vitro maturation, as shown by expression of 
the mature marker CNPase (in red). On the contrary, most cells incorporating a GFP-GPR17 fusion 
vector for GPR17 over-expression (B) do not maturate and do not express CNPase. (C) Histograms 
show quantification of the percentage of transfected cells expressing CNPase over the total 
transfected cell population in the two conditions analyzed: transfection with the control plasmid GFP 
set to 100% (100 ± 8.46%, number of counted cells: 1654) and transfection with GFP-GPR17 (37.03 
± 6.84%, number of counted cells: 720). ***, p<0.001 compared to control, Student T-test.  
 
 
 Results 
 
98 
 
For the quantification, the total number of transfected cells expressing CNPase was 
expressed as the percentage over the total transfected cell population (C) (GFP: 100 ± 8.46%; 
GFP-GPR17: 37.03 ± 6.84%). These data clearly suggest the existence of a timely restricted 
expression of GPR17 and that interferences with this physiological down-regulation of the 
receptor in OPCs result in permanently elevated GPR17 levels and impairment of OPC 
terminal differentiation.  
 
4.3 GPR17 homologous desensitization in primary OPCs 
4.3.1 GPR17 agonists switch the receptor off inducing its desensitization/internalization 
The mechanisms underlying GPR17 physiological down-regulation during OPC 
differentiation still remain to be elucidated. Their characterization is quite important, since 
alterations in these mechanisms leading to excessive/prolonged expression of GPR17 in OPCs 
may contribute to the limited remyelination after demyelinating insults. According to this, 
GPR17 has been found markedly up-regulated in rodents in which focal cerebral 
demyelination was induced through the local injection of lysolecithin (Boda et al., 2011) and 
in MS patients (Chen et al., 2009), suggesting that impaired GPR17 down-regulation may 
contribute to the defective remyelination observed in these pathological conditions.  
In this respect, to explain GPR17 transient expression in OPCs and its effects on cell 
maturation, a current hypothesis is that, by binding to GPR17, its endogenous ligands can first 
induce early precursor cells to undergo differentiation and then switch the receptor off by 
agonist-induced desensitization, thus allowing cell terminal maturation. Thus, by controlling 
the active state of receptors at the plasma membrane, agonist-mediated GPR17 
desensitization/internalization finely regulates cell progression along their differentiation 
pathway. 
Previous studies performed either in a recombinant system (Daniele et al., 2011) or native 
GPR17
+
-cells (Olineu cells) (Fratangeli et al., 2013) have already demonstrated that both 
uracil nucleotides and cystenyl-leukotrienes are able to induce GPR17 
desensitization/internalization with different kinetics. In the present work, by using primary 
cultured OPCs, we investigated in detail the molecular mechanisms underlying GPR17 
desensitization. To this aim, we first performed a cAMP assay as previously described in 
Daniele et al., 2011. Cells were maintained in culture up to the pre-oligodendrocyte stage 
(which corresponds to the peak expression of GPR17) and, then, treated for different times (5-
120 min) with 50 nM LTD4 or 5 µM UDP-glucose (almost 10 times over their EC50 values). 
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After extensively washes, cells were stimulated with the same agonists, but at low 
concentration (UDP-glucose 500 nM; LTD4 5nM) and their ability to inhibit cAMP 
accumulation stimulated by forskolin was measured. As shown in Figure 4.8, both UDP-
glucose and LTD4 decreased GPR17 responses after an initial challenge with a high 
concentration of either agonist. These effects occurred in a time-dependent manner, resulting 
in almost complete inhibition (>85%) of GPR17 activation after 120 minutes of pre-
incubation with both agonists.  
 
Figure 4.8 - Effects of UDP-glucose and LTD4 on GPR17 desensitization in OPCs. 
Cells were treated with 5 μM UDP-glucose or 50 nM LTD4 for different time periods (5-120 min). 
After extensive washing, cells were treated for 15 min with 500 nM UDP-glucose or 5 nM LTD4 in the 
presence of 10 μM forskolin (FK) and intracellular cAMP levels were measured. Data are expressed 
as the percentage of FK-stimulated cAMP levels, set to 100%, and represent the means ± S.E. of four 
independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001 vs FK alone; #, p<0.05; ##, p<0.01; 
###, p<0.001 vs 500 nM UDP-glucose or 5 nM LTD4; one-way ANOVA, followed by Bonferroni’s 
multiple comparison test. 
 
 
4.3.2 GRK2 expression and physical association with GPR17 receptor 
As extensively described in the paragraph 1.3, agonist induced GPCRs desensitization 
classically involves rapid receptor phosphorylation by second messenger-dependent and/or G-
protein coupled receptor kinases (GRKs) (Gurevich et al., 2012). Among GRK isoforms, the 
mammalian GRK 2, 3, 5 and 6 represent the kinases primarily involved in GPCR regulation 
(Ribas et al., 2007; Yang and Xia, 2006). Agonists’ stimulation switches the receptor in an 
active state, triggers its phosphorylation by GRKs and primes the recruitment of regulatory 
proteins termed β-arrestins, leading to receptor desensitization from G protein and to the 
subsequent internalization (Ferguson, 2001). Based on this evidence, we decided to 
investigate whether GPR17 agonists-mediated homologous desensitization requires GRKs. 
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Among all GRKs isoforms, we focused on GRK2 since this isoform is widely expressed 
within the brain (Arriza et al. 1992) and alteration of its expression have been detected in 
leukocytes of patients with MS (Vroon et al., 2005), suggesting a possible role in 
demyelination. 
As a first step, using real time PCR in combination with ICC and WB experiments, we 
performed a detailed analysis of GRK2 mRNA and protein expression, in parallel with that of 
GPR17 and MBP during spontaneous in vitro OPC differentiation. As shown in figure 4.8 (B 
and C), according to our previous data, GPR17 expression (both mRNA and protein) was 
maximal in pre-oligodendrocytes (stage 3) and completely segregated from that of mature 
myelin. In contrast, MBP expression started later: MBP mRNA was already detectable in late 
precursors of stage 2 and MBP protein dramatically increased during the transition from pre-
oligodendrocytes of stage 3 and mature OL of stage 5. Both GRK2 mRNA and protein were 
already present at early differentiation stages. According to these observations, all OPCs 
expressed this kinase (Figure 4.8 A). Interestingly, as GPR17, GRK2 expression reached a 
maximal peak in pre-oligodendrocyte; then, in parallel to GPR17, GRK2 levels progressively 
declined, reaching their lowest levels in the terminal phases of differentiation (Figure 4.8 B 
and C). This pattern of expression may reflect a functional link between GPR17 and GRK2 
function during OPC maturation.  
 
 
Figure 4.9 - GRK2 expression during OPC differentiation. 
(A) Representative image of OPCs at stage 1. Cells were immunolabelled with anti-GRK2 antibody 
(green). Hoechst 33258 was used to label cell nuclei. Image was taken at 40X magnification. Scale 
bar: 25 μm. (B, C) Graph shows mRNA and protein levels of GRK2 (green line), GPR17 (red line) and 
MBP (blue line). Both RNA and protein were obtained from rat OPCs at different maturation stages 
(from stage 1 to 5). Fold changes are expressed as percentage of the peak value of each gene or 
protein, set to 100%. 
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To verify whether agonists-induced GPR17 homologous desensitization involves GRK2, 
we evaluated its recruitment and association upon GPR17 stimulation by co-
immunoprecipitation experiments. To this aim, OPCs were exposed to high concentration of 
either UDP-glucose (5 μM) or LTD4 (50 nM) and, then, GRK2/GPR17 association was 
measured. As shown in figure 4.10, under basal conditions, GPR17 weakly associated with 
GRK2. This association was remarkably increased after UDP-glucose stimulation and, to 
more extent, after LTD4 stimulation (Basal: 1 ± 0.01%; UDP-glucose: 4.93 ± 0.63%; LTD4: 
8.37 ± 0.43%). These data clearly confirmed the involvement of GRK2 in agonist-induced 
GPR17 homologous desensitization, particularly after LTD4 stimulation. 
 
Figure 4.10 - UDP-glucose and LTD4 induce GRK2 association to GPR17. 
Cells, isolated and differentiated at the pre-oligodendrocytes (stage 3), were treated with medium 
alone or with 5 μM UDP-glucose or 50 nM LTD4 for 5 min. Rat GPR17 was immunoprecipitated 
using an anti-GPR17 antibody and immunoprecipitates were probed with anti-GRK2 antibody. (A) 
Representative immunoblots of GPR17 and GRK2 in different experimental conditions. (B) 
Histograms show the result of densitometric analysis. Data are expressed as percentage versus basal 
value and represent the mean ± S.E. of three independent experiments (Basal: 1 ± 0.010%; UDP-glu: 
4.93 ± 0.63%; LTD4: 8.37 ± 0.43%). **, p<0.01; ***, p<0.001 vs basal value; one-way ANOVA, 
followed by Bonferroni’s multiple comparison test. 
 
4.3.3 GRK2 mediates LTD4-induced GPR17 homologous desensitization 
The uncoupling of GPCRs from heterotrimeric G proteins, which occurs during agonists-
induced receptor desensitization, is the consequence of a covalent modification of the receptor 
(phosphorylation) mediated by intracellular kinases. On this basis, we decided to evaluate 
whether GPR17 agonists modify the phosphorylation state of GPR17. To this purpose, OPCs 
were treated with medium alone (basal) or with UDP-glucose (5 μM) or LTD4 (50 nM) and, 
then, cells were lysed and incubated with anti-GPR17 antibody for immunoprecipitation 
experiments. The phosphorylation level of GPR17 was assessed using primary antibodies 
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which can specifically recognize the phosphorylated serine (p-Ser) and threonine residues (p-
Thr). 
As depicted in Figure 4.11, UDP-glucose and LTD4 similarly induced GPR17 
phosphorylation on threonine and on serine residues (for p-THR, Basal: 1 ± 0.058%; UDP-
glu: 1.57 ± 0.042%; LTD4: 2.12 ± 0.038%; for p-SER, Basal: 1 ± 0.058%; UDP-glu: 1.98 ± 
0.038% LTD4: 1.95 ± 0.032%), suggesting that this modification is a prerequisite to the 
subsequent desensitization. 
 
 
Figure 4.11 - UDP-glucose and LTD4 mediated GPR17 phosphorylation on Ser and Thr residues. 
OPCs were treated with 5 µM UDP-glucose or 50 nM LTD4 for 5 minutes. Following incubation, 
GPR17 was immunoprecipitated using an anti-GPR17 antibody, and immunoprecipitates were probed 
with anti-phosphothreonine or anti-phosphoserine antibodies. (A) Representative immunoblots of 
GPR17, phospho-Thr (p-THR) and phosphor-Ser (p-SER) protein levels in different experimental 
conditions. (B) Histograms show the result of densitometric analysis. Data are expressed as 
percentage of basal phosphorylation levels (set to 1) and represent the mean ± S.E. of two independent 
experiments (For p-THR, Basal: 1 ± 0.058; UDP-glu: 1.57 ± 0.042; LTD4: 2.12 ± 0.038. For p-SER, 
Basal: 1 ± 0.058; UDP-glu: 1.98 ± 0.038; LTD4: 1.95 ± 0.032). ***, p<0.001 vs basal value; one-way 
ANOVA, followed by Bonferroni’s multiple comparison test. 
 
 
To further confirm the specificity of GRK2 in LTD4-mediated GPR17 desensitization in 
OPCs, we repeated the cAMP assay in presence of KRX2929, a selective GRK2 inhibitor, 
which has been previously characterized (Gomez-Monterrey et al., 2014). Cells pre-treated 
with the GRK2 inhibitor impaired LTD4-mediated GPR17 desensitization (Figure. 4.12 black 
bars), suggesting that GRK2 selectively mediated GPR17 homologous desensitization 
following to the exposure of this receptor agonist. 
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Figure 4.12 - GRK2 pharmacological inhibition prevents LTD4-mediated GPR17 desensitization in 
OPCs. 
OPCs, isolated and differentiated at pre-oligodendrocytes (stage 3), were treated with 50 nM LTD4 
for different times (5-120 min), in the absence (white bars) or in the presence (black bars) of the 
selective GRK2 inhibitor, KRX29 (1 µM). After extensive washing, cells were treated for 15 min with 
10 µM FK, in the absence or in the presence of 5 nM LTD4. Intracellular cAMP levels were evaluated 
as reported in the method section. Data are expressed as the percentage of FK-stimulated cAMP 
levels, set to 100%, and represent the means ± E.S of six independent experiments. **, p<0.01; ***, 
p<0.001 vs 5 nM LTD4; one-way ANOVA, followed by Bonferroni’s multiple comparison test. 
 
4.3.4 Role of GRK2 in GPR17 agonist-mediated OPC maturation 
To dissect the actual involvement of GRK2 in OPC myelination, we assessed the effects of 
GRK2 knock-down on cell maturation. After 3 days in proliferation medium, OPC 
differentiation was induced by adding T3 in the culture medium and GRK2 silencing was 
obtained by transfecting cells with a pool of four siRNA specifically designed against GRK2. 
In parallel, control cultures were transfected with an ineffective randomly designed pool of 
siRNA. The silencing efficiency of GRK2 and its consequences on OPC differentiation were 
evaluated by WB analysis after 48 and 96 hours, which correspond to pre-oligodendrocyte 
and immature OL stages respectively. As depicted in Figure 4.13, at both times after RNA 
interference, cells transfected with GRK2 siRNAs (siRNA) showed a significant reduction of 
GRK2 protein levels with respect to cultures transfected with ineffective siRNAs (CTRL) 
(CTRL 48h: 100 ± 1.19%; siRNA GRK2 48h: 52.14 ± 8.91%; CTRL 96h: 100 ± 2.13%; 
siRNA GRK2 96h: 66.91 ± 3.27%). 
Once established the efficacy of GRK2 siRNAs, we analyzed the effects of GRK2 knock-
down on the expression of GPR17, CNPase and MBP both in pre-oligodendrocytes and in 
immature OL. As shown in Figure 4.14, GRK2 knock-down did not alter GPR17 expression 
in pre-oligodendrocytes, but induced a significant increase in immature OL (CTRL 48h: 100 
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± 1.71%; siRNA GRK2 48h: 115.3 ± 20.19%; CTRL 96h: 100 ± 3.29%; siRNA GRK2 96h: 
171.4 ± 34.10%).  
 
Figure 4.13 - GRK2 knock down by specific siRNA in primary OPCs. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for 2 or 3 days and, then, 
cell differentiation was induced by adding T3 in the medium. Concomitantly cells were treated with 
either siRNAs (50 nM) specifically designed against rat GRK2 (siRNA GRK2) or ineffective randomly 
designed siRNA utilized as a negative control (CTRL). (A) GRK2 expression was assessed by WB 
analysis, 48 (pre-OL) and 96 hours (immature OL) after transfection. (B) Histograms show the 
quantification of GRK2 protein levels in CTRL and in siRNA GRK2-treated cultures. Scanning 
densitometry was quantified, corrected for the corresponding α-tubulin band on the same WB and 
normalized to CTRL (set to 100%). Data are expressed as mean + S.E. of three independent 
experiments (CTRL 48h: 100 ± 1.19%; siRNA GRK2 48h: 52.14 ± 8.91%; CTRL 96h: 100 ± 2.13%; 
siRNA GRK2 96h: 66.91 ± 3.27%). **, p < 0.01 compared to CTRL, non parametric Mann-Whitney 
test.  
 
 
Figure 4.14 - GRK2 knock down by specific siRNA prevents GPR17 down-regulation at immature 
OL stage. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for 2 or 3 days and, then, 
cell differentiation was induced by adding T3 in the medium. Concomitantly, cells were treated with 
either siRNAs (50 nM) specifically designed against rat GRK2 (siRNA GRK2) or ineffective randomly 
designed siRNA utilized as a negative control (CTRL). (A) GPR17 expression was assessed by WB 
analysis in indicated condition after 48 (pre-OL) and 96 hours (immature OL) from transfection. (B) 
Histograms show the quantification of GPR17 protein levels in CTRL and in siRNA GRK2-treated 
cultures. Scanning densitometry was quantified and normalized to control (set to 100%) on the same 
WB. α-tubulin expression was analyzed from the same samples as an internal control. Data are 
expressed as mean ± S.E. of three independent experiments (CTRL 48h: 100 ± 1.71%; siRNA GRK2 
48h: 115.3 ± 20.19%; CTRL 96h: 100 ± 3.29%; siRNA GRK2 96h: 171.4 ± 34.10%). **, p < 0.01 
compared to CTRL, non parametric Mann-Whitney test. 
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Also for the mature markers CNPase and MBP, no variation was detected in cells 
transfected with GRK2 siRNA after 48 hours (for CNPase, CTRL 48h: 100 ± 0.51%; siRNA 
GRK2 48h: 102.6 ± 8.15%; for MBP, CTRL 48h: 100 ± 1.95%; siRNA GRK2 48h: 101.9 ± 
24.59%). On the contrary, after 96 hours, both CNPase and MBP expression resulted 
markedly reduced in cells transfected with GRK2 siRNAs with respect to control cultures (for 
CNPase, CTRL 96h: 100 ± 0.72%; siRNA GRK2 96h: 80.68 ± 3.03%; for MBP, CTRL 96h: 
100 ± 1.34%; siRNA GRK2 96h: 64.26 ± 11.74%) (Figure 4.15). 
 
 
Figure 4.15 - GRK2 knock down by specific siRNA blocks OPC maturation 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for 2 or 3 days and, then, 
cell differentiation was induced by adding T3 in the medium. Concomitantly, cells were treated with 
either siRNAs (50 nM) specifically designed against rat GRK2 (siRNA GRK2) or ineffective randomly 
designed siRNA utilized as a negative control (CTRL). (A) MBP and CNPase expression was assessed 
by WB analysis in indicated condition after 48 (pre-OL) and 96 hours (immature OL) from 
transfection. (B-C) Histograms show the quantification of MBP and CNPase protein levels in CTRL 
and in siRNA GRK2-treated cultures. Scanning densitometry was quantified and normalized to control 
(set to 100%) on the same WB. α-tubulin expression was analyzed from the same samples as an 
internal control. Data are expressed as mean ± S.E. of three independent experiments (for CNPase, 
CTRL 48h: 100 ± 0.51; siRNA GRK2 48h: 102.6 ± 8.15%; CTRL 96h: 100 ± 0.72%; siRNA GRK2 
96h: 80.68 ± 3.03%; for MBP, CTRL 48h: 100 ± 1.95%; siRNA GRK2 48h: 101.9 ± 24.59%; CTRL 
96h: 100 ± 1.34%; siRNA GRK2 96h: 64.26 ± 11.74%). *, p<0.05; **, p < 0.01 compared to CTRL, 
non parametric Mann-Whitney test. 
 
Globally, these data indicate a significant impairment of OPC maturation after GRK2 
knock-down, which is detectable starting from the immature OL stage, suggesting an active 
involvement of this kinase in the transition from pre-oligodendrocytes to immature OL. 
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Finally, having established that, in primary cultured OPCs, LTD4-mediated GPR17 
desensitization occurs through the primary recruitment of GRK2, we asked whether GRK2 
pharmacological inhibition had any effects on cysLT-promoted cell maturation. To this 
purpose, OPCs were exposed to LTD4 in absence (CTRL) or in presence of the selective 
GRK2 pharmacological inhibitor.  
As shown in Figure 4.16, OPC exposure to LTD4 resulted in appearance of a myelinating 
phenotype in culture and in an increase of the number of MBP
+
-OL (C, E), demonstrating, as 
expected, an acceleration of cell maturation. In contrast, in presence of the specific GRK2 
inhibitor, LTD4-mediated differentiation was significantly inhibited (Figure 4.16 D, E), as 
showed by a similar number of MBP
+
-cells in these experimental conditions with respect to 
control culture. No differences in the number of MBP
+
-OL was observed in cultures treatment 
with only GRK2 inhibitor (B) (CTRL: 100 ± 11.15%; GRK2 inhibitor: 99.38 ± 4.83%; LTD4: 
171.7 ± 12.89%; LTD4 + GRK2 inhibitor: 93.94 ± 9.0%). Also the total number of cells 
(Hoechst 33258 staining) were unaffected by pharmacological treatment (data not shown). 
Globally, these data clearly demonstrate that GRK2-mediated desensitization of GPR17 is 
indeed necessary to enable OPCs to complete their differentiation program. 
 
 
Figure 4.16 – GRK2 pharmacological inhibition blocks LTD4-mediated OPC differentiation. 
OPCs, maintained in differentiating medium, were treated with LTD4 (100 nM) in the absence (CTRL) 
or in the presence of 1 μM of the specific GRK2 inhibitor (KRX29). After 48 hours, cells were fixed to 
determine their maturation degree by immunostaining with anti-MBP antibody. Hoechst 33258 was 
used to label cell nuclei. The number of positive cells was counted in 50 optical fields under a 40X 
magnification (2000 cells/coverslip in the control condition).(A-D) Representative images of CTRL 
(A), GRK2 inhibitor (B), LTD4 (C) and GRK2 inhibitor + LTD4 (D) treated-cells. (E) Histograms 
show the quantification of the percentage of cells expressing the mature marker MBP in control and 
treated cells (with CTRL set to 100%). Data are the mean ± S.E. of cell counts from three independent 
experiments (CTRL: 100 ± 11.15%; GRK2 inhibitor: 99.38 ± 4.83%; LTD4: 171.7 ± 12.89%; LTD4 + 
GRK2 inhibitor: 93.94 ± 9.0%). *, p < 0.05 vs CTRL; **, p< 0.01 vs LTD4 ; non parametric Mann-
Whitney test. 
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4.4 Role of the mTOR pathway in the regulation of GPR17 expression 
As mentioned in the previous paragraphs, the most rapid mechanism through which 
GPCRs are uncoupled from heteromeric G proteins is the covalent modification of the 
receptor as a consequence of phosphorylation by intracellular kinases (both GRKs and second 
messenger-dependent protein kinases). We have already demonstrated above that GRKs are 
involved in GPR17 receptor down-regulation after agonist exposure. However, recruitment of 
these kinases to the receptor may be also independent of agonist stimulation. This has been 
shown for second messenger-dependent protein kinases that do not only phosphorylate 
agonist activated GPCRs, but, under some circumstances, can also phosphorylate receptors 
that have not been exposed to agonists, thus representing an alternative or additional pathway 
to regulate the response of membrane receptors to extracellular signals (Hausdorff et al., 
1989; Lohse et al., 1990). Nevertheless, it is now recognized that GPCRs spontaneously 
isomerize to an activated conformation in the absence of agonist, which suggests that GRKs 
may also contribute to the regulation of basal GPCR activity (Pei et al., 1994; Rim and 
Oprian, 1995). Therefore, the identification of further intracellular signaling pathways that 
can modulate the activity of these kinases in an agonists-independent manner is crucial. On 
this basis, we decided to investigate other intracellular signaling pathways involving kinases 
that, by modulating GPR17 expression/trafficking and/or GRK2 expression/function through 
modifications of its phosphorylate state, may also control OPC maturation.  
In this respect, recent studies have shown that a possible pathway involved in the 
regulation of OPC differentiation is the mTOR signaling cascade (Tyler et al., 2009; 2011; 
Guardiola-Diaz et al. 2012). As widely described in paragraph 1.3.2, this signaling pathway is 
essential for OPC differentiation, since it regulates the transition from pre-oligodendrocytes to 
immature OLs and the subsequent acquisition of a mature myelinating phenotype. In 
particular, mTOR forms two distinct signaling complexes, termed mTORC1 and mTORC2 
which are both involved in controlling OPC maturation, but through distinct mechanisms: 
mTORC2 transcriptionally controls key genes required for OPC differentiation, whereas 
mTORC1 influences the generation of mature OLs through a post-transcriptional mechanism 
(Tyler et al., 2009). Thanks to a proteomic analysis, the same group also demonstrated that 
GPR17 is one of the protein whose expression is altered after OPC treatment with rapamycin, 
a selective inhibitor of mTOR activity (Tyler et al., 2011), suggesting that this transduction 
signaling cascade may be involved in the regulation of GPR17 expression. This result has 
been an important starting point for improving and expanding our knowledge of the 
mechanisms underlying GPR17 physiological regulation. We thus performed different 
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experiments in order to understand the role of the mTOR pathway in regulating GPR17 
expression. 
 
4.4.1 mTOR pathway inhibition blocks OPC terminal maturation preventing GPR17 
down-regulation 
In order to evaluate the effects of mTOR inhibition on OPC terminal maturation, cells were 
maintained for 2 days in proliferating medium and, after 24 hours in differentiating medium, 
they were treated with rapamycin (15 nM). At day 6, when the majority of cells reached the 
mature phenotype, cells were fixed for ICC analysis. 
As shown in Figure 4.17 (A and B), at stage 5 (mature OL) control cultures displayed, as 
expected, a low number of GPR17
+
-cells. In contrast, in rapamycin-treated cultures, the 
number of GPR17
+
-cells was significantly increased and, in parallel, the number of MBP
+
-
cells was dramatically decreased. Histograms in C, summarizing the cell counts of the ICC 
experiments, clearly show that inhibition of the mTOR signaling pathway induced by 
rapamycin treatment slowed OPC maturation and increased GPR17 expression (for GPR17, 
CTRL: 100 ± 7.92%; RAPA: 138.6 ± 8.06%; for MBP, CTRL: 100 ± 9.25%; RAPA: 46.26 ± 
7.59%). No variation in the total number of cells (Hoechst 33258 staining) was observed after 
treatment. 
To confirm the results obtained with the ICC experiments and to extend the analysis to 
other specific markers of OPCs, WB studies were also performed. To this purpose, control 
and rapamycin-treated cells were lysed (according to the procedure described in the 
“Materials and Methods” section) at day 6 in culture and protein lysates were loaded on a 
polyacrylamide gel for electrophoretic separation. GPR17 protein levels were measured in 
parallel to those of the proteoglycan NG2, CNPase and MBP. 
As depicted in Figure 4.17 (D, E), WB analysis confirmed that, at stage 5, cells exposed to 
rapamycin had a higher protein content of GPR17 compared to untreated cells. Furthermore, 
cells treated with rapamycin and maintained in culture up to stage 5 also showed increased 
expression of the proteoglycan NG2 compared to control cells (for NG2, CTRL: 100 ± 
3.45%; RAPA: 141.7 ± 9.79%; for GPR17, CTRL: 100 ± 2.07%; RAPA: 191.5 ± 33.63%). In 
parallel, as shown in figure 4.17 (F, G), the same cultures had a reduced protein content of 
CNPase and MBP (for CNPase, CTRL: 100 ± 0.88%; RAPA: 65.60 ± 2.32%; for MBP, 
CTRL: 100 ± 0.64%; RAPA: 31.32 ± 6.23%). 
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Figure 4.17 – mTOR inhibition by rapamacyn induces a reduction of the mature markers MBP and 
CNPase and in parallel increases GPR17 and the precocious markers NG2. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 in the medium. Rapamycin (15 nM) was added at day 1 and 
day 3. At day 6 (mature OL) cells were fixed for ICC analysis or lysed for WB analysis. (A, B) 
Representative images of control (CTRL) (A) and rapamacyn (RAPA) (B) treated-cells, showing 
double immunostaining with anti-GPR17 (green) and anti-MBP (red) antibodies. (C) Histograms 
show quantification of the percentage of GPR17 and MBP positive cells in control and treated cells 
(with vehicle-treated control cells set to 100%). Hoechst 33258 was used to label cell nuclei. The 
number of positive cells was counted in 10 optical fields under a 20X magnification. Data are the 
mean ± S.E. of cell counts from a total of 3 coverslips/condition from three independent experiments 
(for GPR17, CTRL: 100 ± 7.92%; RAPA: 138.6 ± 8.06%; for MBP, CTRL: 100 ± 9.25%; RAPA: 
46.26 ± 7.59%). **, p<0.01; ***, p<0.001 compared to CTRL, Student T-test. (D, F) Representative 
immunoblots of GPR17, NG2, CNPase and MBP protein levels in different experimental conditions. 
(E, G) Histograms show the result of densitometric analysis. Scanning densitometry was quantified 
and normalized to control (set to 100%) on the same WB. α-tubulin expression was analyzed from the 
same samples as an internal control. Data are expressed as mean ± S.E. of three independent 
experiments (for NG2, CTRL: 100 ± 3.45; RAPA: 141.7 ± 9.79; for GPR17, CTRL: 100 ± 2.07; RAPA: 
191.5 ± 33.63; for CNPase, CTRL: 100 ± 0.88%; RAPA: 65.60 ± 2.32%; for MBP, CTRL: 100 ± 
0.64%; RAPA: 31.32 ± 6.23%). *, p<0.05; **, p < 0.01; ***, p<0.001 compared to CTRL, non 
parametric Mann-Whitney test. 
 
 
To gain insights into the mechanisms by which mTOR regulates GPR17 receptor 
expression, we first measured GPR17 mRNA levels, in parallel to those of MBP and NG2 by 
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quantitative PCR. To this aim, total RNA isolated from control and rapamycin-treated 
cultures at stage 5 was used to generate cDNA that was subjected to real-time PCR. Inhibiting 
mTOR by rapamycin resulted, as expected, in a strong reduction of MBP mRNA levels 
(Figure 4.18 B); in contrast, NG2 mRNA levels were markedly increased in rapamycin-
treated cultures (Figure 4.18 C), whereas GPR17 mRNA levels only displayed a trend of 
increase (Figure 4.18 A) (for MBP, CTRL: 1 ± 0.02; RAPA: 0.57 ± 0.12; for NG2, CTRL: 1 
± 0.07; RAPA: 3.78 ± 1.02; for GPR17, CTRL: 1 ± 0.04; RAPA: 1.57 ± 0.18). 
 
 
Figure 4.18 – Rapamycin significantly reduces mRNA levels of MBP and increases mRNA levels of 
NG2. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 in the medium. Rapamycin (15 nM) was added at day 1 and 
day 3. At day 6 (mature OL stage) total RNA was extracted from control (CTRL) and rapamycin 
(RAPA) treated cells for Real Time PCR analysis. (A-C) GPR17, MBP, and NG2 mRNA levels were 
quantified using 7000 System Software. Fold changes are expressed as mean ± S.E. (with CTRL set to 
1) of data obtained from three independent experiments (for GPR17, CTRL: 1 ± 0.04; RAPA: 1.57 ± 
0.18; for MBP, CTRL: 1 ± 0.02; RAPA: 0.57 ± 0.12; for NG2, CTRL: 1 ± 0.07; RAPA: 3.78 ± 1.02). 
**, p<0.01 compared to CTRL, non parametric Mann-Whitney test. 
 
 
4.4.2 mTOR signaling pathway controls OPC terminal maturation by regulating the 
transition from pre-oligodendrocytes to immature OL 
As already mentioned, the data in literature and those so far shown in this thesis clearly 
demonstrate that the mTOR pathway is required for OPC terminal differentiation. However, it 
has to be highlighted that there are conflicting data on the involvement of this kinase in 
regulating the transition from pre-oligodendrocyte of stage 3 to immature OL of stage 4 
(Tyler et al., 2009; 2011; Guardiola-Diaz et al., 2012). To deeply investigate this issue, the 
consequences of rapamycin treatment on this specific phase of pre-oligodendrocytes’ 
development was assessed by immediately exposing OPCs to rapamycin. Cells were then 
maintained in culture until day 3 or 4, when the majority of cells reached the immature OL 
stage. In parallel, other cells treated or untreated with rapamycin were maintained in culture 
until day 6 (stage 5) in order to confirm the data already shown.  
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As shown in Figure 4.19 (B), at day 4, we already detected a significant increase in GPR17 
protein levels in the cells exposed to the drug compared to the control condition (CTRL: 100 
± 2.52%; RAPA: 138.7 ± 5.22%). Moreover, as expected, the protein levels of the receptor 
still remained high at stage 5 (CTRL: 100 ± 4.58%; RAPA: 156.7 ± 11.81%), confirming the 
data already described in the previous paragraph. Also for the early marker NG2 (Figure 4.19 
C), a significant change in protein levels was observed starting from stage 4 in cells subjected 
to rapamycin treatment (CTRL: 100 ± 1.83%; RAPA: 122.5 ± 3.50%). Of note, as for GPR17, 
the increased protein levels of this early marker persisted until day 6 (CTRL: 100 ± 0.47%; 
RAPA: 230.2 ± 32.99%), stage at which this modulation became much more visible. 
 
 
Figure 4.19 - Rapamycin increases NG2 and GPR17 protein levels both in immature OLs and 
mature OL. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 in the medium. rapamycin (15 nM) was added at day 1 and 
day 3. At day 4 (immature OL) and 6 (mature OL) cells were lysed for WB analysis.(A) Representative 
immunoblots of GPR17 and NG2 protein levels in control (CTRL) and in Rapamycin (RAPA) treated 
cells. (B, C) Histograms show the result of densitometric analysis. Scanning densitometry was 
quantified and normalized to control (set to 100%) on the same WB. α-tubulin expression was 
analyzed from the same samples as an internal control. Data are expressed as mean ± S.E. of two 
independent experiments (for GPR17 stage 4, CTRL: 100 ± 2.52%; RAPA: 138.7 ± 5.22%; for GPR17 
stage 5, CTRL: 100 ± 4.58%; RAPA: 156.7 ± 11.81%; for NG2 stage 4, CTRL: 100 ± 1.83%; RAPA: 
122.5 ± 3.50%; for NG2 stage 5, CTRL: 100 ± 0.47%; RAPA: 230.2 ± 32.99%). *, p<0.05 compared 
to CTRL, non parametric Mann-Whitney test. 
 
Furthermore, the reduction of MBP protein levels (CTRL: 100 ± 3.43%; RAPA: 53.20 ± 
9.31%) observed at stage 4 in cells exposed to rapamycin (Figure 4.20 B) also confirmed that 
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OPC differentiation was already compromised at the immature OL stage, suggesting that 
mTOR pathway regulates the transition from pre-oligodendrocytes to immature OL.  
Globally, these data demonstrate that the mTOR signaling pathway is required for the 
complete maturation of pre-oligodendrocytes. Results also demonstrate that blockade of this 
transduction cascade determines a persistent over-expression of GPR17 that might prevent 
pre-oligodendrocytes from reaching terminal maturation. 
 
 
 
Figure 4.20 - Rapamycin reduces MBP protein levels both in immature OLs and mature OLs. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 in the medium. Rapamycin (15 nM) was added at day 1 and 
day 3. At day 6 (mature OL) cells were lysed for WB analysis. (A) Representative immunoblots of 
MBP protein levels in control (CTRL) and in rapamycin (RAPA) treated cells. (B) Histograms show 
the result of densitometric analysis. Scanning densitometry was quantified and normalized to control 
(set to 100%) on the same WB. α-tubulin expression was analyzed from the same samples as an 
internal control. Data are expressed as mean ± S.E. of two independent experiments (For MBP stage 
4, CTRL: 100 ± 3.43%; RAPA: 53.20 ± 9.31%. For MBP stage 5, CTRL: 100 ± 2.55%; RAPA: 46.68 
± 9.72%). *, p<0.05 compared to CTRL, non parametric Mann-Whitney test. 
 
4.4.3 Involvement of GPR17 in OPC cytoskeletal changes during maturation 
As described in the “Introduction”, OPCs undergo continuous cytoskeletal alterations 
prior to acquire the typical mature OL morphology. Indeed, during differentiation, OPCs with 
a simple bipolar morphology progress through different stages acquiring a more complex 
branched morphology. Notably, at immature OL stage, cellular branched processes appear to 
intertwine to form a ring-like structure. This particular cellular shape has been classified by 
Guardiola-Diaz and co-workers as a more advanced stage of immature OLs (Guardiola-Diaz 
et al., 2012). Since this morphology anticipates the mature OL stage, it has been proposed that 
it may contribute to both establishing interactions with axons to start myelination and to be 
important for microtubule-dependent distribution of myelin proteins, lipids and mRNAs to 
form myelin multiple layers (Bauer et al., 2009).  
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Based on this evidence, it is clear that the cytoskeleton plays a key role in OPC 
differentiation. However, the intracellular mechanisms regulating the cytoskeletal 
modifications are still poorly understood. Recent data have demonstrated an involvement of 
the mTOR pathway. Indeed, Guardiola-Diaz and co-workers showed that OPCs treated with 
rapamycin do not acquire the ring-like structure and that their terminal maturation is blocked 
at the immature OL stage. 
Interestingly, we observed that dot-like structures intensively staining for GPR17 are 
clearly visible in immature OL rings (Fig 4.21A), suggesting that the receptor may actively 
take part to the formation of this “ring-like” circular structure around cell body of immature 
OLs.  
Moreover, as shown in Figure 4.21 (C), we found that the number of cells with this ring-
like morphology was significantly reduced in rapamycin-treated cultures, confirming that the 
mTOR pathway has a role in these morphological changes (CTRL: 100 ± 11.03%; RAPA: 
44.44 ± 10.08%). Highly relevant, interference with GPR17 by rapamycin also clearly 
reduced the number of GPR17
+
-cells that displayed this characteristic morphology, besides 
preventing both ring formation and OPC maturation (Fig. 4.21 CTRL: 100 ± 14.11%; RAPA: 
31.09 ± 7.24%). In addition we observed that, in almost all control GPR17
+
 cells, the receptor 
specifically segregates to these ring-like formations, whereas, in rapamycin treated culture, 
GPR17
+
-cells displayed a simpler multiprocess, branched morphology, with the receptor 
distributed to both the somata and the processes. Altogether, these data indicate that the 
mTOR-GPR17 axis may actively take part to cytoskeleton organization, crucial for a proper 
cell maturation. 
In this respect, to further strengthen the link between cytoskeleton organization and mTOR 
pathway activation, we focused on Sirt2, a NAD-dependent histone deacetylase (North et al., 
2003), that is highly expressed in myelin sheath and in OLs and that takes part to the 
microtubules turn-over and to the subsequent cytoskeleton organization (Li et al., 2007). It 
has been demonstrated that its over-expression significantly inhibits the oligodendroglial 
arborization and tubulin acetylation resulting in the block of OPC differentiation (Li et al., 
2007). Moreover, a recent work has showed that Sirt2 is one of the cytoskeleton-related 
proteins regulated by the mTOR pathway (Tyler et al., 2011). To this purpose, we measured 
the Sirt2 mRNA levels in OPCs after rapamycin treatment. As shown in Figure 4.21 (E), Sirt2 
mRNA levels were remarkably increased after rapamycin exposure (CTRL: 1 ± 0.06; RAPA: 
2.31 ± 0.39), suggesting that its up-regulation may contribute to impairing the acquisition of 
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the mTOR/GPR17-mediated “ring-like” structures, resulting in a block of OPC terminal 
maturation. 
 
  
Figure 4.21 – Involvement of GPR17 in OPCs cytoskeletal changes during maturation 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 in the medium. Rapamycin (15 nM) was added at day 1 and 
day 3. At day 6 (mature OL) cells were fixed for ICC analysis.(A, B) Representative images of control 
(CTRL) (A) and rapamacyn (RAPA) (B) treated-cells, showing double immunostaining with anti-
GPR17 (green) antibody. GPR17 staining is very different in the two experimental conditions: in 
controls, the majority of the GPR17
+
-cells display the ring-like morphology indicating that they are in 
a more advance stage of immature OL, while in rapamycin-treated cultures, GPR17
+
-cells display a 
simpler multiprocess, branched morphology typical earlier stage of immature OL with the receptor 
distributed to both the somata and the processes. (C) Histograms show quantification of the 
percentage of the number of cells with the ring-like morphology on the total number of cells (Hoechst 
33258 staining, C) and on on the total number of GPR17
+
-cells (green, D) in control and treated cells 
(with vehicle-treated control cells set to 100%). The number of cells with ring-like structure was 
counted in 10 optical fields under a 20X magnification. Data are the mean ± S.E. of cell counts from a 
total of 3 coverslips/condition from three independent experiments (for cells with ring-like 
morphology, CTRL: 100 ± 11.03%; RAPA: 44.44 ± 10.08%) (for GPR17
+
-cells with ring-like 
morphology, CTRL: 100 ± 14.11%; RAPA: 31.09 ± 7.24%). **, p<0.01; ***, p<0.001 compared to 
CTRL, Student T-test. (E) Sirt2 mRNA levels were quantified using 7000 System Software. Fold 
changes are expressed as mean ± S.E. (with CTRL set to 1) of three independent experiments (For 
SIRT2, CTRL: 1 ± 0.06; RAPA: 2.31 ± 0.39). **, p<0.01 compared to CTRL, non parametric Mann-
Whitney test. 
 
4.4.4 mTOR signaling pathway regulates GPR17 down-regulation modulating GRK2 
expression and/or activity 
Based on the clear involvement of the mTOR pathway in regulating GPR17 expression, we 
decided to investigate the underlying mechanisms. In this respect, it has been hypothesized 
that in OPCs, similarly to other cellular system, mTOR is able to regulate GPCRs 
expression/trafficking by modulating GRK2 expression or activity that, in turn, might 
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interfere with the physiological down-regulation of GPCRs, which GRKs are associated to. 
This regulation has been already demonstrated in rat glioma cells (Cobelens et al., 2007). 
To assess whether the mTOR pathway is involved in the regulation of GRK2 also in our 
cellular model, we cultured OPCs in presence or absence of rapamacyn up to day 4 or 6 which 
correspond to stages 4 and 5 of the differentiation process in order to evaluate the effects of 
mTOR pathway inhibition both in immature and mature OL. Cells were then lysed for WB 
analysis. As shown in figure 4.22 (B), GRK2 protein levels were significantly reduced in 
rapamycin-treated cultures both at stage 4 (CTRL: 100 ± 0.60%; RAPA: 69.62 ± 7.95%) and 
at stage 5 (CTRL: 100 ± 1.74%; RAPA: 87.54 ± 1.60%) compared to control cultures.  
These data suggest, albeit indirectly, that the reduced expression of GRK2 that is observed 
after rapamycin treatment may be the cause of the persistent expression of GPR17 that occurs 
under these experimental conditions. 
 
 
Figure 4.22 - Rapamycin reduces GRK2 protein levels both in immature OLs and mature OL. 
Primary purified OPCs were cultured in presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 in the medium. rapamycin (15 nM) was added at day 1 and 
day 3. At day 6 (mature OL) cells were lysed for WB analysis. (A) Representative immunoblots of 
GRK2 protein levels in control (CTRL) and in Rapamycin (RAPA) treated cells. (B) Histograms show 
the result of densitometric analysis. Scanning densitometry was quantified and normalized to control 
(set to 100%) on the same WB. α-tubulin expression was analyzed from the same samples as an 
internal control. Data are expressed as mean ± S.E. of two independent experiments (for GRK2 stage 
4, CTRL: 100 ± 0.60%; RAPA: 69.62 ± 7.95%; for GRK2 stage 5, CTRL: 100 ± 1.74%; RAPA: 87.54 
± 1.60%). *, p<0.05 compared to CTRL, non parametric Mann-Whitney test. 
 
 
To test this hypothesis, we examined the involvement of the mTOR pathway in LTD4-
mediated GPR17 desensitization in OPCs, by analyzing the functional responsiveness of the 
receptor to LTD4 in the absence or presence of rapamycin, using the cAMP assay. Cells pre-
treated with rapamycin displayed an impaired LTD4-mediated GPR17 desensitization (Figure. 
4.23 black bars), suggesting that the mTOR pathway takes part to LTD4-mediated GPR17 
homologous desensitization likely selectively regulating GRK2 activity and/or expression. 
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Figure 4.23 - mTOR inhibition prevents LTD4-mediated GPR17 desensitization in OPCs. 
OPCs, isolated and differentiated at pre-oligodendrocytes (stage 3), were treated with 50 nM LTD4 
for different times (5-120 min), in the absence (white bars) or in the presence (black bars) of 
rapamycin (15 nM). After extensive washing, cells were treated for 15 min with 10 µM FK, in the 
absence or in the presence of 5 nM LTD4. Intracellular cAMP levels were evaluated as reported in the 
method section. Data are expressed as the percentage of FK-stimulated cAMP levels, set to 100%, and 
represent the means ± E.S of six independent experiments. *, p<0.05; ***, p<0.001 vs 5 nM LTD4;#, 
p<0.05; ###, p<0.001 vs rapamycin untreated cells, one-way ANOVA, followed by Bonferroni’s 
multiple comparison test. 
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Demyelination is a pathological process that is characterized by the loss of myelin sheath, 
the multilayered membrane that wraps and insulates axons, ensuring the rapid propagation of 
electrical signals. This highly specialized structure is produced and maintained by a specific 
glial cell population: the oligodendrocytes (OLs). As described in the “Introduction”, these 
cells originate from precursors, the NG2
+ 
oligodendrocyte precursor cells (OPCs), that during 
postnatal development differentiate into mature myelinating oligodendrocytes (OLs). 
However, it has to be highlighted that, as already mentioned in paragraph 1.1.5, a significant 
percentage of these NG2
+
-precursors is still present in the adult CNS (both in white and grey 
matter) and constitutes the primary endogenous source of new OLs in case of demyelination. 
In fact, it is known that, after a demyelinating insult, subsequent to infectious, metabolic or 
immune perturbation, these precursors undergo a switch from an essentially quiescent state to 
a regenerative phenotype. This process is called remyelination and allows the generation of 
new OLs, that are able to produce a new myelin sheath.  
Normally, the remyelination process occurs spontaneously; however, in some conditions, 
such as in multiple sclerosis (MS), this process fails or is inadequate (Siffrin et al., 2010; 
Franklin et al., 2008; Fancy et al., 2011; Aktas et al., 2010; Stys et al., 2012). The causes of 
this failed remyelination are not so well understood. It is believed that OPC differentiation 
block and impaired repair may be due to local inflammatory inhibitory signals, intrinsic 
alterations of cell differentiation program, or both (Nishiyama et al., 2009). Whatever the 
mechanism, it is believed that implementation of an effective remyelination strategy 
represents an important goal in a therapeutic perspective for MS and other demyelinating 
diseases. 
In this respect, several approaches could be used to promote endogenous remyelination, 
like (a) enhancing OPC recruitment into demyelinated areas, (b) promoting myelination via a 
specific action on key molecules involved in OPC differentiation, and, (c) removing the 
factors that inhibit remyelination. Regarding the second approach, in the last few years, the 
discovery, in our laboratory, of a new molecular target to be exploited to promote OPC 
differentiation has attracted our attention. 
Our laboratory has, indeed, deorphanized and characterized a new P2Y-like receptor, 
GPR17 (Ciana et al., 2006; Pugliese et al., 2009; Temporini et al., 2009), demonstrating its 
active role in orchestrating OL differentiation and maturation (Lecca et al., 2008; Fumagalli et 
al., 2011; Boda et al., 2011). Specifically, our recent data have indicated that, in vivo, GPR17 
specifically decorates a subset of small cells with fine radiating processes dispersed in both 
grey and white matter, that may represent a source of pre-oligodendrocytes able to turn into 
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myelinating cells when necessary (Lecca et al., 2008). Moreover, our in vitro data 
demonstrated that early GPR17 activation by UDP-glucose promotes OPC maturation toward 
more mature myelinating cells and that its early inhibition by either receptor antagonists (e.g, 
cangrelor or montelukast) (Ciana et al., 2006; Lecca et al., 2008), or specific silencing RNAs 
markedly impairs OPCs differentiation program (Fumagalli et al., 2011).  
In order to extend the pharmacological characterization of GPR17, in the first part of this 
thesis we used rat primary OPC cultures to analyze the consequences of the pharmacological 
treatment with other known GPR17 endogenous ligands, that have already been shown to 
activate the receptor, by reducing intracellular cAMP levels (Fumagalli et al., 2011). To this 
purpose, we assayed the pro-differentiating effects of the uracil nucleotide, UDP, and of two 
cysLTs, LTD4 and LTE4. As depicted in figure 4.2, all the tested agonists markedly increased 
the number of mature myelinating MBP
+
-cells and also showed an increased protein 
expression of the mature marker CNPase. These results are consistent with our previous 
observations and confirm that the activation of this receptor induced by these two classes of 
endogenous mediators accelerates OPC differentiation.  
Moreover, since OPC differentiation and myelination are intimately related step during the 
development of the CNS, we decided to examine whether agonist-induced GPR17 activation 
also affects the myelination process. In this respect, we took advantage of the in vitro model 
OPC/DRG co-cultures and, after an initial characterization of this system, we used it to test 
the capability of either UDP-glucose or UDP to promote myelination. We find that the 
number of MBP positive myelin segments is significantly increased in the presence of both 
GPR17 endogenous ligands, suggesting that the activation of this receptor enhances the 
myelination process. 
These results are at odds with a recent in vitro study, that suggests that both the presence 
and activation of GPR17 inhibit the OL maturation program (Hennen et al., 2013). In this 
paper, in a series of experiments primary OLs isolated from heterozygous GPR17
+/-
 mice 
were treated with a new postulated ligand (the small molecule MDL29,951), and receptor 
activation evaluated through a pathway-unbiased screen based on dynamic redistribution of 
cellular mass. Results led to the opposing view that GPR17 inhibits, instead of stimulating, 
OL maturation (Hennen et al., 2013). Such a main difference is likely related to the way OPCs 
were manipulated and the time at which the pharmacological treatment with the GPR17 
agonist was performed. A different shaking-off procedure to obtain early progenitors from 
brain cortex was used in the two studies; moreover, while we plated OPCs in defined media 
immediately after the shaking, Hennen and coworkers plated only pre/immature OLs purified 
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by immunopanning from mixed glial cell populations that were already positive for the more 
advanced marker O4
+
. As a consequence, also the timing at which cells were exposed to the 
GPR17 agonist is different. In fact, while we treated cells at an early stage at which GPR17 
starts to be expressed at the membrane, the group of Hennen treated cells at a more advanced 
stage, when GPR17 is expressed at high levels and at which the intracellular mechanisms 
responsible for GPR17 down-regulation are already activated. Thus, the use of already 
committed cells suggests that both their intrinsic maturation programs and their abilities to 
respond to GPR17 agonists are different from those of our precursors. It could indeed be 
hypothesized that, at the O4
+
 stage, agonists would induce a complete and precocious down-
regulation of the receptor, which could, in turn, be at the basis of the observed inhibition of 
myelination. Alternatively, as nevertheless suggested by authors themselves, MDL29,951 can 
also have other GPR17-independent effects. Ongoing experiments have been planned to 
investigate this issue in more detail.  
Although GPR17 exact pharmacological profile is still under debate (Ciana et al., 2006; 
Benned-Jensen and Rosenkilde, 2010; Maekawa et al., 2009; Qi et al., 2013; Hennen et al., 
2013), altogether these data suggest that therapeutic promise exists for drug-targeting of 
GPR17 in demyelinating diseases. In this respect, our data confirm the pivotal role of GPR17 
in the initial phases of the differentiation process and further support our hypothesis according 
to which the functional presence of the receptor at early differentiation stages is important to 
keep cells at an immature state, which is necessary to prepare them for myelination.  
Moreover, our previous published data showing that GPR17 is not present in 
morphologically mature MBP positive cells (Fumagalli et al., 2011) arise the hypothesis that 
loss of GPR17 at a relatively advanced differentiation stage is a prerequisite to allow cells to 
proceed to terminal maturation. The results presented in this thesis validate this hypothesis. In 
fact, GPR17 over-expression at a stage during which normally OLs down-regulate it, 
determined a block in the differentiation process at the pre-oligodendrocyte stage. In this 
respect, previous published data showed that myelinogenesis is defective in the CNS of CNP-
GPR17 transgenic mice, a mouse line in which the receptor is over-expressed in CNP-positive 
OLs (Chen et al., 2009). Based on these results, the same authors concluded that GPR17 is a 
negative regulator of OL myelination, but this simplistic conclusion has been then re-
interpreted at the light of more recent data that significantly contributed to defining the 
specific differentiation stages at which OPCs express GPR17 (Fumagalli et al., 2011). In this 
respect, the first results presented in this thesis clearly corroborate the existence of a timely 
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restricted expression of GPR17 and that interference with this pattern of expression 
completely alters the differentiation program of these cells.  
This conclusion is particularly important at the light of exciting recent demonstration that 
GPR17 has been found up-regulated in a lysolecithin-induced demyelination animal model 
(Boda et al., 2011) and in MS patients (Chen et al., 2009), suggesting that impairment of its 
physiological down-regulation can be associated to the block of differentiation observed in 
these pathological conditions.  
Certainly, OPC differentiation in general and the transient nature of GPR17 expression in 
particular are the result of a fine-tuned program based on the integration of both extrinsic and 
intrinsic molecular signals. The actual mechanisms that take part in this regulation are only 
partially understood. Our current hypothesis to explain GPR17 transient expression in OPCs 
is that, by binding to GPR17, its endogenous ligands can first induce early precursor cells to 
undergo differentiation, as shown above, and, then, switch the receptor off by agonist-induced 
desensitization and its physical removal from the membrane, thus allowing OPCs to proceed 
to myelination. A similar process has been associated with specification of other cell lineages, 
where the down-regulation of membrane receptors for trophic or differentiation factors has 
been proposed to be necessary to allow cells to proceed toward terminal differentiation 
(Walrafen et al., 2005). For example, during erythrocyte maturation, stimulation of 
erythropoietin receptors by erythropoietin is necessary to induce erythroid precursor cells to 
proceed to the erythroblast stage; however, at this stage, erythropoietin receptors have to be 
removed from the cell membrane to allow precursors to become functional erythrocytes 
(Flint-Ashtamker et al., 2002). In a similar way, the results described in this thesis indicate 
that GPR17 undergoes phosphorylation and time-dependent desensitization upon a challenge 
with purinergic and cysLT agonists, supporting what was already demonstrated in a 
recombinant system (Daniele et al., 2011) and in cellular lines natively-expressing GPR17 
(Fratangeli et al., 2013).  
Furthermore, for the first time, our results point to the involvement of GRK2 in this 
process. This is a G-protein coupled receptor kinase that is widely expresses within the brain 
whose altered expression levels in peripheral blood circulating cells have been correlated to 
MS (Vroon et al., 2005). As other GRKs, GRK2 is able to phosphorylate the intracellular 
domain of active GPCRs mediating its desensitization. Here, we showed that this kinase, 
whose expression (both protein and transcript) paralleled that of the receptor during the in 
vitro differentiation process reaching the highest levels at the pre-oligodendrocyte stage, is 
primarily involved in the transition from pre-oligodendrocytes to immature OL, since its 
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knock-down by siRNA prevents GPR17 down-regulation and concomitantly blocks OPC 
terminal maturation. Moreover, we demonstrated that recruitment of GRK2 by GPR17 is 
strictly related to receptor activation induced by LTD4; in fact, the pharmacological inhibition 
of this kinase, by blocking GPR17 down-regulation, prevents LTD4-induced OPC 
differentiation. 
It is important to highlight that GRKs activity (and the subsequent GPCRs trafficking 
within the cell) can be also regulated in an agonist-independent manner (Pei et al., 1992; Rime 
and Oprian, 1995). To shed light on this possibility, we decided to investigate other 
intracellular pathways that, through modulation of the expression or activity of regulatory 
molecules, may be involved in GRK dependent processes and take part to OPC 
differentiation. 
In this respect, we focused on the mTOR pathway since its involvement in the regulation 
of OPC terminal maturation has been already partially suggested by previous studies showing 
the role of the serine-threonine kinase Akt in supporting myelination (Zeger et al., 2007; 
Flores et al., 2008). However, only recently, the group of Tyler (2009; 2011) and the group of 
Guardiola–Diaz (2012) have independently demonstrated the key role of the mTOR pathway 
in the regulation of OPC differentiation process. Highly relevant for our studies was the 
finding that GPR17 is up-regulated after mTOR inhibition, as demonstrated by screening 
through a iTRAQ mass spectrometry-based approach (Tyler et al., 2011). 
The results described in this thesis are consistent with the data present in literature. In fact, 
cells exposed to the immunosuppressant drug, rapamycin, and analyzed at the mature OPC 
stage 5, displayed low protein and mRNA levels of the mature markers CNPase and MBP, in 
parallel to a higher content of the proteoglycan NG2 (both transcript and protein). Of note, 
these cells also had a higher content of GPR17 (only protein), suggesting that the mTOR 
signaling pathway controls OPC terminal maturation by regulating its functional expression.  
It has been reported that mTOR regulates OPC differentiation through two distinct 
downstream signaling systems. Indeed, as already described in the “Introduction”, thanks to 
its association with distinct accessory proteins, rictor and raptor, mTOR can give rise to two 
different complexes: mTORC1, that has been demonstrated to regulate OPC differentiation 
mainly by a post-translational mechanisms and is able to interfere with protein translation to 
regulate the synthesis of myelin proteins, of enzymes involved in the synthesis of lipids and 
cholesterol and of cytoskeletal proteins; mTORC2 that, by interfering with the processes of 
mRNA transcription, controls the expression of several transcription factors (e.g. ID2, ID4 
and TCF4) and myelin genes (such as MBP and PLP) (Tyler et al., 2009; 2011). 
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Since in literature there are conflicting data regarding the involvement of mTOR in the 
regulation of the transition from pre-oligodendrocyte of stage 3 and immature OL of stage 4 
(Tyler et al., 2009; 2011; Guardiola-Diaz et al., 2012), specific experiments were designed to 
investigate this effect. To this purpose, immediately after OPC preparation, cells were 
exposed to rapamycin and maintained in vitro until the majority of cells reached the immature 
OL stage (stage 4). As shown in Figure 4.20, at stage 4, GPR17 and NG2 protein levels were 
already significantly increased in cultures exposed to the drug compared to control cultures. 
In parallel, a reduction of MBP protein content was observed (Figure 4.21), indicating that 
terminal differentiation is already altered at this stage.  
The fact that mTOR pathway inhibition blocks OPC differentiation at the pre-OL stage is 
also confirmed by the appearance of alterations in cytoskeleton reorganization that commonly 
occurs during this process. Indeed, increased process extension and branching complexity are 
morphological features typical of cells in transition from OPC/pre-OL to immature OL and 
initiate the program to become mature OLs. Our data confirm that the mTOR pathway is 
related to the cytoskeleton maturation of OLs. As already shown by Guardiola-Diaz and co-
workers, also in our cultures, rapamycin exposure did not arrest the progression of early 
progenitors but inhibited their acquisition of the characteristic ring-like structure (see Figure 
4.19), an event that occurs during the normal progression of the immature OL. This particular 
morphology is considered a more advanced stage of immature OL that immediately precedes 
the mature OL stage. Interestingly, we also observed that dot-like structures intensively 
staining for GPR17 are clearly visible in immature OL rings (Fig 4.21A), suggesting that the 
receptor may actively take part to the formation of this “ring-like” circular structure around 
the cell body of immature OLs. The biological role of this ring-like structure is not yet known, 
but several hypothesis have been put forward: (i) it may contribute to process extension and 
branching complexity that are essential to allow cells establishing interactions with neuronal 
axons to start myelination; (ii) it may contribute to the cytoskeleton-dependent transport of 
myelin proteins, lipids and mRNA. Concerning this second point, it is known that 
microtubules and microfilaments, which compose the OL cytoskeleton, act as intracellular 
transport rails along which myelin-specific proteins and lipids are transported, and that this 
transport is essential to form the multiple layers of myelin sheath (Bauer et al., 2009). In this 
respect, our preliminary data show that GPR17 may play an active role in the cytoskeletal 
changes involved in the local synthesis of myelin proteins. Based on this observation, we 
speculate that mTOR pathway inhibition, by preventing GPR17 down-regulation may, in turn, 
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be responsible for a dysfunction in the formation of this structure, thus resulting in 
impairment of terminal maturation.  
The involvement of mTOR pathway in the cytoskeleton reorganization was already 
suggested by Tyler and co-workers in 2011. Through a proteomic analysis, this group 
identified several cytoskeleton proteins and factors whose expression was altered upon 
rapamycin treatment. Specifically, in parallel to the down-regulation of myelin protein, 
cholesterol and lipid synthesis enzymes, they reported alterations in Sirt2, βIV-tubulin, Gap-
43 and (BASP)-1 (Tyler et al., 2011). Concerning Sirt2, also our results suggest a link 
between the mTOR signaling and this cytoskeletal enzyme. However, while Tyler reported a 
reduction of the Sirt2 expression, we observed increased mRNA levels of Sirt2 after 
rapamycin treatment. This discrepancy may be related to the fact that we measured mRNA 
levels while the group of Tyler directly measured the protein; however, it may also be related 
to the timing at which the analysis has been performed. In fact, it has been reported that Sirt2 
expression is finely regulated during OPC differentiation. Specifically, this enzyme is found 
at high levels in myelin sheaths and mature OLs. Moreover, its expression correlates with the 
appearance of significant morphological changes like highly ramified processes and 
concomitantly increased CNPase expression, suggesting that Sirt2 clearly marks cells entering 
into the pre-myelination stage (Li et al., 2007). Our results are consistent with these findings 
and are also supported by previous data showing that Sirt2 over-expression significantly 
inhibits oligodendroglial arborization and tubulin acetylation, thus slowing down cell 
maturation (Li et al., 2007). Furthermore, in a similar way to Sirt2, also GPR17 expression at 
late maturation stages mainly localizes to oligodendrocytic processes and not to the soma; 
thus, our hypothesis is that a direct link between Sirt2 and GPR17 might exist. In this respect, 
future experiments will be designed to better clarify this relationship. 
Globally, our data confirm the fact that GPR17 down-regulation, either induced by agonist-
binding and/or by the activation of mTOR pathway, is required for OPC terminal maturation. 
We do not rule out the possibility that both these mechanisms take part together to this 
process. Indeed, the capability of the mTOR pathway to regulate GRKs function has already 
been demonstrated in other cellular systems. To assess whether this regulation was also 
present in OPCs, we measured GRK2 proteins levels after mTOR pathway inhibition. WB 
analysis showed that GRK2 protein levels are significantly lower in rapamycin-treated cells 
compared to control cultures, both in immature OL of stage 4 and in mature OL of stage 5. 
Moreover, the fact that the two mechanisms proposed to be responsible for GPR17 down-
regulation may be interconnected to each other is confirmed by the fact that, in the presence 
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of rapamycin (i.e., after mTOR inhibition), LTD4 is not more able to induce GPR17 
homologous desensitization, indicating that, as observed in presence of a specific GRK2 
pharmacological inhibitor, blockade of GRK2 function prevents the removal of GPR17 from 
the cellular membrane. These data indicate that the reduced expression of GRK2 that is 
observed after rapamycin treatment may be the cause of the persistent expression of GPR17 
that occurs under these experimental conditions. Also in this case, experiments are currently 
ongoing to assess whether the effect of mTOR on GPR17 expression is the consequence of a 
direct modulation of GRK2 expression/activity or whether this regulation requires the 
involvement of other molecules. In this respect, our current hypothesis is that Mdm2, an E3 
ubiquitin ligase, which participates in the process of GRK2 ubiquitation by modulating its 
degradation and cellular levels (Salcedo et al., 2006), may be involved in GPR17 
physiological down-regulation. Preliminary data showed that the formation of GRK2/Mdm2 
complexes is strongly enhanced by rapamycin treatment, suggesting that the mTOR pathway 
controls GPR17 down-regulation by directly modulating Mdm2 expression/trafficking. 
Experiments are currently in progress to assess to what extent this mechanism is necessary for 
OPC maturation. 
The role of the GRK2/Mdm2 and of the mTOR pathway in GPR17 physiological 
regulation and in OPC differentiation opens a new scenario for possible pharmacological 
treatments for demyelinating diseases. In this regard, it will be important to evaluate whether, 
in parallel to the GPR17 up-regulation observed in ischemia, traumatic brain or spinal cord 
injury and lysolecithin-induced demyelination (Lecca et al., 2008; Ceruti et al., 2009; Boda et 
al., 2011), there are alterations of the mTOR/GRK2/Mdm2 pathway. 
In conclusion, the results described in this thesis contribute to understanding how GPR17 
expression is regulated during OPC maturation and represent an important starting point for 
the development of new pharmacological or biotechnological approaches to implement the 
endogenous regenerative potential of quiescent NG2
+
-precursors within the adult brain. 
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